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1. ABSTRACT  
Health is not merely absence of a disease. Rather, health is defined as positive 
state of well being in which, the harmonious development of physical and mental 
capacities of the individual lead to the enjoyment of a rich and full life. Health 
involves, primarily, the application of medical science for the benefit of 
individual and society. Health is thus, a vital part of a concurrent and integrated 
program of development of all aspects of community life. Considering the 
importance of health, WHO and UNICEF jointly organized an international 
conference on Primary Health Care at Alma Ata, USSR from 6th to 12th September, 
1978 and took a momentous decision to achieve “Health for All” by the year 2000 
AD. Now, we are entering in the year 2007, but the ‘Health for All’ by the year 
2000 still continues to be a vision. There are various diseases like tropical 
diseases, herpes, AIDS, cancer, diabetes, thalassemia, certain blood disorders etc. 
for which the cure is yet to be found. 
Iron is essential to life because of its unusual flexibility to serve as both an 
electron donor and acceptor. Iron can also be potentially toxic. Its ability to 
donate and accept electrons means that if iron is free within the cell, it can 
catalyze the conversion of hydrogen peroxide into free radicals. Free radicals can 
cause damage to cellular membranes, proteins, and DNA, a wide variety of 
cellular structures, and ultimately kill the cell. To prevent that kind of damage, all 
life forms that use iron, bind the iron atoms to proteins. This allows the cells to 
use the benefits of iron, but also limit its ability to do harm (Andrews NC 1995). 
Most well-nourished people have 4 to 5 grams of iron in their bodies. Of this, 
about 2.5 g is contained in the hemoglobin needed to carry oxygen through the 
blood, and most of the rest is contained in ferritin complexes that are present in 
all cells, but most commonly in bone marrow, liver, and spleen. The liver's stores 
of ferritin are the primary physiologic source of reserve iron in the body (Schrier 
SL 2005). The human body needs iron for oxygen transport. That oxygen is 
required for the production and survival of all cells in our bodies. Human bodies 
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tightly regulate iron absorption and recycling. Iron is such an essential element 
of human life, in fact, that humans have no physiologic regulatory mechanism for 
excreting iron (Schrier and Bacon 2005). 
In medicine, iron overload disorders are diseases caused by the accumulation of 
iron in the body. Iron toxicity results when the amount of circulating iron 
exceeds the amount of transferrin available to bind it. The type of acute toxicity 
from iron ingestion causes severe mucosal damage in gastrointestinal tract, 
among other problems. Iron overload is one of the major causes of morbidity in 
all patients with severe forms of thalassemia, regardless of whether they are 
regularly transfused. A variety of other iron overload diseases are present. These 
are thalassemia, sideroblastic anemia, abnormal red cell production 
(dyseryphropoiesis), iron overload secondary to IV therapy, chronic liver disease 
secondary to alcohol, porphyria cutanea tarda. Iron overload can be inherited 
(genetic) or acquired by receiving numerous blood transfusions, getting iron 
shots or injections, or consuming high levels of supplemental iron. Some of the 
genetic disorders that result in iron overload include are hereditary 
hemochromatosis (all types), African iron overload, sickle cell disease, 
thalassemia, X-linked sideroblastic anemia, enzyme deficiencies (pyruvate 
kinase; glucose-6-phosphate dehydrogenase) and very rare protein transport 
disorders aceruloplasminemia and atransferrinemia. None of these conditions 
should be confused with polycythemia vera (PV), which is not an iron disorder, 
but a condition where the bone marrow produces too many blood cells (red, 
white and platelet). People with PV have abnormally high hemoglobin and are at 
risk for a stroke and progressing to acute myelogenous leukemia (AML).   
Excess iron in vital organs, even in mild cases of iron overload, increases the risk 
for liver disease (cirrhosis, cancer), heart attack or heart failure, diabetes 
mellitus, osteoarthritis, osteoporosis, metabolic syndrome, hypothyroidism, 
hypogonadism, numerous symptoms and in some cases premature death. Iron 
mismanagement resulting in overload can accelerate such neurodegenerative 
diseases as Alzheimer’s, early-onset Parkinson’s, Huntington’s, epilepsy and 
multiple sclerosis. Synthetic agents like desferrioxamine and deferiprone used 
for the treatment of iron overload in thalassemia are accompanied by serious 
side effects and certain limitaions including need for Parenteral administration, 
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arthralgia, nausea, gastrointestinal symptoms, fluctuating liver enzyme levels, 
leucopenia, agranulocytosis and zinc deficiency and obviously the heavy cost. In 
addition, they are not suitable for use during pregnancy (Hebbel et al., 1990; 
Grinberg et al., 1995; Kukongviriyapan et al., 2008). Compared to synthetic 
drugs, herbal preparations are frequently less toxic with fewer side effects. 
Therefore, the search for more effective and safer treatment of thalassemia and 
other blood disorders has become an area of current research activity.  The poor 
oral bioavailability, short plasma half-life and severe side effects of available 
chelators are still not optimal (Filburn et al., 2007; Rachmilewitz et al., 1979; 
Livrea et al., 1996). Within this context and taking in consideration the relative 
paucity of iron chelating agents it is not surprising that clinical scientists put a 
great effort towards finding any potentially useful sources in order to obtain the 
maximum possible benefit with the least possible harm (Loukopoulos, 2005; 
Ebrahimzadeh et al., 2007).  
For thousands of years, mankind has known about the benefits of drugs from 
nature. Plant extracts like wheatgrass juice have been highly regarded for their 
curative effects by ancient civilizations. Even today, plant materials remain an 
important resource for combating illnesses. WHO has approved the use of 
traditional medicines as a part of health programme. To pursue research in these 
systems of medicine, several USA agencies and institutions such as FDA and 
National Institute of Health have setup separate wings. According to the WHO 
survey 80% of the populations living in the developing countries rely almost 
exclusively on traditional medicine for the primary health care needs. In almost 
all the traditional medicine, the medicinal plants play a major role and constitute 
the backbone of the traditional medicine. The potential of plant as a source for 
new drugs is yet to be unexplored systematically. Among the estimated 250,000-
400,000 plant species, only 6% have been studied for biological activity and 
about 15% have been investigated phytochemically (Verpoorte et al., 1998; 
Cragg et al., 1997; Balandrin et al., 1985). India has an ancient heritage of 
traditional medicine. Materia Medica of India provides lots of information on the 
folklore practices and traditional aspects of therapeutically important natural 
products. Indian traditional medicine is based on various system including 
Ayurveda, Siddha and Unani. With the emerging interest in the world to adopt 
and study the traditional system and to exploit their potentials based on 
  
  1. Abstract 
4  
 
different healthcare systems, the evaluation of the rich heritage of the traditional 
medicine is essential. Further, treatment with, one such traditional herbal drug 
viz. Wheatgrass, on patients with ß-thalassemia (major), has been reported to 
have beneficial effects by decreasing iron overload (Desai et al., 2005). Hence, in 
the present project, we planned to investigate iron chelating potential of 
wheatgrass and its various extracts, in iron overload condition.  
Modern science has already, accepted the potential of the herbs as a source of 
new bio-active constituents. There are numerous plants-derived drugs of 
unknown chemical structure that have been found clinically useful in different 
alternative system of medicine, including Ayurveda, Homeopathy and Unani 
system of medicine.  The plants are a rich reservoir of potential leads for drug 
discovery against various disorders. Almost, half of the useful drugs today used 
for various diseases, are derived from natural sources. Only less than two 
percent of all the plants, available on the earth, have been subjected to 
pharmacological investigations. Research on the medicinal herbs can offer useful 
drugs, in time to come, for the treatment of chronic diseases like asthma and 
diabetes etc. The global market of herbal drugs is increasing very rapidly and it is 
expected to touch the $5 trillion by end of 2005 (Pharma Business, 2000). The 
recent development of the science of phyto-pharmaceuticals has generated new 
enthusiasm in herbal drug research to discover new medicines (Patel and Saluja, 
2002). Looking at the dire need of a new safe and economical iron chelating 
molecule, we resolved to isolate probable active constituent of wheatgrass, 
responsible for its possible chelating activity.  
Wheat (Triticum species) a cereal grass of the Gramineae (Poaceae) family, is the 
world's largest edible grain cereal-grass crop. Wheat has been a food crop for 
mankind since the beginning of agriculture. For over fifty years, researchers have 
known that the cereal plant, at this young green stage, is many times richer in the 
levels of vitamins, minerals and proteins as compared to seed kernel, or grain 
products of the mature cereal plant (Schnabel 1940). The young germinated 
plant is a factory of enzyme and growth activity. In the early stages of growth 
they store large amounts of vitamins and proteins in the young blades. After 
jointing stage, the nutritional level in the leaves drops rapidly while the fiber 
content increases rapidly (Kohler 1944). Agriculturally, important species of 
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Triticum include - Triticum aestivum, Triticum durum and Triticum dicoccum. 
Wheatgrass has been traditionally used, since ancient times, to treat various 
diseases and disorders. Presently, there are number of wheatgrass suppliers, in 
almost all cities of India, supply fresh wheatgrass, on daily basis to their regular 
customers by home-delivery system for various ailments and as a health tonic. 
Dr. Ann Wigmore, USA, founder director of the Hippocrates Health Institute, 
Boston, USA, was one of the proponents of the ‘‘Wheatgrass Therapy'. Dr. 
Wigmore claimed that wheatgrass is a safe and effective treatment for ailments 
such as high blood pressure, some cancers, obesity, diabetes, gastritis, ulcers, 
anemia, asthma and eczema. Scientific reports on nutritional analysis of 
wheatgrass have been published frequently in various journals (Kohler 1953, 
Hamilton et al., 1988, Laboratory Analyses 1989). These reports and the 
chemical analyses undertaken reveal that wheatgrass is rich in chlorophyll, 
minerals like magnesium, selenium, zinc, chromium, antioxidants like beta-
carotene (pro-vitamin A), vitamin E, vitamin C, antianemic factors like vitamin 
B12, iron, folic acid, pyridoxine and many other minerals, amino acids and 
enzymes, phenol and flavonoid which have significant nutritious and medicinal 
value (Wigmore 1985). Since, iron overload induces considerable oxidative 
stress and wheatgrass is known to contain significant amount of antioxidants, we 
decided to investigate antioxidant benefits of wheatgrass in iron overload 
condition.    
Platelets are made in the bone marrow similar to other cells in blood such as, 
white blood cells and red blood cells. Platelets originate from megakaryocytes 
which, are large cells found in the bone marrow. Platelets, in general, have a brief 
7 to 10 days life in blood, after which they are removed from the blood 
circulation. The number of platelets in the blood is referred to as the platelet 
count and is normally between 150,000 to 450,000 per micro liter of blood. 
Platelet counts less than 150,000 are termed thrombocytopenia (Maton et al, 
1993). There are a wide range of botanical sources and wide range of active 
constituents that might ultimately contribute to haemostatic action, including 
essential oils, flavonoids, saponins, and alkaloids. The possible mechanisms of 
action of the hemostatic herbs include: increasing the production of platelets, 
promoting the ability of platelets to aggregate when there is blood leakage, 
decreasing capillary permeability, contracting peripheral blood vessels, 
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inhibiting autoimmune attack against platelets. Dr. Wigmore in her programme 
the “wheatgrass” made several clinical trials on wheatgrass and reported that 
plants are a safe and effective treatment for anemia and various bleeding 
disorder like hemophilia and thrombocytopenia. These effects should be 
expected to be observed within a few days of administering the herbs (Wigmore 
1985).  In this context, we decided to investigate beneficial effects of wheatgrass 
in treatment of thrombocytopenia and other bleeding disorders. 
The immune system is a remarkably effective structure that incorporates 
specificity, inducibility and adaptation. Failures of host defense do occur, 
however, and fall into three broad categories: immunodeficiencies, 
autoimmunity and hypersensitivities. The immune system is involved in the 
etiology as well as pathophysiological mechanisms of many diseases. Modulation 
of the immune responses to alleviate the diseases has been of interest for many 
years and the concept of ‘Rasayana’ in Ayurveda is based on related principles 
(Sharma P 1983). Indian medicinal plants are a rich source of substances which 
are claimed to induce paraimmunity, the non-specific immunomodulation of 
essentially granulocytes, macrophages, natural killer cells and complement 
functions (Sainis 1997). Ayurveda, the Indian traditional system of medicine, lays 
emphasis on promotion of health concept of strengthening host defenses against 
different diseases (Thatte 1986). Dr. Wigmore’s opinions are based on her 
experiences. A few clinical studies, have verified that some disease conditions 
can be benefited by the use of wheatgrass. Remarkably, a relatively large number 
of studies indicate that food factors and nutrients found in wheatgrass may 
provide beneficial in immunological disorders. In the light of forgoing discussion, 
we made an attempt to assess immunomodulatory potential of wheatgrass, using 
various animal models.   
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In nutshell the objectives of the present project were –  
1. To carry out pharmacognostic studies of Triticum aestivum (Wheatgrass). 
2. To carry out phytochemical studies of Triticum aestivum and its various 
extracts. 
3. To evaluate iron chelating activity of various extracts of Triticum 
aestivum.  
4. To isolate iron chelating compound from extract of Triticum aestivum, 
using column chromatography. 
5. To evaluate iron chelating activity of isolated compound of Triticum 
aestivum, using pre-clinical study.  
6. To investigate anti-oxidant property of Triticum aestivum in iron overload 
condition. 
7. To investigate therapeutic benefit of Triticum aestivum in 
thrombocytopenia. 
8. To investigate immunomodulatory activity of Triticum aestivum.  
 
In our investigation, certified samples of wheat viz. Triticum aestivum, was 
acquired from the Wheat Research Center, Gujarat Krushi University, Junagadh, 
Gujarat. Adequate quantities of unpolished wheat grain were soaked overnight in 
water, and were grown in plastic trays filled with soil, on the next day. Trays 
were watered adequately every day, for 8 days. On 9th day the wheatgrass was 
harvested. For characterization, wheatgrass was subjected to microscopic study, 
which included transverse sections, surface preparations and powder study, 
using high-resolution microscope.  
In conformation with the description in literature; the leaves were mainly near 
glabrous, auriculate, with blades narrowly to broadly linear; broad to narrow; 2–
20 mm wide; flat; without cross venation (Percival 1974). Observations in 
microscopic studies of different species, also confirmed characteristics reported 
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in literature (Percival 1974). In transverse section, the wheatgrass leaf showed 1. 
elaborate epidermis with characteristic stomata and trichomes 2. green 
assimilating parenchyma, 3. conducting vascular bundles and 4. Longitudinal 
strands of fibrous stereome or supporting tissue. The upper surface of the leaf 
showed a series of longitudinal ridges or ribs, the lower surface being almost flat. 
At the summit of each ridge was a single row of elongated thick-walled and 
pitted cells alternating with hairs. The trichomes or hairs were always 
unicellular and very much in length and stoutness. On the leaves of T. aestivum, 
ample numbers of hair were present. Stomata were observed at the base of the 
ridge arranged in single or double lines. Each stoma on the leaf consisted of four 
cells; the two guard cells being narrow, with specially thickened walls round the 
stomata pore and thin-walled widely dilated ends. Pores of the stomata were 
seen to be in communication with large intracellular cavities in the mesophyll, 
called lacune. The ratio of the number of stomata on the upper and lower 
epidermis respectively was about 10:7, the number on the upper surface 
examined being 7000 per square centimeter. In the furrow between two ridges 
was a band of three to seven rows of motor cells. vascular bundles were 
collateral, with the xylem towards the upper surface of the leaf and the phloem 
bellow. In surface preparation, trichomes or hairs of various lengths were found 
scattered along the rows at more or less at regular intervals. The 
pharmacognostic characteristics observed in our study were in confirmation 
with that reported in the literature. 
Successive solvent extracts of wheatgrass with petroleum ether, chloroform, 
acetone, methanol and water were prepared, employing soxhlet apparatus. 
Highest extractive value was that of water extract (5.3 %), followed by acetone 
(4.3 %), methanol (4.1 %), chloroform (3.4 %) and petroleum ether with lowest 
extractive value of 2.8 %.  
There is a direct relation beteween iron chelatory activity and the contents of 
phenolic and flavonoids in some extracts as reported by Ebrahimzadeh et al., 
2008. Hence, the extracts obtained from successive solvent extraction process 
were subjected to shinoda and FeCl3 tests to determine the presence of 
phenolics, tannins and flavanoids. Methanol and water extracts showed presence 
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of phenolics, tannins and flavanoids, while petroleum ether, chloroform and 
acetone extracts had no phenolic and flavanoids components.  
We also made attempt for in-vitro quantitative determination of phenolic 
contents and iron chelating property of various extracts of wheatgrass using 
Folin-Ciocalteau (FC) and Dinis et al. 1994, methods respectively. In methanol 
and water extracts 506.92 + 16.36 and 198.5 + 10.61 µg Gallic acid equivalent of 
phenol content were detected. Phenolic content of methanol extract was found to 
be higher compared to water extract. In-vitro iron chelating activities of EDTA, 
desferoxamine and both extracts were found to be increased with increase in 
their concentration with highest activity at concentration of 2 mg/ml. The 
chelating activity of methanol extract was found to be significantly higher 
compared to water extract.  
Intraperitoneal injections of iron-dextran (12.5 mg/l00 g body wt.) evenly 
distributed over a 30 days period on Sprague dwaley rats resulted in condition of 
chronic iron overload (serum iron - 6099 ± 252 µg/dl). Control group rats 
injected with an equal volume of dextran showed normal level of iron (serum 
iron - 203 ± 17 µg/dl). There was significant increase in serum ferritin level in 
iron overloaded group rats (1.13 ± 0.07 mg/dl) compared to normal control 
group rats (4.83 ± 0.51 mg/dl). All the studies were carried out for a period of 30 
days. Blood, urine and fecal samples were collected on 15th and 30th days under 
fasting conditions and were subjected for various biochemical parameters. 
After 15 days of treatment, there were significant reductions in serum iron and 
ferritin levels in desferoxamine group (serum iron - 2876 ± 281µg/dl, serum 
ferritin - 2.74 ± 0.42 mg/dl). There were significant reduction in serum iron and 
ferritin levels after treatment with water extract group (serum iron - 3510 ± 264 
µg/dl, serum ferritin - 3.32  ±  0.19 mg/dl) and methanol extract group (serum 
iron - 4636 ± 142 µg/dl, serum ferritin - 3.97 ± 0.29 mg/dl) of wheatgrass 
compared to disease group. Treatment with acetone extract did not significantly 
reduce serum iron or ferritin levels (serum iron - 5222 ± 314µg/dl, serum 
ferritin – 4.64 ± 0.38 mg/dl) compared to disease control. 
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No changes were observed in urine and faces iron in iron overloaded group rats 
(urine iron – 69.2 ± 7.7 µg/dl, faces iron – 9.17 ± 2.5 µg/dl) and placebo group 
(urine iron – 26.2 ± 6.4 µg/dl, faces iron – 2.83 ± 0.3 µg/dl). There was significant 
increase in urine iron and faces iron levels in desferoxamine group (urine iron - 
422.5 ± 79.1 µg/dl, faces iron - 31.0 ± 5.3 µg/dl), water extract group (urine iron 
- 256.0 ± 32.6 µg/dl, faces iron - 17.67 ± 2.1 µg/dl) and methanol extract group 
(urine iron - 296.5± 33.8 µg/dl, faces iron - 30.33 ± 2.5 µg/dl) compared to iron 
overloaded group rats (urine iron - 69.2 ± 7.7 µg/dl, faces iron - 9.17 ± 2.5 µg/dl). 
Increase in urine and fecal excretion of iron in rats treated with water and 
methanol extracts of wheatgrass indicate iron chelating property of wheatgrass 
that was comparable to desferoxamine. Similarly there were beneficial effects 
observed after 30 days treatment period with wheatgrass in iron overloaded rats 
group. Treatment of acetone extracts did not produce any significant increase in 
urine iron (94.0 ± 11.9 µg/dl) and faces iron (12.0 ± 1.01 µg/dl) levels compared 
to diseases control group. These data suggest effectiveness of water and 
methanol extracts in reduction of iron overload in rats by increase iron excretion 
in urine and faeces. 
Excess iron in vital organs, even in mild cases of iron overload, increases the risk 
for liver disease (cirrhosis, cancer), kidney diseases, heart attack or heart failure, 
diabetes mellitus etc. and in some cases, premature death.  
There were significant increases in SGPT (101.9 ± 8.7 µg/l) and SGOT (170.9 ± 
11.3 µg/l) levels in iron overloaded group as compared to normal control group 
(SGPT –  12.4 ± 1.9 µg/l, SGOT - 46.28 ± 5.2 µg/l). After treatment with water and 
methanol extracts of wheatgrass there was significant reduction in these enzyme 
levels (water extract SGPT – 95.65 ± 6.9 µg/l, SGOT - 148.0 ± 6.5 µg/l; methanol 
extract SGPT – 81.9 ± 5.8 µg/l, SGOT - 132.4 ± 8.8 µg/l) indicating protective 
effects of extracts in liver complications due to iron overload.  
Serum creatinine and creatinine kinase levels were significant increased in iron 
overloaded group rats (serum creatinine- 1.76 ± 0.08 mg/dl and creatinine 
kinase- 398.2 ± 23.7 µg/l) as compared to placebo group (serum creatinine- 0.67 
± 0.08 mg/dl and creatinine kinase- 91.8 ± 8.76 µg/l). Methanol and water 
extracts treated animals showed reduction in levels of these enzymes (water 
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extract, serum creatinine- 1.59 ± 0.05 mg/dl and creatinine kinase- 335.7 ± 17.9 
µg/l; methanol extract, serum creatinine- 1.45 ± 0.07 mg/dl and creatinine 
kinase- 316.5 ± 11.5 µg/l) indicating that these extracts prevent damage to vital 
organs like kidney and heart in iron overload complications. 
Results of histopathological study of liver suggested that chronic treatment with 
desferoxamine and water; methanol and acetone extracts of wheatgrass reduce 
iron pigmentation, pleomorphism, vaculation, fibrosis, disarrangement and 
degeneration of hepatocytes as compared to iron overloaded group animals. The 
degree of protection was found to be minimal with acetone extract group. 
Histological findings of kidney (injured brush-border microvilli and swollen 
proximal convoluted tubular cells) in iron overloaded group rats suggested 
protective effects of methanol, water and acetone extracts of wheatgrass in iron 
overload kidney complications. Protective effects were much better in methanol 
extract treated group and lesser in acetone extract treated group. Treatment 
with desferoxamine and methanol and water extracts of wheatgrass showed 
protective effects on myocytes and fibrosis. Vascular hemorrhages were also 
reduced in iron overloaded group rats treated with methanol and water extracts. 
Treatment with acetone extract produced less protective effects as compared to 
water and methanol extracts. 
Accumulation of iron in body leads to suppression of bone marrow resulting in 
reduction of total and differential leucocytes counts. This was observed in iron 
overloaded rats of disease control group (3.89 ± 0.24 103/πl) as compared to 
placebo group (5.98 ± 0.41 103/πl). After 15 and 30 days treatment with 
desferoxamine (4.01 ± 0.23 103/πl), water extract (4.93 ± 0.27 103/πl) and 
methanol extract (4.53 ± 0.32 103/πl) of wheatgrass in iron over loaded rats total 
WBC count was significant increased. The increase in leukocyte count indicates 
that wheatgrass may have stimulating effect on bone marrow and also on 
synthesis of all types of leucocytes. Treatment with acetone extract in iron 
overload rats did not produce any significant increase in total and differential 
leucocytes counts as compared to iron overloaded group rats. These results 
indicate beneficial effect of wheatgrass on immune system. 
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Iron overloaded group rats exhibited significant decrease in Hb count (10.78 ± 
0.84 gm/dl) and RBC count (6.77 ± 0.29 m/cmm) as compared to normal control 
group rats (Hb-14.57 ± 0.61 gm/dl, RBC- 8.65 ± 0.49 m/cmm) suggesting toxic 
effect of iron excess on Hb and RBC synthesis. 15 days treatment with 
desferoxamine (Hb-13.5 ± 0.51 gm/dl, RBC- 7.86 ± 0.58 m/cmm), water extract 
(Hb-13.83 ± 0.31 gm/dl, RBC- 7.69 ± 0.52 m/cmm) and methanol extract (Hb-
14.03 ± 0.68 gm/dl, RBC- 8.13 ± 0.87 m/cmm) in iron over loaded rats produced 
significant increase in Hb levels and RBC counts. The increase in RBC count 
indicates that wheatgrass may have stimulated haemopoietic process while rise 
in hemoglobin content indicates stimulation of hemoglobin synthesis in 
individual RBC. Treatment with acetone extract in iron overload rats did not 
produce any significant increase in Hb level (10.67 ± 0.68 gm/dl) and RBC count 
(7.13 ± 0.44 m/cmm) as compared to iron overloaded rats. Over all, there was 
improvement in Hb level and RBC count after treatment with wheatgrass 
extracts after 15 and 30 days in iron overload rats.  
Similarly, treatment with methanol extract (699.6 ± 38.6 103/πl) and water 
(793.6 ± 43.5 103/πl) extract of wheatgrass, significantly increased platelet 
counts in iron over loaded group rats as compared to diseases control group rats 
(530.2 ± 32.6 103/πl). Acetone extract did not produce any significant increase in 
platelet count (590.5 ± 59.5 103/πl) as compared to disease control group. These 
data indicate beneficial effect of wheatgrass in platelet deficiency disorders.  
In iron overload condition, oxidative stress is ultimately involved in dysfunction 
of vital organs including cardiovascular system (Shinar and Rachmilewitz, 1990; 
Hebbel et al., 1990; Grinberg et al., 1995). Antioxidant and other supportive 
therapies protect RBC against oxidative damage (Kukongviriyapan et al., 2008; 
Filburn et al., 2007). Also, a higher rate of LDL oxidation in thalassemia patients 
is, due to a lower concentration of vitamin E and C in the LDL particles. 
Enrichment with vitamins E and C was effective in preventing LDL oxidation in 
patients with thalassemia (Rachmilewitz et al., 1979; Livrea et al., 1996). Iron 
chelators mobilize tissue iron by forming soluble, stable complexes that are then 
excreted in the feces and/or urine. Chelation therapy reduces iron-related 
complications and thereby improves quality of life and overall survival (Shinar 
and Rachmilewitz, 1990; Hebbel et al., 1990). 
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In our study, at the end of 30 days treatment periods, liver homogenates of iron 
overloaded group rats showed significant increase in OFRs, MDA level (2.56 ± 
0.18 nmoles/mg protein) and decrease in SOD (0.73 ± 0.07 units/min/mg 
protein), catalase (0.98 ± 0.14 units/min/mg protein) and glutathione levels 
(7.22 ± 1.75 µgm/mg protein) compared to normal group rats (MDA- 0.74 ± 0.11 
nmoles/mg protein, SOD- 1.42 ± 0.1 units/min/mg protein, Catalase- 4.59 ± 1.11 
units/min/mg protein , GSH- 12.69 ± 1.04 µgm/mg protein). Treatment with 
methanol and water extracts of wheatgrass significantly reduced MDA level (1.24 
± 0.06 and 1.16 ± 0.08 nmoles/mg protein) in the rat liver homogenates. There 
were significant improvements in GSH, SOD and catalase levels in iron 
overloaded group rats treated with methanol (SOD- 1.29 ± 0.13 units/min/mg 
protein, Catalase- 3.47 ± 0.17 units/min/mg protein, GSH- 10.8 ± 0.7 µgm/mg 
protein) and water extracts (SOD- 1.35 ± 0.11 units/min/mg protein, Catalase- 
3.78 ± 0.69 units/min/mg protein, GSH- 11.82 ± 0.51 µgm/mg protein). No 
significant changes were observed in MDA, SOD, catalase and glutathione levels 
in acetone extract treated group. These data indicate strengthening of 
antioxidant defense by wheatgrass in iron overload condition. 
Since, the results, obtained so far, revealed maximum chelating activity in 
methanol extract group, we decided to process the methanol extract further, for 
the purpose of isolation of active iron chelator constituent. 
Column chromatography fraction 71-76 eluted using methanol: water: acetone: 
glacial acetic acid (1:0-80:0.5:0.1) solvent system followed by concentration 
yielded brown crystals. On recrystallization with methanol produced needle 
shaped crystals of the active compound (PI1), having melting point of 215-218 0C. 
The identity of the isolated compound PI1, was confirmed by comparing the Rf 
value 0.682 on TLC plate. The isolated compound gave black colored spot on 
spraying 5 % ferric chloride solution on TLC plate suggesting phenolic nature.  
The isolated iron chelator compound was subjected to LCMS and IR 
spectroscopic analyses, for its molecular characterization. The compound was 
found to be aromatic in nature containing phenolic group. 
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The total phenolic content in isolated compound from methanol fraction of 
Triticum aestivum, using Folin-Ciocalteau (FC) method, was found to be 434.14 + 
28.02 µg Gallic acid equivalent of phenol. In-vitro iron chelating activity of 
isolated compound was compared with standard iron chelator drug, 
desferoxamine at 1.0 mg/ml concentration level. % inhibition of complex 
formation between Fe2+ -ferrozine were found 61.18 ± 5.37 in desferoxamine 
and 30.27 ± 2.98 in isolated compound PI1.   
Intraperitoneal injections of iron-dextran (12.5 mg/l00g of body wt.), evenly 
distributed over a 2 days period, resulted in condition of acute iron overload, in 
SD rats. Control group rats injected with an equal volume of dextran, showed 
normal serum level of iron. At the end of day 2, urine samples were collected and 
analyzed for iron content. No significant changes in urine iron levels were 
observed in iron overloaded rats (34.25 ± 3.8 µg/dl) and normal control rats 
(26.2 ± 6.4 µg/dl). 2 day’s treatment with desferoxamine (urine iron- 108.75± 
7.4 µg/dl) and isolated compound (urine iron- 62.21 ± 9.4 µg/dl) in iron 
overloaded rats produced significant increase in urine iron levels compared to 
diseases control rats. The chelating power or efficacy of the isolated compound 
was 34.5% compared to that of desferoxamine. 
For evaluation of effects of wheatgrass in thrombocytopenia, busulfan was used 
to induce experimental thrombocytopenia. Busulfan is an alkylating agent with 
myeloablative properties and activity against non-dividing marrow cells and 
possibly, non-dividing malignant cells. Busulfan solution, at concentration of 10 
mg/ml in polyethylene glycol, was prepared and infused in wistar rats at doses 
of 25 mg busulfan/kg body weight each, at 1, 5, 10 and 15 days of interval 
produced pancytopenia with significant reduction in platelet count mimicking 
severe bleeding conditions as found in thrombocytopenia. 
Disease control group rats which, received busulfan showed significant 
reduction in Hb (8.1 ± 0.75 gm/dl) and RBC count (5.4 ± 0.5 m/cmm) compared 
to normal healthy group rats (Hb- 10.9 ± 0.98 gm/dl, RBC- 6.8 ± 0.89 m/cmm) 
indicating anemia in iron overloaded rats. Treatment with fresh wheatgrass juice 
(Hb- 10.5 ± 1.1 gm/dl, RBC- 6.7 ± 0.59 m/cmm), methanol extract (Hb- 10.2 ± 1.2 
gm/dl, RBC- 6.1 ± 0.47 m/cmm) and acetone extract (Hb- 9.7 ± 0.89 gm/dl, RBC- 
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6.3 ± 0.7 m/cmm) of wheatgrass, produced significant increase in Hb levels and 
RBC counts in diseased rats. Decrease in blood Hb level and RBC count in rats 
was significantly prevented by treatment with fresh juice, methanol and acetone 
extracts of wheat grass. Thus, wheatgrass seems to help improve blood 
purification and also, to increase hemoglobin level and RBC count near to 
normal.  
In disease control group rats which received busulfan, there was significant 
reduction in platelet count (523 + 46 103/πl) compared to normal healthy group 
rats (905 + 82 103/πl) indicating thrombocytopenia. Treatment with fresh 
wheatgrass juice (804 + 72 103/πl), methanol extract (761 + 58 103/πl) and 
acetone extract (708 + 63 103/πl) produced significant increase in platelet count 
as compared to disease control group rats. Decrease in platelet count in these 
rats was significantly prevented by treatment with fresh wheatgrass juice, 
methanol and acetone extracts of wheatgrass. 
Disease control group rats which received busulfan showed significant increase 
in bleeding (190 + 18 sec) and clotting time (390 + 35 sec) as a result of 
reduction in platelet counts compared to normal healthy group rats (bleeding 
time- 80 + 12 sec, clotting time- 130 + 22 sec) indicating hemophilia and 
thrombocytopenia in animals. Treatment with fresh wheatgrass juice (bleeding 
time- 98 + 13 sec, clotting time- 150 + 23 sec), methanol extract (bleeding time- 
106 + 17 sec, clotting time- 196 + 24 sec) and acetone extract (bleeding time- 
125 + 15 sec, clotting time- 214 + 30 sec) produced significant reduction in 
bleeding and clotting time in disease suffering rats. Increases in bleeding and 
clotting time in rats were significantly prevented by treatment with fresh juice, 
methanol and acetone extract of wheatgrass. Thus wheatgrass seems to help in 
reducing bleeding and clotting time, near to normal.  
Disease control group rats which received busulfan showed significant reduction 
in total WBC and differential WBC counts compared to normal healthy group 
rats. Treatment with fresh wheatgrass juice, methanol extract produced 
significant increase in total WBC counts and differential WBC counts, in busulfan 
induced pancytopenic rats. Treatment with acetone extract did not produce 
significant increase in total WBC counts. Disease control group rats showed 
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pancytopenia (reduction in all blood cells count) compared to normal healthy 
control group rats. Treatment with fresh wheatgrass juice and different extracts 
showed increase in WBC counts compare to disease control group.   
For investigation of beneficial effects of wheatgrass on immune system, 
reduction in cyclophosphamide-induced neutropenia and carbon clearance test, 
were used in our study. Cyclophosphamide belongs to nitrogen mustard subclass 
of alkylating agents and acts as an immunosuppressive agent by causing 
alkylation of DNA, in turn by interfering in DNA synthesis and function. It is also 
used extensively as an immunosuppressant (Thatte UM et al., 1987). 
Administration of cyclophosphamide (200 mg/kg, sc) produced a decrease in 
neutrophil count in all groups. Water extract of Triticum aestivum decreased 
neutrophil count significantly compared to control group. 
There was significant increase in neutrophil adhesion to nylon fibres and 
increase in macrophage induced phagocytosis in carbon clearance test along 
with reduction in cyclophosphamide induced neutropenia. The methanol extract 
of wheatgrass was more effective than the water extract. The increase in 
adhesion of neutrophil to nylon fibres indicates migration of cells from blood 
vessels and the number of neutrophils reaching the site of inflammation (Shinde 
UA et al., 1999). Increase in neutrophil adhesion to nylon fibres may be due to up 
regulation of β2 integrins that are present on surface of neutrophils through 
which; they adhere firmly to nylon fibres. Hence, it can be inferred that 
wheatgrass causes stimulation of neutrophil migration towards the site of 
inflammation. Results of the present study also suggest that wheatgrass may 
stimulate cell mediated immunity.  
Carbon clearance test was carried out to evaluate effect of drugs on the reticulo-
endothelial system (RES). It is a diffuse system of phagocytic cells, comprising of 
fixed tissue macrophages and mobile macrophages. The phagocytic cells in this 
system comprise of mononuclear phagocyte system (MPS). Macrophages are the 
major differentiated cell in MPS. Cells of the RES and MPS are known to be 
important in the clearance of particles from bloodstream. When colloidal ink 
containing carbon particles is injected directly into the systemic circulation, the 
rate of clearance of carbon from the blood by macrophage is governed by an 
  
  1. Abstract 
17  
 
exponential equation (Das M et al., 1998). Water and methanol extracts of 
wheatgrass showed significant increase in phagocytic index. Hence, we infer that 
wheatgrass may stimulate the reticuloendothelial system. 
Thus, our investigation indicates beneficial effects of wheatgrass in iron overload 
diseases, immnocompromised conditions and thrombocytopenia. We have also, 
isolated a new iron chelator compound from wheatgrass. Further 
characterization as well as detailed toxicological and clinical studies of this new 
iron chelator molecule, may provide a new chemical entity for better 
management of iron overload diseases like thalassemia.    
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2. INTRODUCTION  
The disease-preventive and health-promotive approach of ‘Ayurveda’, which 
takes into consideration the whole body, mind and spirit while dealing with the 
maintenance of health, promotion of health and treating ailments, is holistic and 
finds increasing acceptability in many regions of the world. Ancient Ayurvedic 
physicians had developed certain dietary and therapeutic measures to arrest / 
delay ageing and rejuvenating whole functional dynamics of the body system.  
Health is not merely absence of a disease. Rather, health is defined as positive 
state of well being in which the harmonious development of physical and mental 
capacities of the individual lead to the enjoyment of a rich and full life. Health 
involves primarily the application of medical science for the benefit of individual 
and society. Health is thus, a vital part of a concurrent and integrated program of 
development of all aspects of community life. Considering the importance of 
health, WHO and UNICEF jointly organized an international conference on 
Primary Health Care at Alma Ata, USSR from 6th to 12th September 1978 and took 
a momentous decision to achieve “Health for All” by the year 2000 AD. Now we 
are entering in the year 2007 but the Health for All by the year 2000 still 
continues to be a vision. There are various diseases like tropical diseases, herpes, 
AIDS, cancer, diabetes, thalassemia, certain blood disorders etc. for which the 
cure is yet to be found. 
Iron is an absolute requirement for most forms of life, including humans and 
most bacterial species, because plants and animals all use iron. Iron is essential 
to life because of its unusual flexibility to serve as both an electron donor and 
acceptor. Iron can also be potentially toxic. Its ability to donate and accept 
electrons means that if iron is free within the cell, it can catalyze the conversion 
of hydrogen peroxide into free radicals. Free radicals can cause damage to 
cellular membranes, proteins, and DNA, a wide variety of cellular structures, and 
ultimately kill the cell. To prevent that kind of damage, all life forms that use iron 
bind the iron atoms to proteins. That allows the cells to use the benefits of iron, 
but also limit its ability to do harm (Andrews NC, 1995). Most well-nourished 
  
                     2. Introduction 
19  
 
people have 4 to 5 grams of iron in their bodies. Of this, about 2.5 g is contained 
in the hemoglobin needed to carry oxygen through the blood, and most of the 
rest is contained in ferritin complexes that are present in all cells, but most 
common in bone marrow, liver, and spleen. The liver's stores of ferritin are the 
primary physiologic source of reserve iron in the body (Schrier SL 2005). The 
human body needs iron for oxygen transport. That oxygen is required for the 
production and survival of all cells in our bodies. Human bodies tightly regulate 
iron absorption and recycling. Iron is such an essential element of human life, in 
fact, that humans have no physiologic regulatory mechanism for excreting iron 
(Schrier and Bacon 2005). 
In medicine, iron overload disorders are diseases caused by the accumulation of 
iron in the body. Iron toxicity results when the amount of circulating iron 
exceeds the amount of transferrin available to bind it. The type of acute toxicity 
from iron ingestion causes severe mucosal damage in gastrointestinal tract, 
among other problems. Iron overload is one of the major causes of morbidity in 
all patients with severe forms of thalassemia, regardless of whether they are 
regularly transfused. A variety of other iron overload diseases are present. These 
are thalassemia, sideroblastic anemia, abnormal red cell production 
(dyseryphropoiesis), iron overload secondary to IV therapy, chronic liver disease 
secondary to alcohol, porphyria cutanea tarda. Iron overload can be inherited 
(genetic) or acquired by receiving numerous blood transfusions, getting iron 
shots or injections, or consuming high levels of supplemental iron. Some of the 
genetic disorders that result in iron overload include are hereditary 
hemochromatosis (all types), African iron overload, sickle cell disease, 
thalassemia, X-linked sideroblastic anemia, enzyme deficiencies (pyruvate 
kinase; glucose-6-phosphate dehydrogenase) and very rare protein transport 
disorders aceruloplasminemia and atransferrinemia. None of these conditions 
should be confused with polycythemia vera (PV), which is not an iron disorder, 
but a condition where the bone marrow produces too many blood cells (red, 
white and platelet). People with PV have abnormally high hemoglobin and are at 
risk for a stroke and progressing to acute myelogenous leukemia (AML).   
Excess iron in vital organs, even in mild cases of iron overload, increases the risk 
for liver disease (cirrhosis, cancer), heart attack or heart failure, diabetes 
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mellitus, osteoarthritis, osteoporosis, metabolic syndrome, hypothyroidism, 
hypogonadism, numerous symptoms and in some cases premature death. Iron 
mismanagement resulting in overload can accelerate such neurodegenerative 
diseases as Alzheimer’s, early-onset Parkinson’s, Huntington’s, epilepsy and 
multiple sclerosis. Iron overload is major problem found in thalassemia major 
patients. In untransfused patients with severe ß-thalassemia, abnormally 
regulated iron absorption results in increases in body iron burden that may, 
depending on the severity of erythroid expansion, vary between 2 and 5 grams 
per year (Pippard et al., 1997, Pootrakul et al., 1988). Regular transfusions may 
double this rate of iron accumulation. Although most clinical manifestations of 
iron loading do not appear until the second decade of life in inadequately 
chelated individuals, evidence from serial liver biopsies in young patients 
indicates that the deleterious effects of iron are mediated much earlier. After 
approximately one year of transfusions, iron is deposited in parenchymal tissues, 
where it may cause significant toxicity as compared to that within 
reticuloendothelial cells (Hershko et al., 1998). As iron loading progresses, the 
capacity of serum transferrin, the main transport protein of iron, to bind and 
detoxify iron may be exceeded. Thereafter, the non-transferrin-bound fraction of 
iron within plasma may promote generation of free hydroxyl radicals, 
propagators of oxygen-related damage (Hershko et al., 1998). The effectiveness 
of an iron-chelating agent depends in part on its ability to bind non-transferrin 
bound plasma iron over sustained periods of time, thereby ameliorating iron-
catalyzed toxicity of free radicals.  
Synthetic agents like desferrioxamine and deferiprone used for the treatment of 
iron overload in thalassemia are accompanied by serious side effects and certain 
limitaions including need for Parenteral administration, arthralgia, nausea, 
gastrointestinal symptoms, fluctuating liver enzyme levels, leucopenia, 
agranulocytosis and zinc deficiency and obviously the heavy cost. In addition, 
they are not suitable for use during pregnancy (Hebbel et al., 1990; Grinberg et 
al., 1995; Kukongviriyapan et al., 2008). Compared to synthetic drugs, herbal 
preparations are frequently less toxic with fewer side effects. Therefore the 
search for more effective and safer treatment of thalassemia and other blood 
disorders has become an area of current research activity.  The poor oral 
bioavailability, short plasma half-life and severe side effects of available 
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chelators are still not optimal (Filburn et al., 2007; Rachmilewitz et al., 1979; 
Livrea et al., 1996). Within this context and taking in consideration the relative 
paucity of iron chelating agents it is not surprising that clinical scientists put a 
great effort towards finding any potentially useful sources in order to obtain the 
maximum possible benefit with the least possible harm (Loukopoulos, 2005; 
Ebrahimzadeh et al., 2007; Mahmoudi et al., 2007; Pourmorad et al., 2007).  
Despite the advances of combinatorial chemistry, natural products remain a 
major source of innovative therapeutic agents for numerous ailments including 
infectious diseases, cancer, lipid disorders, thalassema, and several blood 
disorders. Further, they serve as lead compounds for drug development and are 
proven to be invaluable biochemical tools for the identification of novel 
biological targets. For thousands of years, mankind has known about the benefits 
of drugs from nature. Plant extracts like wheatgrass juice have been highly 
regarded for their curative effects by ancient civilizations. Even today, plant 
materials remain an important resource for combating illnesses. WHO has 
approved the use of traditional medicines as a part of health programme. To 
pursue research in these systems of medicine, several USA agencies and 
institutions such as FDA and National Institute of Health have setup separate 
wings. According to the WHO survey 80% of the populations living in the 
developing countries rely almost exclusively on traditional medicine for the 
primary health care needs. In almost all the traditional medicine, the medicinal 
plants play a major role and constitute the backbone of the traditional medicine. 
The potential of plant as a source for new drugs is yet to be unexplored 
systematically. Among the estimated 250,000-400,000 plant species, only 6% 
have been studied for biological activity and about 15% have been investigated 
phytochemically (Verpoorte et al., 1998; Cragg et al., 1997; Balandrin et al., 
1985). India has an ancient heritage of traditional medicine. Materia Medica of 
India provides lots of information on the folklore practices and traditional 
aspects of therapeutically important natural products. Indian traditional 
medicine is based on various system including Ayurveda, Siddha and Unani. With 
the emerging interest in the world to adopt and study the traditional system and 
to exploit their potentials based on different healthcare systems, the evaluation 
of the rich heritage of the traditional medicine is essential. Further, treatment 
with, one such traditional herbal drug viz. Wheatgrass, on patients with ß-
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thalassemia (major) has been reported to have beneficial effects by decreasing 
iron overload (Desai et al., 2005). Hence, in the present project we planned to 
investigate iron chelating potential of wheatgrass and its various extracts, in iron 
overload condition.  
Modern science has already accepted the potential of the herbs as a source of 
new bio-active constituents. There are numerous plants derived drugs of 
unknown chemical structure that have been found clinically useful in different 
alternative system of medicine including Ayurveda, Homeopathy and Unani 
system of medicine.  The plants are a rich reservoir of potential leads for drug 
discovery against various disorders. Almost half of the useful drugs today used 
for various diseases are derived from natural sources. Only less than two percent 
of all the plants available on the earth have been subjected to pharmacological 
investigations. Research on the medicinal herbs can offer useful drugs in time to 
come for the treatment of chronic diseases like asthma and diabetes etc. The 
global market of herbal drugs is increasing very rapidly and it is expected to 
touch the $5 trillion by end of 2005 (Pharma Business, 2000). The recent 
development of the science of phyto-pharmaceuticals has generated new 
enthusiasm in herbal drug research to discover new medicines (Patel and Saluja, 
2002). Looking at the dire need of a new safe and economical iron chelating 
molecule, we resolved to isolate probable active constituent of wheatgrass 
responsible for its possible chelating activity.  
Wheat (Triticum species) a cereal grass of the Gramineae (Poaceae) family is the 
world's largest edible grain cereal-grass crop. Wheat has been a food crop for 
mankind since the beginning of agriculture. For over fifty years, researchers have 
known that the cereal plant, at this young green stage, is many times richer in the 
levels of vitamins, minerals and proteins as compared to seed kernel, or grain 
products of the mature cereal plant (Schnabel 1940). The young germinated 
plant is a factory of enzyme and growth activity. In the early stages of growth 
they store large amounts of vitamins and proteins in the young blades. After 
jointing stage, the nutritional level in the leaves drops rapidly while the fiber 
content increases rapidly (Kohler 1944). Agriculturally, important species of 
Triticum include - Triticum aestivum, Triticum durum and Triticum dicoccum. 
Wheatgrass has been traditionally used, since ancient times, to treat various 
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diseases and disorders. Presently, there are number of wheatgrass suppliers, in 
almost all cities of India, supply fresh wheatgrass, on daily basis to their regular 
customers by home-delivery system for various ailments and as a health tonic. 
Dr. Ann Wigmore, U. S. A. founder director of the Hippocrates Health Institute, 
Boston, U.S.A. was one of the proponents of the ‘‘Wheatgrass Therapy”. Dr. 
Wigmore claimed that wheatgrass is a safe and effective treatment for ailments 
such as high blood pressure, some cancers, obesity, diabetes, gastritis, ulcers, 
anemia, asthma and eczema. Scientific reports on nutritional analysis of 
wheatgrass have been published frequently in various journals (Kohler 1953, 
Hamilton et al., 1988, Laboratory Analyses 1989). These reports and the 
chemical analyses undertaken reveal that wheatgrass is rich in chlorophyll, 
minerals like magnesium, selenium, zinc, chromium, antioxidants like beta-
carotene (pro-vitamin A), vitamin E, vitamin C, antianemic factors like vitamin 
B12, iron, folic acid, pyridoxine and many other minerals, amino acids and 
enzymes, phenol and flavonoid which have significant nutritious and medicinal 
value (Wigmore 1985). Since, iron overload induces increased oxidative stress and 
wheatgrass is known to contain considerable amount of antioxidants, we decided 
to investigate antioxidant benefits of wheatgrass in iron overload condition.    
Platelets are made in the bone marrow similar to other cells in blood such as, 
white blood cells and red blood cells. Platelets originate from megakaryocytes 
which are large cells found in the bone marrow. Platelets, in general, have a brief 
7 to 10 days life in blood, after which they are removed from the blood 
circulation. The number of platelets in the blood is referred to as the platelet 
count and is normally between 150,000 to 450,000 per micro liter of blood. 
Platelet counts less than 150,000 are termed thrombocytopenia (Maton et al, 
1993). There are a wide range of botanical sources and wide range of active 
constituents that might ultimately contribute to haemostatic action, including 
essential oils, flavonoids, saponins, and alkaloids. The possible mechanisms of 
action of the hemostatic herbs include: increasing the production of platelets, 
promoting the ability of platelets to aggregate when there is blood leakage, 
decreasing capillary permeability, contracting peripheral blood vessels, 
inhibiting autoimmune attack against platelets. Dr. Wigmore in her programme 
the “wheatgrass” made several clinical trials on wheatgrass and reported that 
plants are a safe and effective treatment for anemia and various bleeding 
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disorder like hemophilia and thrombocytopenia (Wigmore 1985). These effects 
should be expected to be observed within a few days of administering the herbs.  
In this context, we decided to investigate beneficial effects of wheatgrass in 
treatment of thrombocytopenia and other bleeding disorders. 
The immune system is a remarkably effective structure that incorporates 
specificity, inducibility and adaptation. Failures of host defense do occur, 
however, and fall into three broad categories: immunodeficiencies, 
autoimmunity and hypersensitivities. The immune system is involved in the 
etiology as well as pathophysiological mechanisms of many diseases. Modulation 
of the immune responses to alleviate the diseases has been of interest for many 
years and the concept of ‘Rasayana’ in Ayurveda is based on related principles 
(Sharma P 1983). Indian medicinal plants are a rich source of substances which 
are claimed to induce paraimmunity, the non-specific immunomodulation of 
essentially granulocytes, macrophages, natural killer cells and complement 
functions (Sainis 1997). Ayurveda, the Indian traditional system of medicine, lays 
emphasis on promotion of health concept of strengthening host defenses against 
different diseases (Thatte 1986). Dr. Wigmore’s opinions are based on her 
experiences. A few clinical studies, have verified that some disease conditions 
can be benefited by the use of wheatgrass. Remarkably, a relatively large number 
of studies indicate that food factors and nutrients found in wheatgrass may 
provide beneficial in immunological disorders. Hence, we made an attempt to 
assess immunomodulatory potential of wheatgrass, using various animal models.   
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In nutshell the objectives of the present project were –  
1. To carry out pharmacognostic study of Triticum aestivum. 
2. To carry out phytochemical studies of Triticum aestivum (Wheatgrass) 
and it’s various extracts. 
3. To evaluate iron chelating activity of various extracts of Triticum 
aestivum.  
4. Isolation of iron chelating compound from extract of Triticum aestivum 
using column chromatography. 
5. To evaluate iron chelating activity of isolated compound of Triticum 
aestivum using pre-clinical study.  
6. To investigate anti-oxidant property of Triticum aestivum in iron overload 
condition. 
7. To investigate therapeutic benefit of Triticum aestivum in 
thrombocytopenia. 
8. To investigate immunomodulatory activity of Triticum aestivum.  
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3. REVIEW OF LITERATURE                                                                        
 
 
  
Iron is an absolute requirement for most forms of life, including humans and 
most bacterial species, because plants and animals all use iron. Iron is essential 
to life because of its unusual flexibility to serve as both an electron donor and 
acceptor. Iron can also be potentially toxic. Its ability to donate and accept 
electrons means that if iron is free within the cell, it can catalyze the conversion 
of hydrogen peroxide into free radicals. Free radicals can cause damage to 
cellular membranes, proteins, and DNA, a wide variety of cellular structures, and 
ultimately kill the cell. To prevent that kind of damage, all life forms that use iron 
bind the iron atoms to proteins. That allows the cells to use the benefits of iron, 
but also limit its ability to do harm (Andrews NC 1995). 
Body iron and its physiological role  
Most well-nourished people have 4 to 5 grams of iron in their bodies. Of this, 
about 2.5 g is contained in the hemoglobin needed to carry oxygen through the 
blood, and most of the rest (approximately 2 grams in adult men, and somewhat 
less in women of childbearing age) is contained in ferritin complexes that are 
present in all cells, but most common in bone marrow, liver, and spleen. The 
liver's stores of ferritin are the primary physiologic source of reserve iron in the 
body. The reserves of iron in adults tend to be lower in children and women of 
child-bearing age, than in men and in the elderly. Women who must use their 
stores to compensate for iron lost through menstruation, pregnancy or lactation, 
have lower body stores, which may consist of 500 mg or even less (Schrier SL 
2005).  
Of the body's total iron content, about 400 mg is devoted to cellular proteins that 
use iron for important cellular processes like storing oxygen (myoglobin), or 
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performing energy-producing redox reactions (cytochromes). A relatively small 
amount (3-4 mg) circulates through the plasma, bound to transferrin (Fleming 
and Bacon, 2005). Because of its toxicity, free soluble iron (soluble ferrous ions 
Fe (II)) is kept in low concentration in the body. The most important group of 
iron-binding proteins contains the heme molecules, all of which contain iron at 
their centers. Humans and most bacteria use variants of heme to carry out redox 
reactions and electron transport processes. These reactions and processes are 
required for oxidative phosphorylation. That process is the principal source of 
energy for human cells; without it, most types of cells would die. The iron-sulfur 
proteins are another important group of iron-containing proteins. Some of these 
proteins are also essential parts of oxidative phosphorylation. Humans also use 
iron in the hemoglobin of red blood cells, in order to transport oxygen from the 
lungs to the tissues and to export carbon dioxide back to the lungs. Iron is also an 
essential component of myoglobin to store and diffuse oxygen in muscle cells 
(Fleming and Bacon, 2005). 
The human body needs iron for oxygen transport. That oxygen is required for the 
production and survival of all cells in our bodies. Human bodies tightly regulate 
iron absorption and recycling. Iron is such an essential element of human life, in 
fact, that humans have no physiologic regulatory mechanism for excreting iron. 
Most humans prevent iron overload solely by regulating iron absorption. Those 
who cannot regulate absorption well enough get disorders of iron overload. In 
these diseases, the toxicity of iron starts overwhelming the body's ability to bind 
and store it (Schrier and Bacon, 2005).  
Absorption of iron from diet 
The absorption of dietary iron is a variable and dynamic process. The amount of 
iron absorbed compared to the amount ingested is typically low, but may range 
from 5% to as much as 35% depending on circumstances and type of iron. The 
efficiency with which iron is absorbed varies depending on the source. Generally 
the best-absorbed forms of iron come from animal products. Absorption of 
dietary iron in iron salt form (as in most supplements) varies somewhat 
according to the body's need for iron, and is usually between 10% and 20% of 
iron intake. Absorption of iron from animal products, and some plant products, is 
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in the form of heme iron, and is more efficient, allowing absorption of from 15% 
to 35% of intake. Heme iron in animals is from blood and heme containing 
proteins in meat and mitochondria, whereas in plants, heme iron is present in 
mitochondria in all cells that use oxygen for respiration (Andrews NC 1995). 
Like most mineral nutrients, the majority of the iron absorbed from digested 
food or supplements is absorbed in the duodenum by enterocytes of the 
duodenal lining. These cells have special molecules that allow them to move iron 
into the body. To be absorbed, dietary iron can be absorbed as part of a protein 
such as heme protein or must be in its ferrous Fe2+ form. A ferric reductase 
enzyme on the enterocytes brush border, Dcytb, reduces ferric Fe3+ to Fe2+. A 
protein called divalent metal transporter DMT1, which transports all kinds of 
divalent metals into the body, then transports the iron across the enterocyte's 
cell membrane and into the cell. These intestinal lining cells can then either store 
the iron as ferritin, which is accomplished by Fe3+ binding to apoferritin (in 
which case the iron will leave the body when the cell dies and is sloughed off into 
feces) or the cell can move it into the body, using a protein called ferroportin. 
The body regulates iron levels by regulating each of these steps. For instance, 
cells produce more Dcytb, DMT1 and ferroportin in response to iron deficiency 
anemia (Berg J et al., 2001).  
Our body’s rates of iron absorption appear to respond to a variety of 
interdependent factors, including total iron stores, the extent to which the bone 
marrow is producing new red blood cells, the concentration of hemoglobin in the 
blood, and the oxygen content of the blood. We also absorb less iron during times 
of inflammation. Recent discoveries demonstrate that hepcidin regulation of 
ferroportin is responsible for the syndrome of anemia of chronic disease. While 
Dcytb is unique to iron transport across the duodenum, ferroportin is distributed 
throughout the body on all cells which store iron. Thus, regulation of ferroportin 
is the body's main way of regulating the amount of iron in circulation. 
Hephaestin, a ferroxidase that which can oxidize Fe2+ to Fe3+ and is found mainly 
in the small intestine, helps ferroportin transfer iron across the basolateral end 
of the intestine cells. Iron absorption from diet is enhanced in the presence of 
vitamin C and diminished in the presence of calcium. (Berg J et al., 2001) 
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Figure 3.1: Iron balance in human body (Jonathan Himmelfarb, 2007) 
 
Regulation of iron levels is a task of the whole body, as well as for individual 
cells. When body levels of iron are too low, then hepcidin in the duodenal 
epithelium is decreased. This causes an increase in ferroportin activity, 
stimulating iron uptake in the digestive system. The reverse occurs when there is 
an iron surplus. In individual cells, an iron deficiency causes responsive element 
binding protein to iron responsive elements on mRNA for transferrin receptors, 
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resulting in increased production of transferrin receptors. These receptors 
increase binding of transferrin to cells, and therefore stimulating iron uptake. 
Iron transfer/recycling 
Iron is not free in circulation but exists as transferrin (bound to apotransferrin). 
Most of iron used for red blood cell hemoglobin production is obtained from 
hemoglobin breakdown of senescent RBCs (called recycling). When red blood 
cells reach end of their lifespan (senescent), they are phagocytized by 
macrophages (in the spleen, liver, bone marrow). Hydrolytic enzymes in 
macrophages degrade the ingested RBCs and release hemoglobin. Proteolytic 
digestion of hemoglobin liberates heme and globins. Globins are broken down to 
amino acids which can be used for protein production. The iron is released from 
heme, leaving a porphyrin ring which is converted to bilirubin. For more 
information on this, refer to the page on extravascular hemolysis). Once iron is 
released from the heme, it is utilized by the cell (iron is an essential component 
of many enzymes), exported (via ferroportin), or stored as ferritin (like 
enterocytes). In macrophages, ceruloplasmin (which like hephaestin in intestinal 
cells also requires copper) is a ferroxidase and facilitates transfer of macrophage 
iron to transferrin. So copper deficiency decreases iron release from 
macrophages and affects iron absorption. Like enterocytes, hepcidin down 
regulates ferroportin causing iron sequestration in macrophages. 
Most of the iron in the body is hoarded and recycled by the reticuloendothelial 
system, which breaks down aged red blood cells. However, people lose a small 
but steady amount by sweating and by shedding cells of the skin and the mucosal 
lining of the gastrointestinal tract. The total amount of loss for healthy people in 
the developed world amounts to an estimated average of 1 mg a day for men and 
1.5–2 mg a day for women with regular menstrual periods. People with 
gastrointestinal parasitic infections, more commonly found in developing 
countries, often lose more (Baker MD 2003). This steady loss means that people 
must continue to absorb iron. They do so via a tightly regulated process that 
under normal circumstances protects against iron overload. 
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Iron uptake by eythroid progenitors 
Transferrin-bound iron (from absorption of dietary iron in the intestine or 
released by macrophages) binds to transferrin receptors, which are highly 
expressed on the surface of red cell precursors, and is taken up into the cells 
where it is used to form hemoglobin. Erythroid progenitors cluster around 
macrophages in the bone marrow and spleen (figure 3.2), because they are 
obtaining their iron (required for hemoglobin synthesis) from these iron-storing 
cells, as well as from circulating transferrin. 
Excess iron is dangerous, because it promotes free radical production. Whole 
body iron levels are regulated primarily at the level of absorption by enterocytes, 
there is no regulated pathway for active excretion of iron (can only occur by 
bleeding or sloughing of iron-laden enterocytes). Regulation of iron uptake by 
enterocytes and release of iron stores from macrophages and hepatocytes is 
mediated by the hormone hepcidin, and its effect on ferroportin. Hepcidin 
decreases serum iron by decreasing iron absorption and preventing 
macrophages from releasing iron (causing iron sequestration). Hepcidin is 
regulated by iron levels and erythropoiesis. Increased iron will unregulated 
hepcidin which then decreases iron and vice versa. Active erythropoiesis inhibits 
hepcidin (allowing iron to be absorbed/released for hemoglobin synthesis). 
Hepcidin is increased by inflammatory cytokines, particularly IL6, and reduces 
available iron during inflammatory processes. Inflammation thus causes a 
"functional" iron deficiency because iron is not released from macrophages 
(results in increased iron stores). This contributes to the anemia of inflammatory 
disease. 
Iron absorbed from the intestine is stored as ferritin in intestinal epithelium or 
transported in plasma as transferrin. Erythroid progenitors obtain iron for 
hemoglobin synthesis from plasma transferrin or from recycling of senescent 
erythrocytes by macrophages in bone marrow, spleen and liver. Iron that is in 
excess for that required for hemoglobin production is stored in macrophages as 
ferritin, which is oxidized to hemosiderin. These stores can be released from 
macrophages in times of need (increased erythropoiesis). 
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Figure 3.2: Iron absorption and recycle in human body 
 
In normal subjects when a red cell is broken down into iron and protein, the Iron 
released is recycled. Iron balance is maintained by limiting iron absorption from 
gut. Normal iron absorption is 1-1.5 mg/day; additional iron is absorbed only 
when it is required. Iron absorption is proportional to severity of anemia, serum 
iron levels, erythropoesis (Formation of RBCs), amount of iron in the food, 
presence of vitamin C, presence of sugars and other amino acids. While 
absorption of iron is inhibited by presence of high fiber diet, phytates, tannic 
which binds with iron etc. 
 
Iron deficiency anemia (or iron deficiency anaemia) is a common anemia that 
occurs when iron loss (often from intestinal bleeding or menses) occurs, and/or 
the dietary intake or absorption of iron is insufficient. In iron deficiency, 
hemoglobin, which contains iron, cannot be formed. (Brady PG, 2007)  
Iron deficiency is the most common single cause of anemia worldwide, 
accounting for about half of all anemia cases. It is more common in women than 
men. Estimates of iron deficiency world wide range very widely, but the number 
almost certainly exceeds one billion persons globally. Worldwide, the most 
important cause of iron deficiency anemia is parasitic infection caused by 
Iron deficiency disorders 
3.1.1 Physiology of iron i  human body 
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hookworms, whipworms, and roundworms, in which intestinal bleeding caused 
by the worms may lead to undetected blood loss in the stool. These are especially 
important problems in growing children (Calis JC et al., 2008). Malaria infections 
that destroy red blood cells (although the iron is recycled) and chronic blood loss 
caused by hookworms (where the iron is lost) contribute to anemia during 
pregnancy in most developing countries (Dreyfuss ML et al., 2000). In adults of 
post-menopausal age (over 50 years old) the most common cause of iron-
deficiency anemia is chronic gastrointestinal bleeding from nonparasitic causes, 
such as from gastric ulcer, duodenal ulcer or a gastrointestinal cancer. 
Causes of iron deficiency 
• Chronic bleeding (hemoglobin contains iron)  
 Excessive menstrual bleeding 
 Non-menstrual bleeding 
 Bleeding from the gastrointestinal tract (ulcers, hemorrhoids, etc.) 
 Rarely, laryngological bleeding or from the respiratory tract 
• Inadequate intake (special diets low in dietary iron) 
• Substances (in diet or drugs) interfering with iron absorption 
• Malabsorption syndromes 
• Fever where it is adaptive to control bacterial infection 
• Blood donation 
Though genetic defects causing iron deficiency have been studied in rodents, 
there are no known genetic disorders of human iron metabolism that directly 
cause iron deficiency. 
 
Figure 3.3: Different types of anemia 
  
         3. Review of Literature 
34  
 
Iron deficiency anemia is characterized by pallor (reduced amount of 
oxyhemoglobin in skin or mucous membrane), fatigue and weakness. Because it 
tends to develop slowly, adaptation occurs and the disease often goes 
unrecognized for some time. In severe cases, dyspnea (trouble breathing) can 
occur. Unusual obsessive food cravings, known as pica, may develop. Pagophagia 
or pica for ice is a very specific symptom and may disappear with correction of 
iron deficiency anemia. Hair loss and lightheadedness can also be associated with 
iron deficiency anemia. Other symptoms and signs of iron deficiency anemia 
include anxiety often resulting in OCD type compulsions and obsessions, 
irritability or a low feeling, angina, constipation, sleepiness, tinnitus, mouth 
ulcers, palpitations, hair loss, fainting or feeling faint, depression, breathlessness 
on exertion, twitching muscles, tingling, numbness, or burning sensations, 
missed menstrual cycle, heavy menstrual period, slow social development, 
glossitis (inflammation or infection of the tongue), angular cheilitis 
(inflammatory lesions at the mouth's corners), koilonychia (spoon-shaped nails) 
or nails that are weak or brittle, poor appetite, pruritus (itchiness), dysphagia 
due to formation of esophageal webs (Plummer-vinson syndrome), Restless Legs 
Syndrome. (Rangarajan et al., 2007) 
Iron deficiency anemia affects neurological development in infant by decreasing 
learning ability, altering motor functions, and permanently reducing the number 
of dopamine receptors and serotonin levels. Iron deficiency during development 
can lead to reduced myelination of the spinal cord, as well as a change in myelin 
composition. Additionally, iron deficiency anemia has a negative effect on 
physical growth. Growth hormone secretion is related to serum transferrin 
levels, suggesting a positive correlation between iron-transferrin levels and an 
increase in height and weight.  
Anemia can easily diagnose by routine blood tests, which generally include a 
complete blood count (CBC) which is performed by an instrument which gives an 
output as a series of index numbers. Sufficiently low hemoglobin (HGB) by 
definition makes the diagnosis of anemia, and a low hematocrit (HCT) value is 
also characteristic of anemia. If anemia is due to iron deficiency, one of first 
abnormal values to be noted on a CBC, as body's iron stores begin to be depleted, 
will be a high red blood cell distribution width (RDW), reflecting an increased 
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variability in size of red blood cells (RBCs). In the course of slowly depleted iron 
status, an increasing RDW normally appears even before anemia appears. A low 
mean corpuscular volume (MCV) often appears next during the course of body 
iron depletion. It is the result of many red blood cells which are abnormally 
small. A low MCV, a low mean corpuscular hemoglobin (MCH) and/or Mean 
corpuscular hemoglobin concentration (MCHC), and the appearance of the RBCs 
on visual examination of a peripheral blood smear narrows the problem to a 
microcytic anemia (literally, a "small red blood cell" anemia). (NPS News 70) 
Change in lab values in iron deficiency anemia 
Change Parameter 
Decrease ferritin, hemoglobin, MCV 
Increase TIBC, transferrin, RDW 
 
The blood smear of a patient with iron deficiency shows many hypochromic 
(pale and relatively colorless) and rather small RBCs, and may also show 
poikilocytosis (variation in shape) and anisocytosis (variation in size). With 
more severe iron deficiency anemia the peripheral blood smear may show target 
cells, hypochromic pencil-shaped cells, and occasionally small numbers of 
nucleated red blood cells (Mazza, J et al., 1978). Very commonly, the platelet 
count is slightly above the high limit of normal in iron deficiency anemia (this is 
mild thrombocytosis). This effect which was classically postulated to be to high 
erythropoietin levels in the body as a result of anemia, cross-reacting to activate 
thrombopoietin receptors in precursor cells which make platelets; however, this 
mechanistic effect has been searched for and not corroborated. Such slightly 
increased platelet counts present no danger, but remain valuable as an indicator 
even if their mechanistic origin is not yet known. 
If the cause is dietary iron deficiency, eating more iron-rich foods such as beans 
and lentils or taking iron supplements, usually with iron(II) sulfate, ferrous 
gluconate, or iron amino acid chelate ferrous bisglycinate, synthetic chelate 
NaFerredetate EDTA will usually correct the anemia. If anemia does not respond 
to oral treatments, it may be necessary to administer iron parenterally (e.g. as 
iron dextran) using a drip or hemodialysis. Parenteral iron involves risks of 
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fever, chills, backache, myalgia, dizziness, syncope, rash and anaphylactic shock. 
A follow up blood test is essential to demonstrate whether the treatment has 
been effective. Iron supplements should be kept out of the reach of children, as 
iron-containing supplements are a frequent cause of poisoning in children. 
 
In medicine, iron overload disorders are diseases caused by the accumulation of 
iron in the body. Iron overload is one of the major causes of morbidity in all 
patients with severe forms of thalassemia, regardless of whether they are 
regularly transfused. A variety of other iron overload diseases are present. These 
are usually associated with chronic anemias. These are thalassemia, sideroblastic 
anemia, abnormal red cell production (dyseryphropoiesis), iron overload 
secondary to IV therapy, chronic liver disease secondary to alcohol, porphyria 
cutanea tarda. Iron toxicity results when the amount of circulating iron exceeds 
the amount of transferrin available to bind it, but the body is able to vigorously 
regulate its iron uptake. Thus, iron toxicity from ingestion is usually resulting of 
extraordinary circumstances like iron tablet overdose rather than variations in 
diet. The type of acute toxicity from iron ingestion causes severe mucosal 
damage in gastrointestinal tract, among other problems. 
List of iron overload disorders 
Primary iron overload  
• Type 1: Haemochromatosis  
• Type 2: Juvenile hereditary iron overload   
                    (Mendelian Inheritance in Man (OMIM))  
• Type 3: Hereditary iron overload associated to mutations in transferrin 
receptor 2 genes (Mendelian Inheritance in Man (OMIM))  
• Type 4: Hereditary iron overload associated to mutations in the SLC11A3 
gene (Ferroportin/MTP/IREG-1) (Mendelian Inheritance in Man (OMIM))  
• Aceruloplasminaemia (rare disease)    
      (Mendelian Inheritance in Man (OMIM))  
• Congenital atransferrinaemia (rare disease) 
      (Mendelian Inheritance in Man (OMIM))  
• Others (unidentified genes)  
Iron overload in various diseases   
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   Juvenile haemochromatosis (Mendelian Inheritance in Man (OMIM))  
   Neonatal haemochromatosis (Mendelian Inheritance in Man (OMIM))  
 
Secondary iron overload 
• Dietary iron overload  
• Transfusional iron overload  
• Long term haemodialysis  
• Chronic liver disease  
 Hepatitis C  
 Alcoholic cirrhosis, especially when advanced  
 Non-alcoholic steatohepatitis  
• Porphyria cutanea tarda  
• Post-portacaval shunting  
• Dysmetabolic iron overload syndrome  
 
Excess iron in vital organs, even in mild cases of iron overload, increases the risk 
for liver disease (cirrhosis, cancer), heart attack or heart failure, diabetes 
mellitus, osteoarthritis, osteoporosis, metabolic syndrome, hypothyroidism, 
hypogonadism, numerous symptoms and in some cases premature death. Iron 
mismanagement resulting in overload can accelerate such neurodegenerative 
diseases as Alzheimer’s, early-onset Parkinson’s, Huntington’s, epilepsy and 
multiple sclerosis.  
Iron overload can be inherited (genetic) or acquired by receiving numerous 
blood transfusions, getting iron shots or injections, or consuming high levels of 
supplemental iron. Some of the genetic disorders that result in iron overload 
include are hereditary hemochromatosis (all types), African iron overload, sickle 
cell disease, thalassemia, X-linked sideroblastic anemia, enzyme deficiencies 
(pyruvate kinase; glucose-6-phosphate dehydrogenase) and very rare protein 
transport disorders aceruloplasminemia and atransferrinemia. None of these 
conditions should be confused with polycythemia vera (PV), which is not an iron 
disorder, but a condition where the bone marrow produces too many blood cells 
(red, white and platelet). People with PV have abnormally high hemoglobin and 
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are at risk for a stroke and progressing to acute myelogenous leukemia (AML).  
Part of the therapy for PV is phlebotomy.   
Symptoms, signs and diseases resulting from too much iron (iron overload): 
• chronic fatigue  
• joint pain  
• abdominal pain 
• liver disease (cirrhosis, liver cancer) 
• diabetes mellitus   
• irregular heart rhythm  
• heart attack or heart failure  
• skin color changes (bronze, ashen-gray green) 
• loss of period  
• loss of interest in sex  
• osteoarthritis 
• osteoporosis 
• hair loss  
• enlarged liver or spleen 
• impotence  
• infertility  
• hypogonadism  
• hypothyroidism 
• hypopituitarism  
• depression  
• adrenal function problems  
• early onset neurodegenerative disease  
• elevated blood sugar 
• elevated liver enzymes like SGPT, SGOT 
• elevated iron (serum iron, serum ferritin) 
 
Haemochromatosis or haemosiderosis 
Historically, the term haemochromatosis was initially used to refer to what is 
now more specifically called haemochromatosis type 1 (or HFE-related 
hereditary haemochromatosis). Currently, haemochromatosis (without further 
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specification) is mostly defined as iron overload with a hereditary/primary 
cause or originating from a metabolic disorder (American Heritage Medical 
Dictionary, 2004). However, the term is currently also used more broadly to 
refer to any form of iron overload, thus requiring specification of the cause, for 
example, hereditary haemochromatosis. Hereditary haemochromatosis is an 
autosomal recessive disease with estimated prevalence in the population of 2 in 
1,000 in Caucasians, with lower incidence in other races. The gene responsible 
for hereditary haemochromatosis (known as HFE gene) is located on 
chromosome 6; the majority of hereditary haemochromatosis patients have 
mutations in this HFE gene. Hereditary haemochromatosis is characterized by an 
accelerated rate of intestinal iron absorption and progressive iron deposition in 
various tissues that typically begins to be expressed in the third to fifth decades 
of life, but may occur in children. The most common presentation is hepatic 
cirrhosis in combination with hypopituitarism, cardiomyopathy, diabetes, 
arthritis, or hyperpigmentation. Because of the severe sequelae of this disease if 
left untreated, and recognizing that treatment is relatively simple, early 
diagnosis before symptoms or signs appear is important (Pietrangelo and 
Antonello 2010).  
In general, the term haemosiderosis is used to indicate the pathological effect of 
iron accumulation in any given organ, which mainly occurs in the form of 
haemosiderin. Sometimes, the simpler term siderosis is used instead. 
Other definitions distinguishing haemochromatosis or haemosiderosis that are 
occasionally used include: (American Heritage Medical Dictionary, 2004) 
• Haemosiderosis is haemochromatosis caused by excessive blood 
transfusions, that is, haemosiderosis is a form of secondary 
haemochromatosis. 
• Haemosiderosis is hemosiderin deposition within cells, while 
haemochromatosis is hemosiderin within cells and interstitium. 
• Haemosiderosis is iron overload that does not cause tissue damage, while 
haemochromatosis does. 
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• Haemosiderosis is arbitrarily differentiated from haemochromatosis by the 
reversible nature of the iron accumulation in the reticuloendothelial 
system. 
Haemochromatosis may present with the following clinical syndromes include 
cirrhosis of the liver, diabetes due to pancreatic islet cell failure, cardiomyopathy, 
arthritis (iron deposition in joints), testicular failure, tanning of the skin. 
The causes can be distinguished between primary cases (hereditary or 
genetically determined) and less frequent secondary cases (acquired during 
life)( Pietrangelo A, 2003). People of Celtic (Irish, Scottish, Welsh) origin have a 
particularly high incidence of whom about 10% are carriers of the gene and 1% 
sufferers from the condition. 
Primary haemochromatosis 
The fact that most cases of haemochromatosis were inherited was well known 
for most of 20th century, though they were incorrectly assumed to depend on a 
single gene (Cam Patterson 2006). The overwhelming majority actually depends 
on mutations of HFE gene discovered in 1996, but since then others have been 
discovered and sometimes are grouped together as "non-classical hereditary 
haemochromatosis" "non-HFE related hereditary haemochromatosis" or "non-
HFE haemochromatosis". (Mendes and Ana Isabel, 2008)  
Table 3.1: Genetic mutation in various types of haemochromatosis                                             
(Franchini and Massimo, 2006) 
Description Mutation 
Haemochromatosis type 1:                                    
"classical"-haemochromatosis 
HFE 
Haemochromatosis type 2A:                                    
juvenile haemochromatosis 
Haemojuvelin ("HJV", also known as 
RGMc and HFE2) 
Haemochromatosis type 2B:                                    
juvenile haemochromatosis 
Hepcidin antimicrobial peptide 
(HAMP) or HFE2B 
Haemochromatosis type 3 Transferrin receptor-2                                
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(TFR2 or HFE3) 
Haemochromatosis type 4/ 
African iron overload 
Ferroportin                                
(SLC11A3/SLC40A1) 
Neonatal haemochromatosis  (unknown) 
Acaeruloplasminemia (very rare) Caeruloplasmin 
Congenital atransferrinaemia                  
(very rare) 
Transferrin 
GRACILE syndrome (very rare) BCS1L 
 
Most types of hereditary haemochromatosis have autosomal recessive 
inheritance, while type 4 has autosomal dominant inheritance.  
 Secondary haemochromatosis 
• Severe chronic hemolysis of any cause, including intravascular hemolysis 
and ineffective erythropoiesis (hemolysis within the bone marrow). 
• Multiple frequent blood transfusions (either whole blood or just red blood 
cells), which are usually needed either by individuals with hereditary 
anaemias (such as beta-thalassaemia major, sickle cell anaemia, and 
Diamond–Blackfan anaemia) or by older patients with severe acquired 
anaemias such as in myelodysplastic syndromes. 
• Excess parenteral iron supplements, such as can acutely happen in iron 
poisoning 
• Excess dietary iron 
• Some disorders do not normally cause haemochromatosis on their own, but 
may do so in the presence of other predisposing factors. These include 
cirrhosis (especially related to alcohol abuse), steatohepatitis of any cause, 
porphyria cutanea tarda, prolonged haemodialysis, post-portacaval 
shunting. 
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Treatment 
Routine treatment in an otherwise-healthy person consists of regularly 
scheduled phlebotomies (bloodletting). When first diagnosed, the phlebotomies 
may be fairly frequent, perhaps as often as once a week, until iron levels can be 
brought to within normal range. Once iron and other markers are within the 
normal range, phlebotomies may be scheduled every other month or every three 
months depending upon the patient's rate of iron loading. 
For those unable to tolerate routine blood draws, there is a chelating agent 
available for use. The drug desferoxamine binds with iron in the bloodstream 
and enhances its elimination via urine and faeces. Typical treatment for chronic 
iron overload requires subcutaneous injection over a period of 8–12 hours daily. 
Two newer iron chelating drugs that are licensed for use in patients receiving 
regular blood transfusions to treat thalassemia (and, thus, who develop iron 
overload as a result) are deferasirox and deferiprone. 
Thalassemia  
Thalassemia is one of the most common groups of genetic blood disorder. The 
word thalassemia was derived from two Greek words – ‘Thalassa’ meaning the 
sea and ‘haima’ meaning blood. Thomas Benton Cooley (1871-1945) was the first 
American physician to describe the clinical presentation and features of 
unexplained severe anemia and hence it was coined Cooley's anemia. Countries 
like Italy, Greece and Cyprus have the highest frequency of thalassemia cases in 
the world. There exists a thalassemic "belt" that includes the Mediterranean 
passing through West and Central Asian countries like Turkey, Iran, Afghanistan 
onto Pakistan and India and passes on to the South East Asian countries like 
Indonesia, Burma and Thailand. There are an estimated 240 million carriers of 
thalassemia in the world. India has the largest pool of numbering around 30 
million (every 8th carrier of thalassemia is an Indian). The distribution of ß-
thalassemia gene is not uniform in the Indian subcontinent. The highest 
frequency of ß-thalassemia trait is reported in Gujarat (10-15%), followed by 
Sindh (10%), Tamil Nadu (8.4%), Maharashtra (7.04%), Punjab (6.5%) and 
South India (4.3%) (Varawalla et al., 1991, Balgir, 1996, Sukumaran and Master, 
1974). The condition is uncommon south of Vindhyas. Very high rates have been 
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found in certain communities such as Sindhis 12.4% and in Lohana Gujratis 13.6 
%. The reason is attributed to intra-caste and intra-community marriages. It is 
estimated that every year about 10,000 children are born in India with the 
disorders. A staggering sum of Rs. 150 crores is required to be spent every year, 
in terms of cost of ideal maintenance of these children (Varawalla et al., 1991).  
The thalassemias are characterized by impaired production of one or more 
polypeptide chains of globin. Any of the four polypeptides (α, β, ץ, ∂) that occur in 
normal hemoglobin may be involved. However, the most prevalent thalassemia 
syndromes are those that involve diminished or absent synthesis of the α- or β-
globin chains of HbA1 (Weatherall 1997, Jandl 1987, Steinberg 1988). Two 
distinct types of globin chains (each with its individual heme molecule) combine 
to form hemoglobin. One of the chains is alpha (α). The second chain is "non-
alpha". With the exception of the very first weeks of embryogenesis, one of the 
globin chains is always alpha. A number of variables influence the nature of the 
non-alpha chain in the hemoglobin molecule. The fetus has a distinct non-alpha 
chain called gamma (γ). After birth, a different non-alpha globin chain, called 
beta (β), pairs with the alpha chain. The combination of two alpha chains and 
two non-alpha chains produces a complete hemoglobin molecule (a total of four 
chains per molecule). The combination of two alpha chains and two gamma 
chains form "fetal" hemoglobin, termed "hemoglobin F" i.e. (α2 β2). With the 
exception of the first 10 to 12 weeks after conception, fetal hemoglobin is the 
primary hemoglobin in the developing fetus. The combination of two alpha 
chains and two beta chains form "adult" hemoglobin, also called "hemoglobin A" 
i.e. (α2 β2). Although hemoglobin A is called "adult", it becomes the predominant 
hemoglobin within about 18 to 24 weeks of birth.  
The pairing of one alpha chain and one non-alpha chain produces a hemoglobin 
dimer (two chains). The hemoglobin dimer does not efficiently deliver oxygen, 
however. Two dimers combine to form a hemoglobin tetramer, which is 
functional form of hemoglobin. Complex biophysical characteristics of 
hemoglobin tetramer permit exquisite control of oxygen uptake in the lungs and 
release in the tissues that is necessary to sustain life. The genes that encode the 
alpha globin chains are on chromosome 16. Those that encode the non-alpha 
globin chains are on chromosome 11. Multiple individual genes are expressed at 
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each site. Pseudogenes are also present at each location. The alpha complex is 
called the "alpha globin locus", while the non-alpha complex is called the "beta 
globin locus". The expression of the alpha and non-alpha genes is closely 
balanced by an unknown mechanism. Balanced gene expression is required for 
normal red cell function.  
Alpha Thalassemia -  
Alpha thalassemia occurs when one or more of the four alpha chain genes fails to 
function. Alpha chain protein production, for practical purposes, is evenly 
divided among the four genes. With alpha thalassemia, the "failed" genes are 
almost invariably lost from the cell due to a genetic accident. α-thalassemia has 
four manifestations, which correlate with the number of defective genes. (i) 
Silent carrier state. (ii) Mild alpha-thalassemia. (iii) Hemoglobin H disease. (iv) 
Hydrops fetalis. Since the gene defect is almost invariably a loss of the gene, 
there are no "shades of function" to obscure the matter as occurs in beta 
thalassemia.  
Silent carrier state -   
This is the one-gene deletion alpha thalassemia condition. People with this 
condition are hematologically normal. They are detected only by sophisticated 
laboratory methods.  
Mild alpha-thalassemia –  
These patients have lost two alpha globin genes. They have small red cells and a 
mild anemia. These people are usually asymptomatic. Often, physicians 
mistakenly diagnose people with mild alpha-thalassemia as having iron 
deficiency anemia. Iron therapy, of course, does not correct the anemia.  
Hemoglobin H disease –  
These patients have lost three alpha globin genes. The result is a severe anemia, 
with small, misshapen red cells and red cell fragments. These patients typically 
have enlarged spleens. Bony abnormalities particularly involving the cheeks and 
forehead are often striking. The bone marrow works at an extraordinary pace in 
an attempt to compensate for the anemia. As a result, the marrow cavity within 
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the bones is stuffed with red cell precursors. These cells gradually cause the bone 
to "mold" and flair out. Patients with hemoglobin H disease also develop large 
spleens. The spleen has blood-forming cells, the same as the bone marrow. These 
cells become hyperactive and over expand, just as those of the bone marrow. The 
result is a spleen that is often ten-times larger than normal. Patients with 
hemoglobin H disease often are small and appear malnourished, despite good 
food intake. This feature results from the tremendous amount of energy that 
goes into the production of new red cells at an extremely accelerated pace. The 
constant burning of energy by these patients mimics intense aerobic exercise; 
exercise that goes on for every minute of every day.  
Hydrops fetalis –  
This condition results from the loss of all four alpha globin genes. The affected 
individual usually succumbs to the severe anemia and complications before 
birth.  
Beta thalassemia  
The fact that there are only two genes for the beta chain of hemoglobin makes ß-
thalassemia simpler to understand than α-thalassemia (Rund and Rachmilewitz 
1995). Unlike α-thalassemia, ß-thalassemia rarely arises from the complete loss 
of a β-globin gene. The β-globin gene is present, but produces little β-globin 
protein. The degree of suppression varies. The type of thalassemia usually 
carries the name of the under-produced chain(s). The reduction varies from a 
slight decrease to complete absence of production. For example, when beta 
chains are produced at a lower rate, the thalassemia is termed beta+, whereas 
beta0 thalassemia indicates a complete absence of production of beta chains 
from the involved allele. As per the clinical manifestations, ß-thalassemia is 
classified in to three categories, (i) Thalassemia minor, or thalassemia trait (ii) 
Thalassemia intermedia (iii) Thalassemia major. 
Thalassemia minor or thalassemia trait -  
These terms are used interchangeably for people who have small red cells and 
mild (or no) anemia due to thalassemia. These patients are clinically well, and 
are usually only detected through routine blood testing. Physicians often 
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mistakenly diagnose iron deficiency in people with thalassemia trait. Iron 
replacement does not correct the condition. The primary caution for people with 
beta-thalassemia trait involves the possible problems that their children could 
inherit if their partner also has beta-thalassemia trait. These more severe forms 
of beta-thalassemia trait are outlined below. 
Thalassemia intermedia –  
Thalassemia intermedia is a confusing concept. The most important fact to 
remember is that a thalassemia intermedium is a description, and not a 
pathological or genetic diagnosis. Patients with thalassemia intermedia have 
significant anemia, but are able to survive without blood transfusions.  
Thalassemia major  
This is the condition of severe thalassemia in which chronic blood transfusions 
are needed. In some patients the anemia is so severe, that death occurs without 
transfusions. Other patients could survive without transfusions, for a while, but 
would have terrible deformities. While transfusions are life saving in patients 
with thalassemia major, transfusions ultimately produce iron overload. Chelation 
therapy, usually with the iron-binding agent, desferoxamine (Desferal), is needed 
to prevent death from iron-mediated organ injury.  
Cellular pathophysiology  
As discussed earlier, the basic defect in all types of thalassemia is imbalanced 
globin chain synthesis. However, the consequences of accumulation of the 
excessive globin chains in the various types of thalassemia are quite different. In 
beta thalassemia, excessive alpha chains, unable to form Hb tetramers, 
precipitate in the RBC precursors and, in one way or another, produce most of 
the manifestations encountered in all of the beta thalassemia syndromes. This is 
not the situation in alpha thalassemia. The excessive chains in alpha thalassemia 
are gamma chains earlier in life and beta chains later on. Both are able to form 
homotetramers that, although relatively unstable, nevertheless remain viable 
and able to produce soluble Hb molecules such as Bart (4 gamma chains) and H 
(4 beta chains). These basic differences in the 2 main types of thalassemia are 
responsible for the major differences in their clinical manifestations and severity.  
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Figure 3.4: Pathophysiological features of hemolysis and hypercoagulability and 
accumulation of iron in organ in thalassemia 
 
In β-thalassemia, the synthesis and accumulation of excess normal α-globin chain 
within the red cell, lead to the formation of unstable aggregates, which upon 
oxidation, due to oxidative stress generated by iron overload, may precipitate 
and cause cell membrane damage. These deformed cells undergo premature 
destruction either in the bone marrow (extravascular hemolysis) or the 
peripheral circulation (intravascular hemolysis) (Weatherall 1997, Festa 1985). 
This means that both hemolysis and ineffective erythropoiesis cause anemia in 
the patient with beta thalassemia. The ability of some red cells to maintain the 
production of gamma chains, which are capable of pairing with some of the 
excessive alpha chains to produce HbF, is advantageous. Binding some of the 
excess alpha chains undoubtedly reduces the symptoms of the disease. The 
elevated HbF increases oxygen affinity leading to hypoxia, which, together with 
the profound anemia, stimulates the production of erythropoietin. As a result, 
severe expansion of the ineffective erythroid mass occurs leading to severe bone 
expansion and deformities. Both iron absorption and metabolic rate increase, 
adding more symptoms to the clinical and laboratory manifestations of the 
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disease. The large numbers of abnormal red cells processed by the spleen, 
together with its hematopoietic response to the anemia if untreated, results in 
massive splenomegaly, leading to manifestations of hypersplenism.  
Iron overload in thalassemia -  
In untransfused patients with severe ß-thalassemia, abnormally regulated iron 
absorption results in increases in body iron burden that may, depending on the 
severity of erythroid expansion, vary between 2 and 5 grams per year (Pippard 
et al., 1997, Pootrakul et al., 1988). Regular transfusions may double this rate of 
iron accumulation. Although most clinical manifestations of iron loading do not 
appear until the second decade of life in inadequately chelated individuals, 
evidence from serial liver biopsies in young patients indicates that the 
deleterious effects of iron are mediated much earlier. After approximately one 
year of transfusions, iron is deposited in parenchymal tissues, where it may 
cause significant toxicity as compared to that within reticuloendothelial cells 
(Hershko et al., 1998). As iron loading progresses, the capacity of serum 
transferrin, the main transport protein of iron, to bind and detoxify iron may be 
exceeded. Thereafter, the non-transferrin-bound fraction of iron within plasma 
may promote generation of free hydroxyl radicals, propagators of oxygen-related 
damage (Hershko et al., 1998). The effectiveness of an iron-chelating agent 
depends in part on its ability to bind non-transferrin bound plasma iron over 
sustained periods of time, thereby ameliorating iron-catalyzed toxicity of free 
radicals.  
Management of ß-thalassemia major – 
The management requires patients to have life-long regimen of regular blood 
transfusions coupled with iron chelation therapy (Modell 1994, Cao et al., 1997). 
The frequency of blood transfusion requirement increases with growing age. On 
an average transfusion is required every fortnight. Blood transfusion produces 
on long term, serious and unavoidable side-effects because with each unit of 
blood transfused 200 to 250 mg of iron gets deposited in the heart, liver, 
pancreas and other glands in the body. This may lead to heart failure, cirrhosis of 
liver, diabetes mellitus and malfunctioning of other glands. Generally, regular 
blood transfusions and iron chelation treatment with desferoxamine are initiated 
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early in life; therefore, the patients and their families have to sustain regular 
treatment throughout their childhood, adolescent, and adult years (Olivieri et al., 
1994, Zurlo et al., 1989).  
 
Cardiac complications –  
The commonest cause of death in cases of thalassemia major is heart failure. In 
the absence of chelating therapy, iron accumulation results in progressive 
dysfunction of the heart, liver and endocrine glands (Olivieri and Brittenham 
1997). In response to iron loading, human myocytes in vitro upregulate the 
transport of non-transferrin-bound iron (Parkes et al., 1993), thereby possibly 
aggravating cardiac iron loading. Extensive iron deposits are associated with 
cardiac hypertrophy and dilatation, myocardial fiber degeneration and, rarely, 
fibrosis (Buja and Roberts 1971). In many patients abnormal function is 
observed in the absence of symptoms (Fiorillo et al., 2000). In transfused, 
unchelated patients, symptomatic cardiac disease is observed after about ten 
years following the start of transfusions (Wolfe et al., 1985) and may be 
aggravated by myocarditis (Kremastinos et al., 1996) and pulmonary 
hypertension (Aessopos et al., 1995, Du et al., 1997). Survival is determined by 
the magnitude of iron loading within the heart (Brittenham et al., 1994, Olivieri 
et al., 1994). 
Liver damage -  
Iron-induced liver disease is a common cause of death in transfused patients 
(Zurlo et al., 1989). Within two years following the start of transfusions, collagen 
formation (Iancu et al., 1977) and portal fibrosis (Thakerngpol et al., 1996) are 
observed; in the absence of chelating therapy, cirrhosis may develop in the first 
decade of life (Jean et al., 1984). As in cultured heart cells, upregulation of 
transport of non-transferrin-bound iron is observed in cultured hepatocytes 
(Parkes et al., 1995), possibly aggravating iron loading in vivo.  
 
 
Clinical impact of iron overload  
  
 
3.1.1 Physiology of iron in human body 
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Endocrinal disorders -  
In cases of thalassemia major, increasingly severe impairment of the endocrine 
system can be observed as the years go by and as more blood transfusions are 
administered. Iron deposition in the interstitial tissues and in the secreting cells 
of the endocrine glands results in disorders such as diabetes mellitus, 
hypothyroidism, hypoparathyroidism, hypoadrenalism, and hypogonadism. 
Already during the early stages of the disease, involvement of the α and β cells in 
the pancreas manifests itself in the form of disorders affecting insulin secretion 
and glucose tolerance. In transfused patients, iron loading within the anterior 
pituitary results in disturbed sexual maturation in approximately 50% of males 
and females. Diabetes mellitus is observed in about 5% of adults (Cavallo-Perin 
et al., 1995). Chronic iron deposition also damages the thyroid, parathyroid, 
adrenal glands, and exocrine pancreas (Magro et al., 1990, Sklar et al., 1987, 
Gullo et al., 1993) and may provoke pulmonary hypertension, right ventricular 
dilation, and restrictive lung disease (Tai et al., 1996, Piatti et al., 1997). 
Hypofunction of the adrenal cortex may give rise quite early on to an increase in 
melanin production and skin pigmentation, as well as to the appearance of low 
voltage waves in the ECG, which, however, are unaccompanied by any evidence 
of organic damage to the heart. Growth retardation in patients with thalassemia 
major can occur for a number of reasons, depending on how the patient is 
managed. A poorly transfused or non-transfused patient has severe anemia, with 
or without multiple infections and accompanied by failure to thrive. A child on 
regular transfusions without iron chelation therapy will have stunting as a result 
of the iron overload. In this case, the poor growth results from the effect of iron 
on pituitary function, leading to a lack of puberty, and/or from poor liver 
function and a consequent interference with somatomedin metabolism, leading 
to short stature. Desferal treatment itself, if too intensive, has been reported to 
result in short stature. 
Hyperbilirubinaemia and gallstones -  
The severe hemolysis occurring in thalassemia major gives rise to 
hyperbilirubinaemia, which in turn leads to bilirubinuria, a condition causing 
dark brown discoloration of the urine; after the fourth year of life it may also 
result in the formation of gallstones, the incidence of which rises to 75% by the 
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15th year of life. In addition, this hemolysis leads to an increase in the serum 
concentrations of various substances released as the erythrocytes break down, 
e.g. lactic dehydrogenase, alkaline phosphatase, glutamic acid, uric acid, and iron. 
One consequence of the damage sustained by the liver is deficiencies affecting 
blood coagulation factors. 
Splenomegaly -  
The important functions of the spleen are summarized below: A) Immune 
functions, including clearance of particulate matter and microorganisms and 
generation of humoral and cellular response to foreign antigens. B) 
Sequestration of normal and abnormal cells. C) Regulation of portal blood flow. 
D) Site of extramedullary erythropoiesis. Increased erythrocyte production, 
coupled with increased phagocytosis and storage of stroma from broken down 
erythrocytes, leads to hyperplasia of the reticulo-endothelial system. 
Splenomegaly produces enlargement of the abdomen, which may eventually 
assume massive proportions. Hypersplenism is defined as a condition in which 
the spleen removes circulating red blood cells, granulocytes and platelets in 
excessive quantity. Hypersplenism is diagnosed if the following criteria are 
fulfilled: 1) pancytopenia 2) normal or hypercellular bone marrow 3) 
splenomegaly and 4) correction of cytopenia after splenectomy. 
Sexual development -  
Sexual development in these patients shows a stronger correlation with bone age 
rather than with chronological age. Delayed sexual development – like the other 
complications such as cardiac lesions, diabetes mellitus, and liver cirrhosis – 
seems to be largely caused by the hemosiderosis; however, menstruation and 
spermatogenesis appear to be normal in some patients. 
Skeletal changes and facial appearance -  
Changes occurring in the skeleton are due to chronic over activity of the bone 
marrow, which results in widening of the medullary spaces. Included among 
these changes are osteoporosis, thinning of the cortex, and trabecular atrophy. 
Owing to such lesions, deformities of the spinal column tend to occur, as well as 
pathological bone fractures in response to minor injuries25. Excessive 
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prominence of the cheekbones, forehead, and parietal eminence, coupled with 
depression of the root of the nose, gives the face a characteristic Asiatic 
appearance. Premature fusion of the epiphyses in the long bones often leads to 
shortening or angulation of the limbs. Arthropathy, synovitis, and arthralgia of 
the knees and ankles, together with oedema of the ankles and feet, are 
attributable to a combination of secondary haemosiderosis and hyperuricaemia.  
 
Both direct and indirect means for the assessment of body iron are available; no 
single indicator or combination of indicators is ideal for the evaluation of iron 
status in all clinical circumstances. The measurement of plasma or serum ferritin 
is the most commonly used indirect estimate of body iron stores (Brittenham et 
al., 2001). Interpretation of ferritin levels may be complicated by a variety of 
conditions that alter concentrations independently of changes in body iron 
burden, including ascorbate deficiency, fever, acute infection, chronic 
inflammation, acute and chronic hepatic damage, hemolysis and ineffective 
erythropoiesis (Brittenham et al., 2001). Serum iron, transferrin, transferrin 
saturation and transferrin receptor concentration, or urinary iron excretion 
following an infusion of DFO do not quantitatively reflect body iron stores. The 
availability of a simple assay for monitoring non-transferrin-bound plasma iron 
could provide a useful measurement of iron status but has not been applied 
widely (Breuer et al., 2001). A variety of studies have been directed at imaging 
tissue iron by computed tomography, nuclear resonance scattering, and 
magnetic resonance imaging. Measurement of hepatic iron concentration is the 
most quantitative, specific, and sensitive method for determining body iron 
burden Breuer et al., 2001). Iron in biopsy samples is assessed most frequently 
using atomic absorption spectroscopy. 
 
Iron chelating therapy -  
Iron overload may be treated or prevented with a chelating agent capable of 
complexing with iron and promoting its excretion. The only iron-chelating agent 
presently available for clinical use in the US is desferrioxamine (Desferal).  
Assessment of body iron burden 
Treatment of iron overload  
  
 
3.1.1 Physiology of iron in uman body 
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Desferoxamine (Desferal) –  
Desferoxamine is a chelating agent with a strong affinity for iron. Discovered in 
1960 as a result of work undertaken conjointly in the laboratories of Ciba and of 
the Swiss Federal Institute of Technology in Zürich, it was introduced in 1963. 
The active substance of Desferal is desferrioxamine B, an iron-chelating 
compound derived from ferrioxamine B, which is an iron-bearing metabolite 
produced by Actinomycetes (Streptomyces pilosus) and belongs to the group of 
the sideramines. Desferrioxamine B is present in Desferal in the form of the 
methane sulphonate, a chain molecule of the following structure: 
         
                Desferoxamine B     Desferal 
Figure 3.5: Structure of Iron chelator used in iron overload conditions  
Trivalent iron reacts with desferrioxamine B to form ferrioxamine B, an 
octahedral iron complex: Subcutaneous infusion at a daily dose 40 mg/kg over 8-
12 hours has become the standard schedule of delivery for over 20 years.  
Biodistribution and metabolism -  
DFO is hydrophilic, and this property together with its high molecular weight 
means that uptake into cells and subcellular compartments is generally slow 
relative to hydroxypyridinones (such as deferiprone), taking several hours for 
equilibration (Hoyes et al., 1993, Cooper et al., 1996). Uptake into hepatocytes is 
rapid, however, probably by a facilitated process, making access to intrahepatic 
iron relatively efficient (Porter et al., 1988). Due to the positive charge of both 
DFO and FO, egress from cells by diffusion will be slow (Singh et al., 1990). DFO 
is relatively stable for several hours in plasma, and the majority of metabolism 
takes place within hepatocytes by oxidative deamination of the N-terminus, 
yielding metabolite B as the predominant product (Singh et al., 1990). The iron 
free form of metabolite B can diffuse back into plasma rapidly, due to its negative 
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charge (Singh et al., 1990), where it is rapidly cleared from plasma (t1/2 = 1.3 
hours) and eliminated in the urine (Lee et al., 1993). 
Clinical toxicity -  
Toxicity from DFO in thalassemia major is unlikely provided that doses do not 
exceed 40 mg/kg/day, that DFO is not introduced at too young an age (see 
below), and that the dose is reduced as iron loading falls. Systemic reactions with 
fever, muscle aches and arthralgia are uncommon and anaphylaxis may 
occasionally occur. 
Infections –  
There is an increased risk of Yersinia infection in iron overload, and this risk 
increases further with DFO treatment as Yersinia does not make a natural 
siderophore and uses iron from FO to facilitate its growth (Robins-Browne and 
Prig, 1985). Patients who present with diarrhea, abdominal pain or fever should 
stop DFO until appropriate stool samples, blood cultures and serological testing 
can reasonably exclude Yersinia infection. The growth of other organisms (e.g. 
Klebsiella) may also be facilitated by FO and it is wise to withhold DFO in a 
febrile patient until the source of the fever has been identified.  
Deferiprone -  
Pharmacology and pharmacokinetics –  
Deferiprone (1,2 dimethy-3-hydroxypyridin-4-one) is a member of a family of 
hydroxypyridin-4-one (HPO) chelators (Hider et al., 1982) that require three 
molecules fully to bind Fe+3, each molecule providing two co-ordination sites 
(bidentate chelation). The pM of deferiprone for Fe+3 (pM = 20) is less than that 
of DFO, which reflects the lower stability of the iron-chelate complex. Other 
metals such as Ga, Al3+ and In 3+ are bound tightly with relative affinities for 
other metals being Cu2+ > Zn2+ > Ca2+ > Mg2+ (Hider et al., 1994). The molecular 
weight of deferiprone is approximately one-third that of DFO and this together 
with its neutral charge and relative lipophilicity account for its rapid absorption 
from the gut. These same properties also allow more rapid access by deferiprone 
and related HPOs to intracellular iron (Porter et al., 1988), to labile intracellular 
iron (Zanninelli et al., 1997) as well as more rapid access to intra-lysosomal iron 
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pools and to iron containing enzymes (Abeysinghe et al., 1996, Cooper et al., 
1996). 
Deferiprone appears in plasma within 5 to 10 minutes of ingestion, the peak 
concentrations (Cmax) occurring within 1 hour, reaching levels in excess of 300 
µM after oral ingestion of a 50 mg/kg dose (Kontoghiorghes et al., 1990, Al-
Refaie et al., 1995). However, these levels are short-lived with an elimination t1/2 
of 1.52 hours. Unlike DFO, where approximately half of iron excretion is fecal, 
there is little fecal iron excretion with deferiprone (Kontoghiorghes et al., 1988, 
Collins et al., 1994, Olivieri et al., 1990). 
Metabolism -  
Deferiprone is metabolized to the inactive glucuronide that is the predominant 
form recovered in the urine (Lange et al., 1993). 
Toxicities –  
Neutropenia and agranulocytosis: Agranulocytosis is the most serious unwanted 
effect of this drug so far identified. This was initially reported in 3-4% of patients 
treated with deferiprone; mild neutropenia was found in an additional 4% (Al-
Refaie et al., 1992, Al-Refaie et al., 1995).  
Arthropathy: Painful swelling of the joints, particularly the knees, occurs in 6-
39% of patients (Agarwal et al., 1992). This complication usually but not always 
resolves after stopping therapy. Arthritis was the most common side effect in the 
Indian study in which many of the patients were heavily iron overloaded 
(Agarwal et al., 1992). Other unwanted effects include nausea (8%), zinc 
deficiency (14%) and fluctuation in liver function tests (44%) (Al-Refaie et al., 
1995).  
Liver fibrosis: In a retrospective analysis, fibrosis was reported to progress in 5 
of 12 patients on deferiprone and in none of 12 age-matched control subjects 
receiving regular DFO (Olivieri et al., 1998).  
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Thrombocytopenia is a lower than normal number of platelets in the blood. 
Platelets play an important role in clotting and bleeding. Platelets are made in 
the bone marrow similar to other cells in blood such as, white blood cells and red 
blood cells. Platelets originate from megakaryocytes which are large cells found 
in the bone marrow. Platelets, in general, have a brief 7 to 10 days life in blood, 
after which they are removed from the blood circulation. The number of platelets 
in the blood is referred to as the platelet count and is normally between 150,000 
to 450,000 per micro liter (one millionth of a liter) of blood. Platelet counts less 
than 150,000 are termed thrombocytopenia. Platelet counts greater that 450,000 
are called thrombocytosis. (Maton et al., 1993) 
The function of platelets is very important in clotting system. They circulate in 
blood vessels and become activated if there is any bleeding or injury in body. 
Certain chemicals are released from injured blood vessels or other structures 
that signal platelets to become activated and join the other components of the 
system to stop the bleeding. When activated, platelets become sticky and adhere 
to one another and to blood vessel wall at the site of injury to slow down and 
stop bleeding by plugging up the damaged blood vessel or tissue (hemostasis).  
Low platelet count in severe cases may result in spontaneous bleeding or may 
cause delay in normal process of clotting. In mild thrombocytopenia, there may 
be no adverse effects in the clotting or bleeding pathways.  
 
Some of the most common and important causes or thrombocytopenias are 
outlined below.  
1. Decreased platelet production  
Decreased platelet production is usually related to a bone marrow problem 
(agranulocytosis). In most of these conditions, red blood cell and white blood cell 
productions may also be affected. (http://archive.rubicon-foundation.org) 
                                                          vbbbbbbbbbbb 3.2 Thrombocytopenia  
 
                    
 
Pathophysiology of thrombocytopenia 
 
 
3.1.1 Physiology of iron in human body 
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• Viral infections affecting the marrow for example: parvovirus, rubella, 
mumps, varicella (chickenpox), hepatitis C, Epstein-Barr virus, and HIV. 
• Aplastic anemia is a general term used when the bone marrow fails to 
produce any blood cells (red cells, white cells, and platelets), also called 
pancytopenia. This can be caused by some viral infections (parvovirus or 
HIV), medications or radiation, or rarely, it can be congenital (Fanconi's 
anemia). 
• Chemotherapy drugs and thiazide diuretics frequently cause bone marrow 
suppression resulting in thrombocytopenia. 
• Cancers of the bone marrow and blood (leukemia) or cancers of the lymph 
nodes (lymphoma) can cause various degrees of thrombocytopenia. 
• Cancers from other organs can sometimes infiltrate (invade) the bone 
marrow and result in impaired production of platelets. 
• Long term alcohol can cause direct toxicity of the bone marrow. 
• Deficiency of vitamin B12 and folic acid can result in low platelet production 
by the bone marrow. 
2. Increased platelet destruction or consumption 
Increased platelet destruction or consumption can be seen a number of medical 
conditions. They can be divided into immune related and non-immune related 
causes. Many medications can cause low platelet count by causing immunologic 
reaction against platelets, called drug-induced thrombocytopenia. Some 
examples may include:  
• Sulfonamide antibiotics, carbamazepine anti-seizure drug, digoxin, quinine, 
quinidine, acetaminophen, and rifampin.  
• Heparin, a commonly used blood thinner, and similar medications like 
enoxaparin can occasionally induce an immune response against platelets 
resulting in rapid destruction of platelets. This condition is termed heparin-
induced thrombocytopenia or HIT. 
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• Idiopathic thrombocytopenic purpura (ITP) is a condition where the 
immune system attacks platelets. In severe conditions, ITP can result in 
very low platelet counts. 
• Some rheumatologic condition, such as systemic lupus erythematosus (SLE) 
or other autoimmune conditions (connective tissue diseases), can cause 
platelet destruction. 
• Transfusion of blood products and organ transplantation can sometimes 
cause immunologic disturbances resulting in thrombocytopenia.  
• Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic 
syndrome (HUS) are similar conditions that can cause non-immune related 
consumptive thrombocytopenia resulting from some viral illnesses, 
pregnancy, some metastatic cancers, or chemotherapy. Other 
manifestations of these conditions include kidney insufficiency, confusion, 
anemia (hemolytic), and fever.  
• HELLP syndrome (hemolysis elevated liver tests low platelets) is another 
non-immune thrombocytopenia that may occur during pregnancy and can 
include elevation of liver enzyme and anemia (specifically, hemolytic 
anemia or rupturing of red blood cells). 
• Disseminated intravascular coagulopathy (DIC) is a rare but severe 
condition that may be a complication of overwhelming infections, traumas, 
burns, or pregnancy. 
• Injury to or inflammation of blood vessels (vasculitis) and, sometimes, 
artificial heart valves can cause increased destruction of platelets as they 
pass by. 
• Severe infections (sepsis) or trauma can sometimes cause consumptive 
thrombocytopenia (without DIC).  
3. Splenic sequestration 
• Common causes of thrombocytopenia due to splenic enlargement may 
include advanced liver disease (cirrhosis, for example, from chronic 
hepatitis B or C) and blood cancers (leukemias or lymphomas). 
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• Pseudo thrombocytopenia (false thrombocytopenia) is also one of a 
commonly encountered condition where the number of platelets seen on a 
complete blood count analysis (CBC) may falsely appear low because of the 
clumping of platelets together. This can lead to a smaller number of platelets 
seen throughout the slide reviewed by the technician. If this is suspected, the 
blood can be redrawn in a tube with a material that prevents clumping of 
platelets for repeat analysis.  
• Thrombocytopenia can also be present at birth, called neonatal 
thrombocytopenia. Most of these cases can be caused by processes similar to 
above, although, they are occasionally related to rare genetic conditions.  
 
In many instances, thrombocytopenia may have no symptoms, especially if mild, 
and it can be detected only incidentally on routine blood work done for other 
reasons. If thrombocytopenia is severe, for example less than 20 per micro liter, 
it can potentially manifest as increase bleeding when a person is cut or injured or 
increased bleeding during menstrual period.  
Spontaneous bleeding can also happen with severe thrombocytopenia (less than 
10,000 to 20,000 platelets). This type of bleeding usually occurs under the skin 
or the mucus membrane (the inner lining of the oral cavity, gastrointestinal tract, 
or the nasal cavity). Petechiae may be seen in patients with very low platelet 
counts. Petechiae are small (pin head size) red, flat spots seen under the skin on 
the dependent parts of the body because of increased pressure due to gravity, for 
example, on the lower legs. These happen because of bleeding out of the tiny 
blood vessels under the skin or the mucus membrane. Petechiae are generally 
not palpable or painful. 
Other rashes or bruises seen in thrombocytopenia are called purpura, which are 
small, purple spots under the skin as a result of hemorrhage. These are typically 
greater than 3 millimeters in diameter and may represent a confluence of 
petechiae.  
 
Symptoms of thrombocytopenia 
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Thrombocytopenia is usually detected incidentally from routine complete blood 
count (CBC). Platelet counts less than 150,000 are termed thrombocytopenia. If 
thrombocytopenia is seen for the first time, it is prudent to repeat the complete 
blood count in order to rule out pseudo thrombocytopenia. If the repeat CBC 
confirms low platelet counts, then further evaluation can begin. Once detected, 
the cause of thrombocytopenia may be investigated by the doctor. The most 
essential part of this evaluation includes a thorough physical examination and 
medical history of the patient. In the medical history, the complete list of all 
medications is routinely reviewed. Some of the other important components of 
the history include reviewing previous known history of low platelet count, 
family history of thrombocytopenia, recent infections, any previous cancers, 
other autoimmune disorders, or liver disease.  
A review of the symptoms related to excessive bleeding or bruising can also 
provide additional information. As a part of a thorough physical examination, 
special attention may be given to the skin and mucus membrane in the oral 
cavity for petechiae or purpura or other signs of bleeding. On the abdominal 
examination, an enlarged spleen (splenomegaly) can provide important 
diagnostic clues. The urgency to perform additional testing and evaluation is 
largely dependent on how low the platelet count is on the blood count, and what 
the clinical situation may be. For instance, in a person who needs a surgery and 
has a platelet count of less than 50 the investigation will take precedence over 
one whose thrombocytopenia was detected on a yearly blood work with a 
platelet of 100. 
A comprehensive review of the other components of the CBC is one of the most 
important steps in the evaluation of low platelet count. The CBC can tell us 
whether other blood disorders may be present, such as, anemia (low red cell 
count or hemoglobin), erythrocytosis (high red blood cell count or hemoglobin), 
leukopenia (low white cells count), or leukocytosis (elevated white blood cell 
count). These abnormalities may suggest bone marrow problems as the potential 
cause of thrombocytopenia. Abnormally shaped or ruptured red cells 
(schistocytes) seen on the blood smear may suggest evidence of HELLP, TTP, or 
Diagnosis of thrombocytopenia 
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HUS. Another clue in the CBC is the mean platelet volume or MPV, which is an 
estimate of the average size of platelets in the blood. A low MPV number may 
suggest platelet production problem, whereas, a high number may indicate 
increased destruction. 
It is important to also review other blood work including the complete metabolic 
panel, coagulation panel, and urinalysis. Certain abnormalities in these tests can 
suggest advanced liver disease (cirrhosis), kidney problems (renal failure), or 
other pertinent underlying medical conditions. In some causes of 
thrombocytopenia, such as HIT or ITP, additional testing with antibodies or 
assays may be done. Bone marrow biopsy can sometimes be performed if a bone 
marrow problem is suspected.  
 
Treatment is guided by etiology and disease severity. The main concept in 
treating thrombocytopenia is to eliminate the underlying problem, whether that 
means discontinuing suspected drugs that cause thrombocytopenia, or treating 
underlying sepsis. Diagnosis and treatment of serious thrombocytopenia is 
usually directed by a hematologist. 
Specific treatment plans often depend on the underlying etiology of the 
thrombocytopenia. 
Condition Treatment 
Thrombotic thrombocytopenic purpura                        
(is caused by spontaneous aggregation of 
platelets and activation of coagulation in the 
small blood vessels. Platelets are consumed 
in the coagulation process, and bind fibrin, 
the end product of the coagulation pathway. 
These platelet-fibrin complexes form 
microthrombi which circulate in the 
vasculature and cause shearing of red blood 
cells, resulting in hemolysis.) (Moake JL 
2002) 
Application of plasmapheresis. this 
treatment theoretically works by 
removing antibodies directed against 
the von Willebrand factor cleaving 
protease, ADAMTS-13. The 
plasmapheresis procedure also adds 
active ADAMTS-13 protease proteins 
to the patient, restoring a more 
physiological state of von Willebrand 
factor multimers.  
 Treatment of thrombocytopenia 
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Idiopathic thrombocytopenic purpura ITP 
 Prednisone and other corticosteroids  
 Intravenous immune globulin  
 Splenectomy  
 Danazol, Rituximab, Romiplostim  
Heparin-induced thrombocytopenia 
patients are usually treated with a 
type of blood thinner called a direct 
thrombin inhibitor such as lepirudin 
or argatroban, bivalirudin and 
fondaparinux. Platelet transfusions  
Congenital amegakaryocytic 
thrombocytopenia 
Bone Marrow/Stem Cell Transplant is 
the only thing that ultimately cures 
this genetic disease.  
 
 
Prevention of thrombocytopenia  
In general, thrombocytopenia can be prevented if the cause is known and it is 
preventable. If a certain medication is found to induce low platelet count in an 
individual, then its future use needs to be avoided. Alcohol avoidance should be 
encouraged in people with known alcohol-induced thrombocytopenia. Current 
and future use of all heparin products must be avoided in people diagnosed with 
heparin-induced thrombocytopenia. 
 
There are a wide range of botanical sources and wide range of active 
constituents that might ultimately contribute to hemostatic action, including 
essential oils, flavonoids, saponins, and alkaloids. The possible mechanisms of 
action of the hemostatic herbs include: 
• Increasing the production of platelets 
• Promoting the ability of platelets to aggregate when there is blood 
leakage 
• Decreasing capillary permeability 
• Contracting peripheral blood vessels  
• Inhibiting autoimmune attack against platelets 
Herbs for thrombocytopenia 
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These effects should be expected to be observed within a few days of 
administering the herbs.  In most of the Chinese medical reports, improvements 
in symptoms (such as spontaneous bleeding and petechia) were observed within 
about 10 days.  Changes in bone-marrow functions and autoimmune processes 
may require somewhat longer therapy, at least several weeks (typically one to 
three months treatment time), with increasing effect in responsive patients.  The 
reported changes include higher platelet counts and lower IgG levels.   Three 
groups of active constituents are known to have some hemostatic effects and 
may influence autoimmune processes: 
• Anthraquinones, found in rubia and rumex and also an ingredient of rhubarb 
root (which has hemostatic effects, but is not included in the ITP formulas) 
• Flavanoids, found in eclipta and agrimony, and also in scute (used to inhibit 
bleeding but rarely in the ITP formulas) 
• Alkaloids, found in lotus (all plant parts), eclipta, and san-chi. 
The role of essential oils (which usually dilate vessels; some might increase 
bleeding), triterpenes, and saponins found in several of the herbs remains 
unknown.  One of the most frequently-used herbs in the formulas, raw 
rehmannia, contains iridoid glycosides that have hemostatic effects (see: 
Rehmannia).  The same active constituents are found in gardenia, which is 
mentioned in a few of the ITP treatments, as well as in scrophularia and cornus 
(only rarely mentioned in the ITP formulas). 
Table 3.2: Hemostatic herbs used for thrombocytopenia. 
All of the herbs listed here are reported to shorten bleeding time in laboratory testing.   
Common 
Name 
Pinyin 
Botanical Name 
Active Constituents 
Comments 
Agrimony 
xianhecao 
Agrimonia pilosa;  
agrimonin (essential 
oil); agriminolide 
(flavonoid) 
Agrimonin has been developed into a 
hemostatic drug in China, but 
pharmacology studies give conflicting 
results.  The clinical effectiveness is not 
confirmed. 
Biota tops 
ceboye 
Biota orientalis 
essential oils: juniperic 
acid, thujone 
Biota leaves are frequently used (applied 
topically and taken internally) to treat 
alopecia, which is thought to involve an 
autoimmune disorder. 
Eclipta 
hanliancao 
Eclipta prostrata 
(ecliptine, 
Though classified as a yin tonic, it is often 
used to control bleeding.  The flavonoids 
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Common 
Name 
Pinyin 
Botanical Name 
Active Constituents 
Comments 
wedelolactone) may reduce capillary permeability. 
Imperata 
maogen 
Imperata cylindrica 
triterpenes: simiarenol, 
fernenol 
The triterpenes reduce inflammation; 
there may be flavonoids in the flower that 
reduce capillary permeability. 
Lotus node 
oujie 
Nelumbo nucifera 
alkaloids: nuciferine, 
liriodenine 
The alkaloids shorten bleeding time. 
Rubia 
qiancaogen 
Rubia cordifolia 
alizarin, purpurin 
anthraquinones 
The herb extract dilates vessels and 
shortens bleeding time. 
Rumex 
(yangdi; 
suanmo) 
Rumex spp. 
anthraquinones: emodin 
Although not frequently mentioned in the 
Chinese literature, the rumex plants are 
recommended for bleeding in association 
with blood stasis. 
San-chi 
sanqi 
Panax notoginseng 
Dencichine 
This is the key ingredient in the popular 
hemostatic remedy Yunnan Baiyao. 
Sanguisorba 
diyu 
Sanguisorba officinalis 
saponins: sanguisorbin 
Sanguisorba is especially used in cases of 
rectal bleeding. 
 
Hemophilia is a bleeding disorder caused by a deficiency in one of two blood 
clotting factors: factor VIII or factor IX. There are two forms of hemophilia. 
Hemophilia A, which accounts for about 80% of all cases, is a deficiency in 
clotting factor VIII. Hemophilia B is a deficiency in clotting factor IX. The bleeding 
patterns and consequences of these two types of hemophilia are similar. 
Deficiency of clotting factor XI also causes a hereditary bleeding disorder. About 
50% of cases of factor XI deficiency occur among people of Eastern European 
Jewish ancestry. Factor XI deficiency affects both males and females and may 
cause bleeding after injury or surgery. Spontaneous bleeding episodes are 
usually less frequent and milder than in hemophilia A or B. Hemophilia is caused 
by several different gene abnormalities. They are sex-linked, which means that 
the gene abnormalities are inherited through the mother and that nearly 
everyone with hemophilia is male. If you have hemophilia, your blood will not 
clot normally and you may bleed for longer than normal, or you may bleed 
internally, particularly into joints such as your knees, elbows and ankles. 
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The immune system is a remarkably effective structure that incorporates 
specificity, inducibility and adaptation. Failures of host defense do occur, 
however, and fall into three broad categories: immunodeficiencies, 
autoimmunity, and hypersensitivities. Components of Immune system involve 
antigen, antibody (produced by lymphocytes), and antigen presenting cells 
(APCs) like macrophages, basophils, monocytes and direct killer cells like 
neutrophills. 
 
Macrophages engulf antigens, process them internally, then display parts of them 
on their surface together with some of their own proteins. This sensitizes the T 
cells to recognize these antigens. All cells are coated with various substances. CD 
stands for cluster of differentiation and there are more than one hundred and 
sixty clusters, each of which is a different chemical molecule that coats the 
surface. CD8+ is read "CD8 positive." Every T and B cell has about 105 = 100,000 
molecules on its surface. B cells are coated with CD21, CD35, CD40, and CD45 in 
addition to other non-CD molecules. T cells have CD2, CD3, CD4, CD28, CD45, and 
other non-CD molecules on their surfaces. 
The large number of molecules on the surfaces of lymphocytes allows huge 
variability in the forms of the receptors. They are produced with random 
configurations on their surfaces. There are some 1018 different structurally 
different receptors. Essentially, an antigen may find a near-perfect fit with a very 
small number of lymphocytes, perhaps as few as one. T cells are primed in the 
thymus, where they undergo two selection processes. The first positive selection 
process weeds out only those T cells with the correct set of receptors that can 
recognize the MHC molecules responsible for self-recognition. Then a negative 
selection process begins whereby T cells that can recognize MHC molecules 
complexed with foreign peptides are allowed to pass out of the thymus. Cytotoxic 
or killer T cells (CD8+) do their work by releasing lymphotoxins, which cause cell 
lysis. Helper T cells (CD4+) serve as managers, directing the immune response. 
                                                          vbbbbbbbbbbb 3.3 Diseases of Immune system 
 
Cell-mediated immunity and Humoral immunity 
 
 
3.1.1 Physiology of iron in human body 
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They secrete chemicals called lymphokines that stimulate cytotoxic T cells and B 
cells to grow and divide, attract neutrophils, and enhance the ability of 
macrophages to engulf and destroy microbes. Suppressor T cells inhibit the 
production of cytotoxic T cells once they are unneeded, lest they cause more 
damage than necessary. Memory T cells are programmed to recognize and 
respond to a pathogen once it has invaded and been repelled. 
 
 
Figure 3.6: Cell mediated and Humoral immunity 
Humoral immunity 
An immuno competent but as yet immature B-lymphocyte is stimulated to 
maturity when an antigen binds to its surface receptors and there is a T helper 
cell nearby (to release a cytokine). This sensitizes or primes the B cell and it 
undergoes clonal selection, which means it reproduces asexually by mitosis. 
Most of the family of clones becomes plasma cells. These cells, after an initial lag, 
produce highly specific antibodies at a rate of as many as 2000 molecules per 
second for four to five days. The other B cells become long-lived memory cells.  
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Antibodies, also called immunoglobulins or Igs [with molecular weights of 150–
900 Md], constitute the gamma globulin part of the blood proteins. They are 
soluble proteins secreted by the plasma offspring (clones) of primed B cells. The 
antibodies inactivate antigens by, (a) complement fixation (proteins attach to 
antigen surface and cause holes to form, i.e., cell lysis), (b) neutralization 
(binding to specific sites to prevent attachment—this is the same as taking their 
parking space), (c) agglutination (clumping), (d) precipitation (forcing 
insolubility and settling out of solution), and other more arcane methods.  
Constituents of gamma globulin are: IgG-76%, IgA-15%, IgM-8%, IgD-1%, and 
IgE-0.002% (responsible for autoimmune responses, such as allergies and 
diseases like arthritis, multiple sclerosis, and systemic lupus erythematosus). IgG 
is the only antibody that can cross the placental barrier to the fetus and it is 
responsible for the 3 to 6 month immune protection of newborns that is 
conferred by the mother. IgM is the dominant antibody produced in primary 
immune responses, while IgG dominates in secondary immune responses. IgM is 
physically much larger than the other immunoglobulins. 
Immune response is a reaction or response that occurs in the body against a 
great variety of foreign organic macromolecules. The immune response is 
referred to as allergy or hypersensitivity in many instances. 
Immunomodulators: These are substances that modulate the intensity of 
immune responses by inducing maturation of potentially immuno-competent 
cells, expression of epitopes on the cell membranes, differentiation of 
responsiveness to specific antigens or regulation of cell metabolism. 
Immunoenhancers: These are agents that increase the immunity. 
Immunosuppressant: These are agents that suppress the immune system. They 
are useful in organ transplantation, in treatment of autoimmune diseases like 
myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, 
psoriasis, ulcerative colitis, etc. and in treatment of Rh-hemolytic disease. 
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Studies have indicated that immunomodulator drugs also contain antioxidant 
components, which can slow down the cellular ageing process and booster the 
immune system as well. 
 
Immunodeficiencies occur when one or more of the components of the immune 
system are inactive. The ability of the immune system to respond to pathogens is 
diminished in both the young and the elderly, with immune responses beginning 
to decline at around 50 years of age due to immunosenescence (Silva 2007, 
Chandra RK 1997). In developed countries, obesity, alcoholism, and drug use are 
common causes of poor immune function (Chandra RK 1997). However, 
malnutrition is the most common cause of immunodeficiency in developing 
countries (Chandra RK 1997). Diets lacking sufficient protein are associated with 
impaired cell-mediated immunity, complement activity, phagocyte function, IgA 
antibody concentrations, and cytokine production. Deficiency of single nutrients 
such as iron; copper; zinc; selenium; vitamins A, C, E, and B6; and folic acid 
(vitamin B9) also reduces immune responses (Chandra RK 1997). Additionally, 
the loss of the thymus at an early age through genetic mutation or surgical 
removal results in severe immunodeficiency and a high susceptibility to infection 
(Miller JF 2002). 
Immunodeficiency can also be inherited or 'acquired'. Chronic granulomatous 
disease, where phagocytes have a reduced ability to destroy pathogens, is an 
example of an inherited, or congenital, immunodeficiency. AIDS and some types 
of cancer cause acquired immunodeficiency (Joos L 2005). 
 
Overactive immune responses comprise the other end of immune dysfunction, 
particularly the autoimmune disorders. Here, the immune system fails to 
properly distinguish between self and non-self, and attacks part of the body. 
Under normal circumstances, many T cells and antibodies react with “self” 
peptides (Miller JF 1993). One of the functions of specialized cells (located in the 
thymus and bone marrow) is to present young lymphocytes with self antigens 
Immunodeficiencies disorders 
 
Autoimmunity 
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produced throughout the body and to eliminate those cells that recognize self-
antigens, preventing autoimmunity (Sproul TW 2000). 
 
Hypersensitivity is an immune response that damages the body's own tissues. 
They are divided into four classes (Type I–IV) based on the mechanisms involved 
and the time course of the hypersensitive reaction. Type I hypersensitivity is an 
immediate or anaphylactic reaction, often associated with allergy. Symptoms can 
range from mild discomfort to death. Type I hypersensitivity is mediated by IgE, 
which triggers degranulation of mast cells and basophils when cross-linked by 
antigen (Ghaffar 2006). Type II hypersensitivity occurs when antibodies bind to 
antigens on the patient's own cells, marking them for destruction. This is also 
called antibody-dependent (or cytotoxic) hypersensitivity, and is mediated by 
IgG and IgM antibodies (Ghaffar 2006). Immune complexes (aggregations of 
antigens, complement proteins, and IgG and IgM antibodies) deposited in various 
tissues trigger Type III hypersensitivity reactions. Type IV hypersensitivity (also 
known as cell-mediated or delayed type hypersensitivity) usually takes between 
two and three days to develop. Type IV reactions are involved in many 
autoimmune and infectious diseases, but may also involve contact dermatitis 
(poison ivy). These reactions are mediated by T cells, monocytes, and 
macrophages (Ghaffar 2006). 
Another important role of the immune system is to identify and eliminate 
tumors. The transformed cells of tumors express antigens that are not found on 
normal cells. To the immune system, these antigens appear foreign, and their 
presence causes immune cells to attack the transformed tumor cells. The 
antigens expressed by tumors have several sources; (Andersen MH 2006) some 
are derived from oncogenic viruses like human papillomavirus, which causes 
cervical cancer, (Andersen MH 2006) while others are the organism's own 
proteins that occur at low levels in normal cells but reach high levels in tumor 
cells. One example is an enzyme called tyrosinase that, when expressed at high 
levels, transforms certain skin cells (e.g. melanocytes) into tumors called 
melanomas (Castelli C 2000). A third possible source of tumor antigens are 
proteins normally important for regulating cell growth and survival, that 
Hypersensitivity 
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commonly mutate into cancer inducing molecules called oncogenes (Renkvist N 
2001). 
The immune system is involved in the etiology as well as pathophysiological 
mechanisms of many diseases. Modulation of the immune responses to alleviate 
the diseases has been of interest for many years and the concept of ‘rasayana’ in 
Ayurveda is based on related principles. (Sharma P 1983) Indian medicinal 
plants are a rich source of substances which are claimed to induce 
paraimmunity, the non-specific immunomodulation of essentially granulocytes, 
macrophages, natural killer cells and complement functions (Sainis 1997).  
Ayurveda, the Indian traditional system of medicine, lays emphasis on promotion 
of health concept of strengthening host defenses against different diseases 
(Thatte 1986). 
Immunology plays an important and increasing role in the understanding and 
diagnosis of disease. Also it is involved in the etiology as well as the 
pathophysiologic mechanisms of many diseases. Immunology is not only the 
most rapidly developing area of biomedical research but has the great promise of 
major advances in the prevention and treatment of a wide range of disorders. 
Arthritis, ulcerative colitis, asthma, allergy, parasitic and infectious diseases are 
now primarily considered to be immunological disorders, while immune 
mechanisms are also involved in variety of other diseases such as diabetes 
mellitus, cancer, myocardial diseases, cirrhosis and atherosclerosis. 
A significant development has been the new approach to control and manipulate 
the immunological mechanisms by drugs causing immunostimulation or 
immunosupression and their application in therapy. Immunity is the ability of 
the living body or the processes thereof to resist various types of organisms or 
toxins that tend to damage the tissues and organs. 
Free radicals are natural by-products of our own metabolism, such as in 
respiration and some cell mediated immune functions. They are also generated 
through environmental pollutants, cigarette smoke, automobile exhaust, 
radiation, air-pollution, pesticides etc. These are electrically charged molecules 
that attack our cells, tearing through cellular membranes to react and create 
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havoc with the nucleic acids, proteins and enzymes present in the body. These 
attacks by free radicals, collectively known as oxidative stress, are capable of 
causing cells to loose their structure, function and can eventually destroy them. 
A majority of the present day diseases are reported to be due to the shift in the 
balance of the pro-oxidant and the antioxidant homeostatic phenomena in the 
body. Pro-oxidant conditions dominate either due to the increased generation of 
the free radicals caused by excessive oxidative stress of the present day life or 
due to the poor scavenging/quenching in the body caused by depletion of the 
dietary antioxidants. Free radicals may be designated as molecular sharks that 
damage molecules in cell membranes, mitochondria, DNA and are very unstable, 
tend to rob electrons from the molecules in the immediate surroundings in order 
to replace their own losses. Reactive oxygen species (ROS) is collective term, 
which includes not only the oxygen radicals (O˚2, ˚OH and NO˚) but also some 
non-radical oxygen derivatives like hydrogen peroxide (H2O2), hypochlorous acid 
(HOCl) and ozone (O3). 
Over about 100 disorders like rheumatoid arthritis, hemorrhagic shock, CVS 
disorders, cystic fibrosis, metabolic disorders, neurodegenerative disorders, 
gastrointestinal ulcerogenesis and AIDS have been reported as ROS mediated. 
Some specific ROS mediated diseases include alzheimer’s disease, parkinson’s 
disease, atherosclerosis, cancer, down’s syndrome and ischemic reperfusion 
injury in different tissues including heart, liver, brain, kidney and 
gastrointestinal tract. The role played by ROS in stress induced gastric ulcer and 
inflammatory bowl diseases have been well established.  
Antioxidant defenses include the antioxidant enzymes like superoxide dismutase 
(SOD), CAT, and glutathione peroxidase (GSH-px) etc. It also includes proteins 
that minimize the availability of peroxidase such as iron ions, copper ions and 
heame and law molecular mass agents visually ascorbic acid, α- tocopherol that 
scavenge ROS (Singh VK et al,1996). 
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Table 3.3: Indigenous rasayana plants with suggested immunomodulatory 
properties: (Gulati K et al., 2002) 
Botanical Name Ayurvedic Name 
Acorus calamus Vacha 
Abutilon indicum Atibala 
Aloe vera Ghrit-Kumari 
Argyreia speciosa Vriddhadara 
Asparagus racemosus Satavari 
Azadirachta indica Nimba 
Bacopa monnieri Nir-brahmi 
Boerhaavia diffusa Sothaghni 
Cissampelos pareira Paatha 
Commiphora mukul Guggulu 
Convolvulus pluricaulis Shankhpushpi 
Curculigo orchioides Krishna Musalee 
Curcuma longa Haridra 
Desmodium gangeticum Shalaparni 
Dioscorea bulbifera Raktalukum 
Emblica officinalis Aamalaki 
Embelia ribes Vidanga 
Glycerrhiza glabra Yashtimadhu 
Gmelina arborea Kasmari 
Hemidesmus indicus Anantamula 
Ipomoea digitata Vidaree 
Leptadenia reticulate Jeevantee 
Piper longum Pippali 
Plumbago zeylanica Chitrak 
Psoralea corylifolia Vakuchibheda 
Pterocarpus marsupium Bijasar 
Semecarpus anacardium Bhallatak 
Sida spinosa Nagbala 
Sida cordifolia Bala 
Solanum nigrum Kakamachi 
Sphaeranthus indicus Mundi 
Terminalia bellirica Bibhitaka 
Terminalia chebula Haritaki 
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Tinospora cordifolia Guduchi 
Withania somnifera Ashwagandha 
 
Oxidative stress -  
Free radicals and oxidative stress -  
Free radicals and reactive oxygen species (ROS) are short-lived reactive chemical 
species having one or more electrons with unpaired spins. The roles for such 
electronically activated species (e.g., superoxide and singlet oxygen) in the 
normal function of cells and tissues and in the etiology of certain diseases in man 
have been extensively studied. Radical generating processes may be key 
components in the toxicity of many drugs (Reynolds et al., 1980, Reynolds et al., 
1981, Pryor 1980, McGinness et al., 1978, McGinness et al., 1982) in 
antimicrobial defense (Babior 1982, Hammerschmidt and Jacob 1982) and in 
inflammation (Kuehl et al., 1982). The generation of reactive oxygen species 
(ROS) is a steady-state cellular event in respiring cells.  
 
 
 
 
Figure 3.7 - Formation of reactive oxygen species. 
In biologic systems molecular oxygen is reduced to water in four one-electron 
steps. Reduction of molecular oxygen to superoxide, and of peroxide to hydroxyl 
radical are "spin forbidden" and thus are slow unless catalyzed by a heavy ion. 
Alternative spin-permitted pathways for the reduction of 02 include interaction 
of molecular oxygen with the excited triple state of another molecule to produce 
singlet oxygen from light or an excited state molecule and jumps to a higher 
energy orbital on the same atom (Kuel et al., 1979). Excited-state species 
produced may be highly reactive and participate in reactions not unlike those of 
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free radicals. Singlet oxygen, itself a strong oxidizing agent, may be responsible 
for some of the effects assigned to other active oxygen species such as 
superoxide. Roles for singlet oxygen have also been postulated in 
photosensitized reactions, and in antimicrobial defense (Foote 1976). 
Oxidative stress in pathological processes -  
In addition to environmental causes such as oxygen (McLennon and Autor 1982), 
light, or ionizing radiation (Foote 1976) three physiological circumstances result 
in extraordinarily high local fluxes of radical species: (1) activation of the P-450-
centered mixed function oxidase systems of endoplasmic reticulum, (2) 
activation of NADPH oxidase in phagocytes in response to antimicrobial defense 
and inflammation and (3) the presence of extraordinarily high levels of 
compounds which can reduce oxygen directly in auto oxidation reactions. Under 
such circumstances, the rate of active species generation may exceed the local 
capacity of the antioxidant defense and may contribute to injury.  
Electron donors act as pro-oxidants by reducing less reactive species, such as 
molecular oxygen and peroxide, to more reactive species via reactions, which are 
typically mediated by the cyclical reduction/oxidation of transition-metal ions. 
The reduction of peroxide to hydroxyl radical by ferrous iron is known as 
Fenton's reaction." Peroxide and superoxide can also react in the presence of a 
metal ion to produce hydroxyl radical and molecular oxygen. This latter reaction 
is called the "Haber Weiss Reaction" (Crichton 1979). Transition metal ions are 
remarkably good promoters of free radical reactions (Hill 1981). Organisms use 
superoxide dismutases, catalase, and glutathione peroxidase as protection 
against generation of reactive oxygen species. Organisms also keep as many iron 
and copper ions as possible safely bound in storage or transport proteins 
(Halliwell et al., 1988, Halliwell and Gutteridge 1986, Aruoma and Haliwell 
1987). There is three times as much transferrin iron-binding capacity in plasma 
as iron needing to be transported, so that there are essentially no free iron ions 
in the plasma (Halliwell and Gutteridge 1986). Iron ions bound to transferrin 
cannot stimulate lipid peroxidation or formation of free .OH radicals. The same is 
true of copper ions bound to the plasma proteins ceruloplasmin or albumin 
(Halliwell et al., 1988, Halliwell and Gutteridge 1986, Aruoma and Haliwell 1987, 
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Grootveld et al., 1989). The value of this sequestration is shown by an inspection 
of the pathology suffered by patients with iron-overload disease, in whom iron 
ion-citrate chelates circulate in the blood (Grootveld et al., 1989). These patients 
can suffer liver damage, diabetes, joint inflammation, and hepatoma, among 
other problems (McLaren et al., 1983). Metal ion sequestration is an important 
antioxidant defense. For example, recent papers have referred to ascorbic acid as 
a major antioxidant in plasma. However, ascorbate can only exert antioxidant 
properties in the absence of transition metal ions (Halliwell 1990).  
Oxidative stress in thalassemia -  
Sickle cell anemia, thalassemia, and glucose-6-phosphate-dehydrogenase 
deficiency are all hereditary disorders with higher potential for oxidative 
damage due to chronic redox imbalance in red cells that often results in clinical 
manifestation of mild to serve hemolysis in patients with these disorders. The 
release of hemoglobin, during hemolysis, and the subsequent therapeutic 
transfusion lead to systemic iron overloading that further potentiates the 
generation of ROS in thalassemia (Chan et al., 1999). The synthesis and 
accumulation of excess normal globin chain (i.e. β-chain in α-thalassemia and α-
chain in β-thalassemia), within the red cell, lead to the formation of unstable 
aggregates, which upon oxidation, due to oxidative stress generated by iron 
overload, may precipitate and cause cell membrane damage. These deformed 
cells undergo premature destruction either in the bone marrow (extravascular 
hemolysis) or the peripheral circulation (intravascular hemolysis) (Weatherall 
1997, Festa 1985). There is also an increase in erythropoietic activity in the bone 
marrow and in extramedullary sites (i.e. liver, spleen and lymph nodes) in 
several forms of thalassemias (e.g. β-thalassemia major) (Weatherall 1997, Festa 
1985). The ineffective erythropoiesis and microcytic hypochromic anemia, 
described earlier, are associated with a compensatory increase in the absorbance 
of dietary iron. This may contribute to the iron overload that often results from 
blood transfusion therapy. Further, our results point out that the iron-induced 
liver damage in thalassemia may play a major role in the depletion of lipid-
soluble antioxidants (Livrea et al., 1996). 
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Role of antioxidants -  
Reactive oxygen species are constantly formed in the human body and removed 
by antioxidant defenses. An antioxidant is a substance that when present at low 
concentrations compared to that of an oxidizable substrate significantly delays 
or prevents oxidation of that substrate. Antioxidants can act by scavenging 
biologically important reactive oxygen species ([O2].,[H2][O2], .OH, HOCl, ferryl, 
peroxyl, and alkoxyl), by preventing their formation, or by repairing the damage 
that they do. In biological systems the sources of the electrons are generally 
enzymes (e.g., NAD(P)H oxidase) and reducing substances (electron-donors). 
Simplistically, electron-donors act as antioxidants by (e.g.) reducing more 
reactive species such as trichloromethyl, superoxide, or hydroxyl radicals to less 
reactive species such as chloroform, peroxide, or water. Antioxidants come only 
from two sources - both natural: endogenous or exogenous. 
Endogenous Antioxidants -  
Three important intracellular enzymes constitute antioxidant defense; 
superoxide dismutase (SOD), catalase, and the GSH peroxidase/GSSG reductase 
system. SOD catalyzes the dismutation of superoxide, catalase the conversion of 
hydrogen peroxide to H2O and O2 (Willson 1979). Various organelle specific 
isoenzymes of superoxide dismutase exist (Fridovich 1979). The Zn-Cu SOD is 
cytoplasmic, while the Zn-Mn enzyme is chiefly mitochondrial. Neither 
isoenzyme is found in high concentrations in extracellular fluids (Fridovich 
1979). GSH peroxidase transfers electrons from GSH to reduce peroxides to 
water. The oxidized glutathione produced (GSSG) is re-reduced back to GSH by 
glutathione reductase utilizing NADPH produced by the HMP shunt acting as an 
enzyme cofactor (Carrell et al., 1978).  
The enzymatic production of active oxygen species by inflammatory cells may 
contribute to the pathophysiology of leukocyte dependent inflammatory 
processes (Huber 1980). Further, peroxidase release from eosinophils may play 
a similar role in inhibition of the inflammatory response while the antioxidant 
properties of ceruloplasmin may also give this compound antiinflammatory 
property. Production of active oxygen species by activated phagocytes may also 
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have a role in vascular (and other) damage following endotoxin shock, burn-
induced plasma volume loss and even in atherosclerosis (Huber 1980).  
It is not surprising that antioxidants, SOD (Huber 1980) and catalase (McCord et 
al., 1982) should ameliorate inflammatory symptoms in human and animal 
systems. This is of some clinical importance, since an antiinflammatory 
pharmaceutical preparation rich in SOD ("orgotein") is used in veterinary 
medicine and recently has been shown to be both effective and apparently safe in 
the treatment of various inflammatory lesions in man. Catalase has also been 
used in the treatment of arthritic disease in man with reported success (Riu et al., 
1971). 
 
 
 
Taxonomical details -  
    Kingdom  Plantae – Plants  
    Subkingdom Tracheobionta – Vascular plants  
    Superdivision Spermatophyta – Seed plants  
    Division  Magnoliophyta – Flowering plants  
    Class  Liliopsida – Monocotyledons  
    Subclass  Commelinidae –  
    Order  Cyperales –  
    Family  Poaceae – Grass family  
    Genus  Triticum L. – wheat  
    Species  T. aestivum 
 
Wheat, a cereal grass of the Gramineae (Poaceae) family and of the genus 
Triticum and its edible grain, is the world's largest cereal-grass crop. It has been 
a food crop for mankind since the beginning of agriculture. The Middle East is 
probably the area of origin, and wheat apparently spread throughout Europe not 
later than the Stone Age. Historians believe it has been growing since Paleolithic 
times and cultivated for at least 6,000 years. Its status as a staple is second only 
                                      3.4 
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to rice. One reason for its popularity is that, unlike other cereals, wheat contains 
a high amount of gluten, the protein that provides the elasticity necessary for 
excellent bread making. Although over 30,000 varieties of wheat exist, the two 
major types are bread wheat and durum wheat. Global production of wheat is 
approximately 600 million tons; with international trade approximately 100 
million tons annually. Wheat is Asia's second most important staple and has been 
growing much faster than rice. Wheat now provides one-fifth of total developing 
country food supply, up from 15 % in the early 1970s. In 1992-94, developing 
countries accounted for 45 % of world wheat production (551 million tons) and 
46 % of world wheat area (219 million hectors). 
The wheat plant is an annual grass. It is mainly grown as a winter annual in 
milder climates, with seeding in the fall and harvest from June through August 
depending on the length of the winter. In areas with rigorous winter climates it is 
mainly spring seeded. Planting is as early as soil can be worked, and harvest is in 
late summer and early fall. In early growth stages the wheat plant consists of a 
much-compressed stem or crown and numerous narrowly linear or linear-
lanceolate leaves. Leaves are mainly near glabrous. Buds in the leaf axils below 
the soil surface grow into lateral branches termed tillers. From both the main 
crown and the tillers, elongated stems develop later and terminate in a spike or 
head in which the flowers, and finally the seed or grain, develop. Stems of wheat 
reach from 18 inches to 4 or more feet in height depending on kind and growing 
conditions.  
Although over 30,000 varieties of wheat exist, they are of two major types:  
bread wheat and durum wheat. In U. S. Dept. of Agriculture- Technical Bulletin 
1287 has classified wheat into 10 species of Triticum. Six of these are cultivated 
and four are non-cultivated, or rarely so. Agriculturally, important species of 
Triticum include -   
1. Triticum aestivum (Common wheat, bread wheat, local varieties - Lok1, 
GW273) - Triticum aestivum comprises nearly 95 percent of the wheat 
grown. Its principal use is for flour. It is the most important variety for 
agriculture. 
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Figure 3.8: Triticum aestivum (Wheat grass) and wheat grass juice 
2. Triticum durum (Durum wheat, local variety Raj 1555) - Triticum durum is 
used mainly for the manufacture of semolina, which is made into macaroni, 
spaghetti and related products. It is next in importance to Triticum aestivum.  
3. Triticum dicoccum (Emmer wheat, local variety DDK) - Triticum dicoccum is 
one of the most ancient of cultivated cereals. Emmer was formerly grown in 
the United States for feed on a limited acreage but now has substantially 
disappeared from cultivation. 
Macroscopy (Triticum aestivum) 
Triticum aestivum is a bisexual plant with bisexual spikelets and hermaphrodite 
florets. Culm nodes are hairy, or glabrous. Culm internodes are solid, or hollow. 
Leaves are auriculate with blades narrowly to broadly linear. Leaves are 2–20 
mm wide, flat, without cross venation and persistent. Inflorescence is a single 
elongated spike. Rachides are hollow. Spikelets are solitary; distichous and 
sessile. Female-fertile spikelets are 9–16 mm long, laterally compressed and 
disarticulating above the glumes. Rachilla are prolonged beyond the uppermost 
female-fertile floret. The rachilla extension is incomplete florets. Hairy callus is 
absent. Callus is very short and blunt. Glumes are two and more or less equal in 
size. They are shorter than the adjacent lemmas and lateral to the rachis; without 
conspicuous tufts or rows of hairs. Lower glume is 5–11 nerved. Upper glume is 
5–11 nerved. Spikelets are usually with incomplete florets. The incomplete 
florets are distal to the female-fertile florets. The distal incomplete florets are 
usually 1, or 2 in number. Female-fertile florets have lemmas similar in texture to 
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the glumes. Awns when present are much shorter than the body of the lemma or 
much longer than the body of the lemma. Lemmas are hairy or hairless but 
scabrid. Palea is present and is relatively long, entire or apically notched. Palea 
keels are somewhat winged. Lodicules are membranous and ciliate. 3 stamens 
are present. Anthers are not penicillate with 2–4.5 mm length. Ovary is hairy. 
Styles are free to their bases. Stigmas are 2 in number and white in color. Fruit is 
free from both lemma and palea. It is medium sized or large i.e. up to 11 mm 
long, ellipsoid, longitudinally grooved, compressed dorsiventrally and with hairs 
confined to a terminal tuft. Hilum is long and linear. Embryo is large to small. 
Endosperm is hard; without lipid and contains only simple starch grains. 
Embryonic leaf margins are meeting. Seedling has a short mesocotyl and a tight 
coleoptile. First seedling leaf has a well-developed lamina. The lamina is narrow 
and erect.  
Microscopy (Triticum aestivum)  
Leaf-blade epidermis has conspicuous costal zonation. Papillae are absent. There 
are long-cells of similar wall thickness. Mid-intercostal long-cells are rectangular 
and fusiform, having markedly sinuous walls. Microhairs are absent. Stomata are 
common with 63–69 microns length. Subsidiaries are parallel-sided or dome-
shaped. Guard cells are overlapped by the interstomatals. Intercostal short-cells 
are common (e.g. T. polonicum) or absent or very rare. Crown cells are present. 
Costal zones have short cells. Costal short-cells are predominantly paired (T. 
polonicum) or neither distinctly grouped into long rows nor predominantly 
paired. Costal silica bodies are horizontally elongated.   
Transverse section of leaf blade shows parenchymatous cells without a 
suberised lamella. Mesophyll has non-radiate chlorenchyma. Leaf blade has 
distinct and prominent abaxial ribs of more or less constant size. Midrib is 
conspicuous with one bundle only or has a conventional arc of bundles. The 
lamina is symmetrical on either side of the midrib. Bulliform cells are present in 
discrete and regular abaxial groups in the furrows). Many of the smallest 
vascular bundles are unaccompanied by sclerenchyma. Combined sclerenchyma 
girders are present (rarely) or are absent. Sclerenchyma is all associated with 
vascular bundles.  
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Nutritional analysis of wheatgrass  
Scientific reports on nutritional analysis of wheatgrass have been published 
frequently in various journals (Kohler 1953, Hamilton et al., 1988, Laboratory 
Analyses 1989). Also, several reputed companies involved in growing and selling 
of wheatgrass have published analyses of wheatgrass. As is evident from table 
3.5 and table 3.6, wheatgrass is a rich source of chlorophyll, various minerals like 
iron, magnesium, calcium, phosphorus, antioxidants like beta carotene, insoluble 
dietary fibers while being low in fat content. 
Table 3.4: Nutritional analysis of wheatgrass 
 
Protein                                           1.959  Calories                                  21.0 Cal 
 Carbohydrates total                    2.09  Moisture                                        95.9 
 Ash                                               0.0489  Magnesium                               24 mg  
Selenium                                    <1 ppm Potassium                                    1 479 
 Zinc                                                 0.33g Phosphorus                                  75.2g 
 Calcium                                     24.2 mg  Sodium                                      10.3 mg  
Iron                                             0.61 mg  Vitamin A                                   427 ILI  
Vitamin B1                                  0.8 mg                                                   Vitamin B2                                0.13 mg 
 Vitamin B                                 0.11 mg  Vitamin B5                                  6.0 mg 
 Vitamin                                  96.0.2 mg  Vitamin B12                              <1 mcg  
Vitamin C                                   3.65 mg  Vitamin E                                    15.2 IU 
 Folic Acid                                   29 mcg  Biotin                                          10 mcg 
Dietary Fiber (total)                      0.1g  Lecithin                                     0.03 gm  
Chlorophyll                               42.2 mg  Choline                                      92.4 mg 
Aspartic: Acid                            260 mg  L-Arginine                                 135 mg 
                     All above constituents are present in per 100g juice.  
   Data based on scientific laboratory analysis by Irvine Analytical Laboratories Inc., Irvine, CA, USA. 
 
Table 3.5: Major ingredients in wheatgrass juice powder 
Main Ingredients              Content %  
Carbohydrates                         23.5 Fat  3.7 
Moisture                               0 Protein  46.7 
  Ash (Minerals) 26.1 
  Mineral & trace minerals mg/gm  
Boron                                   .0055 Calcium  4.9 
Chloride                                 .49 Chromium  .0012 
Cobalt                                   <0.0005 Copper  .027 
Fluoride                                .0065 Germanium  <.011 
Iodine                                    <0.0005 Iron  .051 
Magnesium                              4.4 Manganese  .026 
Molybdenum                           <0.0005 Nickel  <0.0005 
Phosphorous                        29 Potassium  2.8 
Selenium                             <0.0005   
Silicon                                      .16 Sodium  .11 
Tin                                        <0.0005 Titanium  <0.0005 
Vanadium                              <0.0005 Zinc  .066 
  Vitamins mg/g  
Biotin  .00011 Choline  .0011 
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Cyanocobalamin (B12 ) .00001 Folic Acid  .0012 
Inositol  <0.011 Niacin (B3 ) .09 
Panotothenic Acid  .0196 Pyridoxine HCL B6  .0065 
Riboflavin  .0031 Thiamin (B1)  .0098 
Vitamin A (Retino)l  501 IU/Gm Vitamin C  .185 
Vitamin D  <0.1 IU/Gm Vitamin E  .02 IU/Gm 
Others mg/g   Chlorophyll  1.2 
Cholesterol  <0.01 Sugars 48 
Essential Amino Acids mg/g  
Isoleucine  15.8 Leucine  31.5 
Lysine  22.6 Methionine  3.5 
Phenylalanine  19.8 Proline  17.1 
Threonine  14.8 Valine  22.1 
Non-Essential Amino Acids mg/g  
Alanine  24.8 Arginine  22.1 
Aspartic Acid  46.9 Glutamine  77.4 
Glycine  20.4 Histidine  7.4 
Serine  15.9 Tyrosine  6.9 
            Source – EPA, USDA 
 
Table 3.6: Comparison of contents of wheatgrass with other vegetables. 
 
 
Wt. Protein Fiber Calcium Vit. A Iron Selenium Magnesium Potassium 
Vegetable gr. gr. gr. mg. IU mg. mcg. Mg. mg. 
Dehydrated  
Wheat grass 
100 25 17 515 66,08 57.1 99.7 197.5 1,425 
Beets (raw) 100 1.7 0.8 17 22 0.7 - 23.3 339 
Bib Lettuce 
(raw) 
100 1.3 0.5 35 964 2.1 - 9 264 
Broccoli (raw) 100 3.6 1.5 103 2,500 1.1 - 24 380 
Cabbage (raw) 100 0.9 0.8 34 90 0.3 1.5 13 163 
Cauliflower 100 2.7 1 25 60 1.1 0.7 24 295 
Celery, raw 100 0.9 0.6 39 266 0.3 - 21.6 39 
Collards  (raw) 100 3.6 0.9 401 6,500 1 - 57 401 
Corn (cooked) 100 3.2 0.7 163 396 3 - 20 163 
Cucumber 
(raw)  
100 0.9 0.6 25 245 1.1 0.1 11.2 158 
Eggplant (raw) 100 1.2 0.9 12 10 0.7 - 16 214 
Green Pepper 
(raw) 
100 1.3 1.4 9 425 0.8 0.6 18 213 
Kale (raw) 100 4.2 1.3 179 8,900 0.5 - 37 318 
Mushrooms 
(raw) 
100 2.7 0.8 6 5 0.8 12 10.8 406 
Okra (raw) 100 2.4 1 249 520 0.6 - 41 - 
Onions (raw) 100 1.5 0.6 27 41 0.5 1.5 11.8 155 
Peas (raw) 100 6.3 2 26 632 1.9 - 34.5 311 
Potato (raw) 100 2.2 0.8 7 5 0.6 - - 409 
Radish (raw) 100 1 0.7 28 5 1 4.2 14 290 
Spinach (raw) 100 3.5 0.6 97 8,109 3.2 - 80 471 
Sweet Potato 
(baked) 
100 1.6 1.2 31 3,400 0.7 - - 233 
Tomato (raw) 100 1.1 0.5 10 905 0.6 0.5 14.1 245 
Turnips (raw) 100 1 0.8 38 5 0.5 0.6 18.8 261 
Source: Nutrition Almanac and published scientific papers on cereal grass by Dr. George Kohler (Kohler 
1944) 
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Traditionally, wheatgrass has been used as a medicinal herb in India. In western 
countries neutraceutical science is gaining momentum and wheatgrass is now 
being advocated as a food supplement. A closer look at table - 3.3 reveals that 
compared to most of the vegetables, which are part of our daily food, wheatgrass 
has higher contents of all the nutritional factors and minerals. Thus, wheatgrass 
is not just an herb or a food supplement, but it is a complete food and may be 
taken daily, even by healthy people. 
In today’s fast lifestyle and fast-food world, deficiency of any or many of these 
biochemical factors could easily occur culminating into a disease or disorder. For 
example, as reported by Altura and Altura (1995), ‘It is now becoming clear that 
a lower than normal dietary intake of magnesium can be a strong risk factor for 
hypertension, cardiac arrhythmias, ischemic heart disease, atherogenesis and 
sudden cardiac death. Deficiency in serum magnesium is often associated with 
arrhythmias, coronary vasospasm and high blood pressure’. Wheatgrass juice, 
being a rich source of magnesium, may replenish the deficiency of magnesium 
and improve the clinical picture.  
Conversely, a disease state may cause deficiency of a nutrient. According to Rude 
(1993), ‘A large body of evidence demonstrates the prevalence and adverse 
clinical consequences of magnesium deficiency in patients with diabetes mellitus. 
It would be prudent for physicians who treat these patients to consider 
magnesium deficiency as a contributing factor in many diabetic complications 
and in exacerbation of the disease itself. Repletion of the deficiency or 
prophylactic supplementation with oral magnesium may help avoid or 
ameliorate such complications as arrhythmias, hypertension, and sudden cardiac 
death and may even improve the course of the diabetic condition’. Regular intake 
of wheat grass juice could correct the secondary magnesium deficiency and thus, 
may be helpful in averting long-term clinical complications of diabetes mellitus. 
The movement for the human consumption of wheatgrass began in the western 
world in the 1930’s and was initiated by Charles F. Schnabel, known as the father 
of wheatgrass (Anderson 1986). He said ‘Fifteen pounds of wheatgrass is 
Therapeutic uses of wheatgrass 
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equivalent to 350 pounds of the choicest vegetables.’ Later Wigmore (1940) 
healed herself of cancer from the weeds she found in vacant lots in Boston.  She 
began a study of natural healing modalities—and with the help of a friend, Dr. 
Earp Thomas, she found that there are 4700 varieties of grass in the world and 
all are good for man.   
Dr. Wigmore reported that the “wheatgrass” used in her program contain 
abscisic acid and laetrile, both of which may have anti-cancer activity. It was also 
reported that young grasses and other chlorophyll-rich plants are a safe and 
effective treatment for ailments such as high blood pressure, some cancers, 
obesity, diabetes, gastritis, ulcers, pancreas and liver problems, fatigue, anemia, 
asthma, eczema, hemorrhoids, skin problems, halitosis, body odor and 
constipation (Wigmore 1985). Dr. Wigmore’s opinions are based on her 
experiences with her guests at Hippocrates. A few clinical studies have verified 
that some disease conditions can be benefited by the use of wheatgrass. 
Remarkably, a relatively large number of studies indicate that food factors and 
nutrients found in wheatgrass may provide relief from many of the conditions 
claimed by Ann Wigmore. 
Clinical studies on wheatgrass 
Ulcerative colitis is a common and sometimes serious disorder of the large 
intestine that can cause abdominal pain, diarrhea, and bleeding. Ben-Ayre et al., 
(2002) reported that people taking wheat grass juice experience a significant 
improvement of their ulcerative colitis symptoms on a scale that measured 
overall disease activity, compared with people taking a placebo. Wheat grass 
juice also significantly reduced the severity of rectal bleeding and abdominal 
pain. The initial dose of wheatgrass juice, 20 ml (two-thirds of an ounce) per day, 
was increased over a period of several days to a maximum of 100 ml (3.5 ounces) 
per day. In addition to the positive results mentioned above, an examination of 
the colon (sigmoidoscopy) showed improvement in 78% of the people receiving 
wheat grass juice, compared with only 30% of those receiving placebo. No 
serious side effects were seen. Although nausea was reported by 33% of the 
participants receiving wheat grass juice, 41% noted an increase in vitality while 
taking the supplement. 
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A clinical pilot study was carried out by Marwaha et al., (2004) at the Advanced 
Pediatric Centre, Postgraduate Institute of Medical Education and Research, 
Chandigarh, India. It was reported that during period of wheatgrass juice 
ingestion: all participants experienced lower blood transfusion requirements, 
50% had at least 25% reduction in transfusion requirements, the mean interval 
between transfusions increased 29.5%, overall, hemoglobin levels were not 
compromised by reduced transfusion volumes. 
 
It has been recognized that flavanoids show antioxidant activity and their effects 
on human nutrition and health are considerable. The mechanisms of action of 
flavanoids are through scavenging or chelating process (Kessler et al., 2003; 
Cook and Samman, 1996). Phenolic compounds are a class of antioxidant 
compounds which act as free radical terminators (Shahidi and Wanasundara, 
1992). The compounds such as flavanoids, which contain hydroxyl functional 
groups, are responsible for antioxidant effect in the plants (Das and Pereira, 
1990; Younes, 1981). There was a direct relation between chelatory activity and 
the content of active compounds, phenol and flavanoids in some extracts in this 
study. Some extracts with high phenol and flavonoid contents showed good 
chelating of Fe2+. For example, E. hirsutum and M. arvensis that contained highest 
phenol and flavanoids contents showed the best chelating activity. 
Patients with chronic anemia such as thalassemia, require regular blood 
transfusions in order to improve both quality of life and survival. Humans are 
unable to eliminate the iron released from the breakdown of transfused red 
blood cells and the excess iron is deposited as hemosiderin and ferritin in the 
liver, spleen, endocrine organs and myocardium. The accumulation of toxic 
quantities of iron causes tissue damage and leads to complications such as heart 
failure, endocrine abnormalities like diabetes, hypothyroidism, liver failure and 
ultimately early death (Taher et al., 2006; Rund and Rachmilewitz, 2005; 
Loukopoulos, 2005). Thalassemia major is characterized by anemia, iron 
overload, further potentiation of reactive oxygen species (ROS) and damage to 
major organs, especially the cardiovascular system. Oxidative stress is ultimately 
involved in endo-thelial dysfunction, a condition which is evident in adults 
Wheatgrass and iron overload   
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suffering from various cardiovascular diseases including thalassemia (Shinar and 
Rachmilewitz, 1990; Hebbel et al., 1990; Grinberg et al., 1995). Antioxidant and 
other supportive therapies protect red blood cells (RBC) against oxidant damage 
(Kukongviriyapan et al., 2008; Filburn et al., 2007). Also a higher rate of LDL 
oxidation in thalassemia patients is due to a lower concentration of vitamin E 
and C in the LDL particles. Enrichment with vitamins E and C was effective in 
preventing LDL oxidation in patients with thalassemia (Rachmilewitz et al., 
1979; Livrea et al., 1996). Iron chelators mobilize tissue iron by forming soluble, 
stable complexes that are then excreted in the feces and/or urine. Chelation 
therapy reduces iron-related complications and thereby improves quality of life 
and overall survival (Shinar and Rachmilewitz, 1990; Hebbel et al., 1990). The 
poor oral bioavailability, short plasma half-life and severe side effects makes 
available chelators suboptimal (Hebbel et al., 1990; Grinberg et al., 1995, 
Kukongviriyapan et al., 2008; Filburn et al., 2007).  
Clinically it was proved that different varieties of wheatgrass extracts are 
therapeutically used in treatment of anemia, thalassemia (major), cancer and 
bacterial diseases (Desai et al., 2005). It was reported that aqueous extract of 
wheatgrass have mild to moderate antibacterial activity against four common 
opportuinistic pathogenic bacteria viz. Staphylococcus aureus, Bacillus cereus, 
Salmonella typhimurium and Kleibsella pneumoneae (Desai et al., 2005).  
Potential benefits of Triticum aestivum in iron overload in thalassemia and 
other blood disorders 
Some research workers have studied chlorophyll, one of the major ingredients 
present in wheatgrass. Chlorophyll is not so unique in its chemical structure. It is 
built around a porphyrin ring, which occurs in a variety of natural organic 
molecules. The most interesting group of molecules which contain porphyrin 
rings are those involved in cellular respiration, or the transportation and 
consumption of oxygen. These include hemoglobin, myoglobin, and the 
cytochromes. The chemical similarity between hemoglobin and chlorophyll was 
first suggested by Verdel in 1855 (Carpenter 1949), and specifically 
demonstrated in the early 1920s. One of the major differences between 
chlorophyll and hemin is that chlorophyll contains magnesium while the hemin 
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molecule contains iron as its central atom. Owing to the close molecular 
resemblance between chlorophyll and hemoglobin, it was hypothesized that 
chlorophyll is nature's blood-building element for all herbivorous animals and 
humans. 
Some studies have indicated that feeding chlorophyll-rich foods to rats 
stimulates the regeneration of red blood cells (Scott and Delor 1933). 
Researchers were able to demonstrate that this effect was not due to the iron or 
copper in the green foods (Rothemund et al., 1934). Hughes and Latner (1936) 
fed several doses and forms of chlorophyll to anemic rabbits and found that very 
small doses of purified chlorophyll or large doses of a crude chlorophyll extract 
produced a very favorable effect on hemoglobin regeneration. They suggested 
that the chlorophyll is acting as a physiological stimulant of the bone marrow 
and is not really concerned with the actual chemistry of regeneration of the 
porphyrin.  
Synthetic agents like desferrioxamine and deferiprone used for the treatment of 
iron overload in thalassemia are accompanied by serious side effects and certain 
limitaions including the need for parenteral administration, arthralgia, nausea, 
gastrointestinal symptoms, fluctuating liver enzyme levels, leucopenia, 
agranulocytosis and zinc deficiency and obviously the heavy cost. In addition, 
they are not suitable for use during pregnancy. Compared to synthetic drugs, 
herbal preparations are frequently less toxic with fewer side effects. Therefore 
the search for more effective and safer treatment of thalassemia and other blood 
disorders has become an area of current research activity.  
consideration the relative paucity of iron chelating agents, it is not surprising 
that clinical scientists are putting a great effort towards finding any potentially 
useful sources in order to obtain the maximum possible benefit with the least 
possible harm (Loukopoulos, 2005; Ebrahimzadeh et. al., 2006; Pourmorad et al., 
2006; Hosseinimehr et al., 2007; Pourmorad et al., 2007). For thousands of years, 
mankind has known about the benefit of drugs from nature. Plant extracts, for 
the treatment of various ailments, were highly regarded by the ancient 
civilizations. Even today, plant materials remain an important resource for 
combating illnesses. Some medicinal plants traditionally used for management of 
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diseases were selected and their phenol and flavanoids content and iron 
chelating activities were evaluated in this study. 
Table 3.7: Total phenol and flavonoid content and iron chelating IC50 of the  
herbs. 
Plant 
Common 
name 
Part of 
plant 
tested 
Medical use/disease treated 
Myrtaceae                    
Feijoa sellowiana  
Feijoa, 
Pineapple 
Guava, 
Guavasteen  
Fruits peels 
and leaves  
Human food  
Caprifoliaceae  
Danewort, 
Dwarf  
Fruits  
Antinociceptiv; anti 
inflammatory activity  
Sambucus ebulus  
Elder,   Antiphlogistic;Cholagogue; 
Diaphoretic;  
   Diuretic; Expectorant; 
Homeopathy; Poultice; 
Purgative.  
Rosaceae   Fruits  Hypotensive; cardiotonic  
Crataegus pentagyna  -   
Juglandaceae  Caucasian 
wingnut,  
Fruits and 
stem barks  
Diaphoretic  
Pterocarya 
fraxinifolia  
Pterocarya  
  
 caucasica    
Anacardiaceae  Mastic gum  Gum  
Antimicrobial;antioxidant;hep
atoprotective;  
Pistacia lentiscus  
  Analgesic; Antitussive; 
Carminative; Diuretic;  
   Expectorant; Odontalgic; 
Sedative; Stimulant  
Fabaceae  Yellow Melilot  Arial parts  
Antispasmodic; Aromatic; 
Carminative;  
Melilotus arvensis  
  Diuretic; Emollient; 
Expectorant; Ophthalmic;  
   Vulnerary  
Onagraceae  
Great 
Willowherb,  
Leaves  
Antimotility;antibacterial; anti-
inflammatory;  
Epilobium hirsutum  Greater Hairy 
Willowherb  
 analgesic activity  
Graminaceae,   
Maize silk, 
mealie  
The silk on 
the cob are  
Diuretic; kidney Stones; 
cystitis;  
Corn silk                        
(Zea mays)  
 silk and Yu mi 
shu.  
used for 
making the  
demulcent;anti-inflammatory; 
tonic;anti  
   brew  diarrhea;anti itching; 
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prostateproblems;  
    blood sugar decreasing; 
intestinal and liver  
    function regulatory effect  
Ebenaceae 
Diospyros 
lotus  
 Persimmon  Fruit  
Anticeptic, sedative, anti fever, 
antidiabetic, antitumor  
Rosaceae   Pear  Fruit  Antioxidant  
Pyrus boissieriana     
Lamiaceae  Jupiter's distaff  Arial parts  Antimicrobial  
Salvia glutinosa     
 
Aantioxidants present in wheatgrass -  
Beta-carotene -  
Excited-state derivatives such as singlet oxygen and the excited triplet (diradical) 
states of other molecules may be quenched by interactions with conjugated 
diene systems such as those found in carotenes (Huber 1980), tocopherols or the 
melanins (Forrest et al., 1974). Vitamin A, itself, can pose a hazard to human 
health and even the risk of birth defects when taken in excess. Its precursor, β-
carotene, can be taken in virtually any quantity without harmful effect. At the 
same time it provides the body with a store of the raw material from which it 
produces vitamin A naturally according to needs. β-carotene has been positively 
linked to increased protection against many forms of cancer, including lung, 
bladder, rectal, oral and dermal (skin) cancers. 
Vitamin C - 
Vitamin C acts synergistically with vitamin E and assists not only in the 
prevention of the formation of arterial cholesterol plaque but also, in sufficient 
quantities, has been shown to actually assist in the chelation ("dissolving") of 
existing cholesterol plaque thereby helping clear occluded (blocked) arteries, 
particularly coronary. Vitamin C is also specifically known to assist in the 
prevention of many forms of cancer, including pancreatic, rectal, cervical, 
esophageal and oral cancer. It is also a powerful free radical scavenger and 
thereby helps clean up the residues of cigarette smoke and other forms of air 
pollution. 
Vitamin E -  
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As well as the primary defenses (scavenger enzymes and metal-ion 
sequestration), secondary defenses are also present. The cell membranes and 
plasma lipoproteins contain α-tocopherol, a lipid soluble molecule that functions 
as a chain-breaking antioxidant. Attached to the hydrophobic structure of α-
tocopherol is an -OH group whose hydrogen atom is easily removed. Hence, 
peroxyl and alkoxyl radicals generated during lipid peroxidation preferentially 
combine with the antioxidant instead of with an adjacent fatty acid side chain. 
This therefore terminates the chain reaction, whence the term chain-breaking 
antioxidant. It also converts the α-tocopherol into a new radical, tocopherol-α, 
which is poorly reactive and unable to attack adjacent fatty acid side chains, 
consequently stopping the chain reaction. Evidence exists (Esterbauer et al., 
1989, Wefers and Sies 1988) that the tocopherol radical can migrate to the 
membrane surface and reconvert to α-tocopherol by reaction with ascorbic acid 
(vitamin C). Both vitamin C and α-tocopherol seem to minimize the 
consequences of lipid peroxidation in lipoproteins and in membranes, should 
this process begin (Wefers and Sies 1988). α-tocopherol is the most effective 
lipid-soluble chain breaking antioxidant in-vivo in humans (Ingold et al., 1986). 
The content of α-tocopherol in circulating low-density lipoproteins helps to 
determine their resistance to lipid peroxidation and thus may affect the 
development of atherosclerosis, a disease in which lipid peroxidation is involved 
(Gey et al., 1987). Low plasma levels of α-tocopherol and vitamin C correlate 
with an increased incidence of myocardial infarction and of some forms of cancer 
(Gey et al., 1987). Vitamin E is present in small quantities in many foods but its 
uptake is all too often inhibited by low-fat or no-fat diets as fats or oils are the 
essential carriers of vitamin E without which absorption or uptake of this, the 
most powerful of the antioxidant vitamins, is severely restricted. Vitamin E is 
known to fight infection, promote healing and to assist in the prevention of lung 
and gastro-intestinal (including bowel) cancer. It achieves this by again 
preventing free radicals from entering cells where nuclear and DNA damage 
would otherwise ensue. 
Wheatgrass is rich in chlorophyll, magnesium, Iron, selenium, zinc, chromium, 
and antioxidant vitamins like vitamins A, E, C, B12, folic acid, pyridoxine, host of 
other minerals and amino acids that have significant nutritious and medicinal 
value. Since deformation of RBC, caused by oxidation of excess α-chains, is the 
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main causative factor for hemolysis and therefore, increased frequency of 
repeated blood transfusions in thalassemia; antioxidants and magnesium 
present in wheatgrass may reduce the need of such repeated transfusions.  
In the light of foregoing discussion the present study is planned to investigate 
beneficial effects of Tritium aestivum for management of iron overload and other 
blood disorder like thrombocytopenia, hemophilia and immunomodulatory 
effects. In order to narrow down work we are planned to find out mechanism of 
action and possible active ingredients from Triticum aestivum responsible for 
these beneficial effects.  
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4. OBJECTIVES   
   Objectives of the present project were – 
1. To carry out pharmacognostic study of Triticum aestivum. 
2. To carry out phytochemical studies of Triticum aestivum (Wheatgrass) 
and its various extracts. 
3. To evaluate iron chelating activity of various extracts of Triticum 
aestivum.  
4. To isolate iron chelating constituent from extract of Triticum aestivum, 
using column chromatography. 
5. To evaluate iron chelating activity of isolated constituent of Triticum 
aestivum, using pre-clinical study.  
6. Investigation of anti-oxidant property of Triticum aestivum in iron 
overload condition. 
7. Evaluation of therapeutic benefits of Triticum aestivum in 
thrombocytopenia. 
8. Assessment of immunomodulatory activity of Triticum aestivum. 
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5. Materials and Methods  
 
 
5.1 Pharmacognostic studies of Triticum aestivum (wheatgrass). 
5.2 Preparation of various extracts of wheatgrass. 
5.3 Phytochemical studies of various extracts of wheatgrass. 
5.4 In-vitro evaluation of iron chelating activity in various extracts of 
wheatgrass. 
5.5 In-vivo evaluation of iron chelating activity in various extracts of 
wheatgrass. 
5.6 Isolation and characterization of iron chelating active constituent of 
wheatgrass.  
5.7 In-vitro evaluation of iron chelating activity in active constituent of 
wheatgrass. 
5.8 In-vivo evaluation of iron chelating activity of active constituents of 
wheatgrass. 
5.9 Investigation into anti-oxidant property of Triticum aestivum in iron 
overload condition. 
5.10 Evaluation of therapeutic benefit of Triticum aestivum in 
thrombocytopenia. 
5.11 Assessment of immunomodulatory activity of Triticum aestivum. 
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Certified sample of species of wheat Triticum aestivum was acquired from Wheat 
Research Center, Gujarat Krushi University, Junagadh, Gujarat. The authenticity 
of this certified sample was also confirmed by comparing their morphological 
characters with description mentioned in different standard texts and floras 
(Percival J 1974). These wheat varieties were grown in plastic trays as per 
standard procedure described below (Wigmore 1985).  
 
Procedure for growing wheatgrass - 
1. Adequate quantity of unpolished wheat grain was soaked overnight in 
water in a container.  
2. On the next day, the soaked wheat-grain were spread on the surface of the 
soil filled in plastic trays. Care was taken so that the grains did not touch 
one another.  
3. A thin layer of soil was sprinkled on the wheat grains.  
4. The tray was covered with a newspaper to provide darkness, which helps 
the sprouting.  
5. The tray was kept in a covered balcony. 
6. Next day the tray was uncovered to spray on some water and was covered 
again with the newspaper.  
7. Step 6 was repeated every day until sprouting took place, after which the 
tray was left uncovered and watered everyday for 8 days.  
8. On 9th day the wheatgrass was harvested by cutting it with a clean pair of 
scissors about 1/2" above the surface of the soil.  
To characterize this variety of T. aestivum, the grass were subjected to 
microscopic study, which included transverse section, surface preparation and 
powder study. For powder study grass was cleaned and dried in a dark place for 
four days. It was powdered, passed through 40# and stored in airtight bottles.
  
                                                          vbbbbbbbbbbb 5.1   Pharmacognostic studies of Triticum aestivum (wheatgrass) 
 
ticum aestivum (wheatgrass) 
Identification and growing of wheatgrass  
 
 Cultivation and collection procedure for wheat grass (Wigmore 1985) 
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a. Macroscopic study: 
Both fresh and dried samples of T. aestivum were subjected to study for their 
morphological characters.  
b. Microscopic study: 
Free hand transverse sections of fresh aerial part of T. aestivum were studied 
under microscope and compared with literature. Powder study of wheatgrass 
was performed for sample and compared with literature.  
 
 
 
Various extracts of wheatgrass were prepared by different solvents using soxhlet 
apparatus. Dried powder (60#) of Triticum aestivum was defatted with 
petroleum ether (60˚-80˚) (3 X 500ml) for 1 hour; allowing macerating for 24h 
each time. The combined extracts, upon concentrating in vacuum, yielded 
greenish yellow semisolid residue. (Ext P, 2.8 % w/w). 
After defatting, powder was subjected to air dried and for extraction (60˚-80˚) 
with chloroform, exhaustively. The chloroform extract (Ext C) was concentrated 
to yield 3.4 % w/w. Afterwards the chloroform extract marc was air dried and 
extracted with acetone. The acetone extract (Ext A) was concentrated to yield 4.3 
% w/w. After acetone extract, marc was air dried and extracted with methanol. 
The methanol extract (Ext M) was concentrated to yield 4.1 % w/w. Marc of 
methanol extract was successively extracted with water. Water extract (Ext W) 
was separately concentrated to yield 5.3 % w/w. 
Solid powder obtained from these successive extractions of acetone, methanol 
and water were subjected for evaluation of pharmacological activities like iron 
over load induce thalassemia model, thrombocytopenia model, 
immunomodulatory activities. 
Pharmacognostic studies 
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ticum aestivum (wheatgrass) 
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Powder of aerial part of Triticum aestivum 
                                                               Petroleum ether 
 
 
Petroleum ether extract                       Defatted powder 
(Ext P, 2.8 % w/w)                Chloroform   
          
  Chloroform extract                                       Dried powder 
  (Ext C, 3.4 % w/w)                   Acetone    
  
 
      Acetone extract                         Dried powder 
     (Ext A, 4.3 % w/w)                       Methanol    
 
      Methanol extract          Dried powder 
     (Ext M, 4.1 % w/w)        Water 
 
                               Water extract 
             (Ext W, 5.3 % w/w) 
  
Figure 5.1: Scheme for successive extraction of aerial part of Triticum aestivum 
using soxhlet apparatus. 
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Petroleum ether, chloroform, acetone, methanol and water extracts of 
wheatgrass were subjected to various tests to determine presence of 
phytoconstituents specifically, flavonoids and phenolic compounds. 
‘Controls’: Controls were prepared for each test. This includes similar 
treatment/procedure as the ‘test’ sample, but no tests samples i.e. 
powder/extract were added. All inferences/conclusions were based on 
comparison of ‘test’ with ‘control’, and not with ‘test’ alone. 
Test for flavonoids: 
Shinoda test (Geissman A 1955) 
1 gm of powder of different extracts of wheatgrass were extracted with 10 ml of 
ethanol (95%) for 15minutes, on a boiling water bath and filtered. To the filtrate 
a small piece of magnesium ribbon and 3 to 4 drops of concentrated sulphuric 
acid were added. Formation of red color indicated presence of flavonoids in 
extracts (Flavanone).  
Tests for phenolic compounds:  
a. Test with FeCl3:  (Clerk J et al, 1947) 
Freshly prepared FeCl3 solution was added to each extracts of wheatgrass. 
Development of brownish green color indicated presence of phenolic content 
in extracts.  
b. Test with Folin ciocalteu reagent: (Harborne JB , 1973) 
Folin ciocalteu reagent was added to each extracts of wheatgrass. 
Development of bluish green color in extracts indicated presence of phenolic 
contents with catechol or hydroquinone nuclei.  
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Quantitative determination of total phenolic in various extracts and 
isolation compound using Folin-Ciocalteau method   
(Singleton VL and Rossi JA 1965, Somers TC 1980) 
Folin-Ciocalteau (FC) colorimetry method is based on a chemical reduction of the 
reagent, a mixture of tungsten and molybdenum oxides. The products of the 
metal oxide reduction have a blue color that exhibits a broad light absorption 
with a maximum at 765 nm. The intensity of light absorption at that wavelength 
is proportional to the concentration of phenols.  
Materials 
Sample: methanol and water extracts of T. aestivum 
Standard: Gallic acid  
Reagent:  Folin-Ciocalteau (FC) reagent, stored in dark and discarded if reagent 
becomes visibly green, freshly prepared Sodium carbonate solution. 
Apparatus: Spectrophotometer set to 765 nm, with 2-ml plastic or glass cuvettes. 
Reagents and Solutions 
 Deionized or distilled water were used in all recipes and protocol steps.  
 Gallic acid calibration standards 
0.5 gm gallic acid was dissolved in 10 ml ethanol and then dilute to 100 ml 
with water (5 g/liter final). Different concentrations of gallic acid solution 
were prepared using water (50, 100, 250, and 500 mg/liter 
concentrations).  
 Standards will retain 98% of their potency for 2 weeks if kept closed 
under refrigeration (4°C), but this potency is retained for only 5 days at 
room temperature. 
 Sodium carbonate solution 
A fresh sodium carbonate solution was prepared by using dissolved 200 
gm anhydrous sodium carbonate in 800 ml water and boiled. After 
cooling, solution was filtered through Whatman no. 1 filter paper.  
Procedure:  
1. 50 μl sample of gallic acid calibration standard, or blank (deionized or distilled 
water) was added to a test tube. 
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2. 1.58 ml water followed by 100 μl FC reagent was added to this sample. These 
solutions were inverted and incubated for 1 to 8 minutes. The incubation 
period was not more than 8 minutes.  
3. 300 μl sodium carbonate solution was added, mixed and incubated again for 2 
hr at room temperature. A final volume of 2 ml was made using distilled 
water. 
4. Absorbance of samples was measured at 765 nm and analyzed in UV-visible 
spectrophotometer.     
 
 
   5.4 In-vitro evaluation of iron chelating activity in various                                         
extracts       and isolated   compound of wheatgrass  
The chelation of ferrous ions by extracts was estimated by method of Dinis et al., 
1994.  Briefly, 50 μl of 2 mM FeCl2 was added to 1 ml of different concentrations 
of the methanol extract (0.2, 0.4, 0.8, 1.6 and 3.2 mg/ml) of wheatgrass. The 
reaction was initiated by the addition of 0.2 ml of 5 mM ferrozine solution. The 
mixture was vigorously shaken and left to stand at room temperature for 10 min. 
The absorbance of the solution was thereafter measured at 562 nm. The 
percentage inhibition of ferrozine–Fe2+ complex formation was calculated as 
[(A0- AS)/ AS] X 100, where A0 was the absorbance of the control, and As was the 
absorbance of extract/standard. Na2EDTA was used as positive control. 
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BIOLOGICAL EVALUATION / PHARMACOLOGICAL STUDIES OF VARIOUS 
EXTRACTS OF Triticum aestivum  
Various extracts and isolated compounds of T. aestivum were subjected to 
evaluation of iron overload induced thalassemia model, thrombocytopenia 
and immunomodulatory activity in various animal models. 
SELECTION OF ANIMALS 
All animals were housed at ambient temperature (22±10C), in relative humidity 
(55±5%) and 12h/12h light dark cycle. Animals had free access to standard 
pellet diet and water given ad libitum. The protocol of the experiment was 
approved by the institutional animal ethical committee as per the guidance of the 
Committee for the Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA), Ministry of Social Justice and Empowerment, Government of 
India (Protocol No. RKCP/COL/RP/09/01 dated 7th March, 2009). 
 
 
 
Male Sprague-Dawley rats initially weighing 150-200 gm were used for present 
study. The rats were given six Intraperitoneal injections of iron-dextran (12.5 
mg/l00 g body wt.) evenly distributed over a 30 days of period which results in 
condition of chronic iron overload, which was very resemble to iron overload in 
thalassemia. Control rats were injected with an equal volume of dextran at the 
same time. (Hachiro et al 2002, British journal of hematology, 1990, Addison GM 
et al., 1972) 
The experimental animals were divided into six groups, (n=6). 
Group 1: Normal control received dextrose solution 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) 
Group 4: Disease control treated with water extract of T. aestivum                                                 
(100 mg/kg, p.o., per day) 
Group 5: Disease control treated with methanol extract of T. aestivum                                                    
(100 mg/kg, p.o., per day) 
Group 6: Disease control treated with acetone extract of T. aestivum                                              
(100 mg/kg, p.o., per day) 
                                                          vbbbbbbbbbbb 5.5. In-vivo valuation of iron chelating activity in various extracts of wheatgrass 
 
Induction of Iron overload 
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All the studies were carried for a period of 30 days. During the study, blood 
samples, urine samples and fecal sample were collected on 15 and 30 days under 
fasting conditions. Histopathology of heart, liver and kidney were performed at 
the end of 30 days to study iron overload complications. 
 
At the end of 15 days and 30 days of treatment period, blood samples were 
collected from rats under fasting conditions, from retro orbital plexuses using 
light ether anesthesia, in clean dry centrifuge tubes.  Blood sample were 
subjected for estimation of -  
A. Hematological parameters 
a. Hemoglobin content 
b. Total RBC, PCV, MCV, MCH, MCHC 
c. Total WBC count  
d. Differential WBC count 
Neutrophil, Lymphocyte, Eosinophil, Basophil counts and Total 
lymphocyte count and  
e. Platelet count                                                                                                                                                                                             
using fully automated hematoly analyzer - Model XS-800i – Sysmex.  
Collected blood samples were allowed to clot for 30 min at room temperature 
and serum were separated by cooling centrifugation at 5000 rpm (REMI CM-12 
cooling centrifuge) for 20 min and stored at –20 C until the analysis was carried 
out.  
Serum samples were subjected to estimation of - 
B. Serum Iron: Sampling, reagent delivery, mixing, processing and printing of 
results are automatically performed by fully automated biochemistry 
Dimension-Rx L Max-Dade Behring Analyzer. 
C. Serum Ferritin: Sampling, reagent delivery, mixing, processing and printing 
of results are automatically performed by fully automated immunology 
Analyzer- sysmex-XS-800i ® system. 
D. SGPT  
E. SGOT  
F. Creatinine    
Blood sample collection and analysis for biochemical parameters  
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G. Creatine kinase (CKMB)  
 Urine and fecal sample collection and analysis for iron content  
Animals were placed in metabolic cages after treatment with extracts for a 
period of 12 hours. At the end of day 15 and day 30, urine and fecal samples 
were collected using metabolic cage. Total volume of urine and weight of faces 
were recorded and subjected for determination of iron in sample using fully 
automated biochemistry Dimension-Rx L Max-Dade Behring Analyzer. 
Analysis of iron in urine 
All urine samples were centrifuged at 14000 rpm for 5 min to remove mucus 
and epithelial cells. After approximately dilutions with water, the supernatant 
was directly injected into fully automated biochemistry Dimension-Rx L Max-
Dade Behring Analyzer. 
Analysis of iron in faces 
The fecal samples were subjected to dry at a constant weight in 20 minutes at 
medium power in a microwave. An accurately weighed amount of dried feces 
(100-300 mg) was mixed with a known volume of water in a glass mortar and 
grounded well to form a uniform homogenate. Typically concentrations of fecal 
in homogenate were prepared in range of 20–25 % w/v. An accurately weighed 
amount of homogenate was then placed in a crucible and dried for 10 min at 
medium power in microwave oven. To the dried residue 250 micro liter of 
concentrated nitric acid was added and subjected for digestion at medium power 
for 10 min. Digestion was repeated with three of four more additions of nitric 
acid to obtain residue which was reconstituted with 500 micro liters of 5 mM HCl 
by bath sonicator. These prepared samples were subjected to estimation of iron 
using fully automated biochemistry Dimension-Rx L Max-Dade Behring Analyzer. 
(British journal of hematology, 1990) 
All above mentioned parameters were estimated to find out in-vivo iron 
chelating property of various extracts of Triticum aestivum and to find out 
its beneficial effects in prevention of complication in heart, liver and 
kidney due to iron overload.  
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A. Estimation of hematological parameters 
   Various hematological parameters like  
f. Hemoglobin content 
g. Total RBC, PCV, MCV, MCH, MCHC 
h. Total WBC count  
i. Differential WBC count 
Neutrophil, Lymphocyte, Eosinophil, Basophil counts and Total 
lymphocyte count and  
j. Platelet count  
   were estimated using fully automated hematoly analyzer - Model XS-800i – 
Sysmex.  
B. Estimation of serum iron (Hachiro et al., 2002)  
Principle 
Under acidic conditions (pH 4.5), iron (Fe+3) bound to protein transferrin is 
released in presence of reducing agent, ascorbic acid, (Fe+3) is reduced to (Fe+2). 
The resulting product, Fe+2 forms a blue complex with 3-(2-pyridyl)-5, 6-bis-2-
(5-furyl sulfonic acid)-1,2,4- triazine, disodium salt (Ferene®). The absorbance of 
the complex, measured using a bichromatic (600, 700 nm) endpoint technique, is 
directly proportional to concentration of transferrin-bound iron in serum. 
Fe+3- transferrin —› Fe+3 + Transferrin 
2 Fe+3 + Ascorbic Acid —› 2 Fe+2 + Dehydroascorbic Acid + 2 H+ 
 Fe+2 + 3 Ferene® —› Fe+2- Ferene®3 complex  
                                           (absorbs at 600 nm) 
Procedure: 
Test conditions: 
 Sample size   -   50 µl 
 Reagent 1 volume  -   100 µl 
 Reagent 2 volume   -   25 µl 
 Diluents size   -   225 µl 
 Test temperature   -   37o C 
 Wavelength   -   600 and 700 nm 
 Type of measurement   -   bichromatic endpoint 
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Sampling, reagent delivery, mixing, processing and printing of results were 
automatically performed by fully automated biochemistry Dimension-Rx L Max-
Dade Behring Analyzer. 
C. Serum ferritin (Addison GM et al, 1972) 
Ferritin is major soluble iron storage protein from which iron may be mobilized 
for synthesis of hemoglobin, myoglobin and other iron containing proteins. 
Ferritin is present in high concentrations in the cytoplasm of reticuloendothelial 
cells, liver cells, spleen cells and developing red precursors in bone marrow. 
Studies on patients with iron-deficiency and iron overload abnormalities 
confirmed that measurement of serum ferritin concentration reflect amount of 
storage iron in body. 
Principle  
Ferritin present in test sample is bound with monoclonal antibody immobilized 
on a magnetic solid phase and enzyme-labeled monocolonal antibody in the 
reagent. The magnetic beads are washed to remove unbound enzyme-labeled 
monoclonal antibody and are then incubated with a fluorogenic substrate, 4-
methyl-umbelliferyl phosphate (4MUP). The amount of enzyme-labeled 
monoclonal antibody that binds to the beads is directly proportional to the 
ferritin concentration in test sample. A standard curve is constructed and 
unknown sample concentrations are calculated using this curve.   
Sampling, reagent delivery, mixing, processing and printing of results were 
automatically performed by fully automated immunology Analyzer- sysmex-XS-
800i ® system. 
D. Serum Glutamic Pyruvic Transaminase (SGPT /ALT/GPT) 
(Span Diagnostics Ltd., India) 
Principle 
Glutamic Pyruvic Transaminase catalyse the reaction between α–ketoglutaric 
acid and alanine giving L- Glutamic acid and Pyruvic acid. Pyruvic acid in the 
presence of lactate dehydrogenase reacts with NADH giving lactic acid and NAD. 
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The rate of NADH consumption is determined photometrically and is directly 
proportional to GPT activity in the sample. 
Reagents 
Reagent I:  Buffer reagent 
Reagent II:  Enzyme reagent 
Sample 
Serum or Plasma 
Reagent preparation 
4 ml of buffer reagent was mixed with 1 ml of enzyme reagent. 
Procedure 
Pipette into test tubes 
Sample 100 πl 
Reagent 1000 πl 
  
Reactive samples were subjected to fully automated biochemistry Dimension-Rx 
L Max-Dade Behring Analyzer which gives direct reading of SGPT. 
  
E. Serum Glutamate Oxaloacetate Transaminase (SGOT/AST/GOT)                                                   
(Span Diagnostics Ltd., India) 
Principle 
Aspartate transaminase catalyses reaction between alpha- ketoglutaric acid and 
L- aspartame giving glutamate and oxaloacetate. Oxaloacetate in presence of 
malate dehydrogenase reacts with NADH giving malate and NAD rate of NADH 
decrease is determined photometrically and is directly proportional to GOT 
activity in the sample. 
Reagents 
Reagent I:  Buffer reagent 
Reagent II: Enzyme reagent  
 Sample 
Serum or plasma 
Reagent preparation 
 4 ml of buffer reagent was mixed with 1 ml of enzyme reagent. 
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Procedure 
Pipette into test tubes   
Sample 100 πl 
Reagent 1000 πl 
Reactive sample subjected to fully Semi-auto analyzer RA-50 Bayer co. which 
gives direct reading of SGOT. 
F.  Estimation of serum creatinine (Picrate method, Henry et al., 1974)                                                     
(Span Diagnostics Ltd., India) 
Principle 
Creatinine in a protein free solution reacts with alkaline picrate and produces a 
red colored complex, which is measured colorimetrically at 520nm. 
Procedure: 
Deproteinization of test sample 
0.5 ml of serum sample was mixed well with 0.5 ml distilled water and 3 ml 
picric acid (Reagent 1). It was kept in boiling water bath exactly for one minute 
and cooled immediately under running tap water and centrifuged. 
2.0 ml of supernatant from the above step was mixed with 1.0 ml sodium 
hydroxide solution (Reagent 2). 0.5 ml of distilled water and working creatinine 
standard mixed with 1.5 ml picric acid and 0.5 ml sodium hydroxide solution 
served as blank and standard respectively. All the tubes were allowed to stand 
at room temperature after thorough mixing for 20 min. The absorbance of blank, 
standard and samples were measured immediately against distilled water at 
520nm.   
G. Creatine kinase (CKMB)  
(Span Diagnostics Ltd., India) 
Principle 
This procedure involves measurement of creatine kinase (CK) activity in the 
presence of an   antibody to CK-M monomer. This antibody completely inhibits 
the activity of CK-MM and half of CK-MB while not affecting the B subunit of CK-
MB and CK-BB. Then the CK method is used to quantitatively determine CK-BB 
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activity. CK catalysis the reaction between creatine phosphate and ADP, giving 
creatine and ATP. ATP and glucose in the presence of G6PDH oxidizes, and 
reduces NAD to NADH. The rate of NADH formation is determined 
photometrically at 340 nm and is directly proportional to CK-BB activity. The 
CK-MB activity is calculated by multiplying CK-BB X 2. 
Reagents 
 Reagent I: Enzyme Reagent I 
 Reagent II: Enzyme Reagent II 
Sample 
 Serum free of haemolysis, heparinised plasma, protected from light.  
Reagent preparation 
4 ml of enzyme reagent I was mixed with 1 ml of enzyme reagent II. 
Procedure 
Pipette into test tubes   
Sample 50 l 
Reagent 1ml 
 
Solution was mixed well and change in absorbance was measure after 10 min at 
37o C. procedure was repeated and reading was taken at every min for next 5 
min and ∆A/ min was calculated. 
Calculation 
∆A/ min × 3376 = U/ I CKBB 
CKMB= CKBB X 2 
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Histopathological study of major organs included heart, liver and kidney were 
carried out to study protective effects of different extracts of T. aestivum on iron 
overload induce complications on animals. 
Fixation of the tissues 
Dissected tissues were washed with normal saline and then kept in 10% formal 
saline. The tissues were then kept in Bouin’s fixative for 18 to 24h. Tissues were 
then washed twice with distilled water and kept in 70% alcohol. A pinch of 
lithium carbonate was added to remove excessive stain. The tissues were 
washed and kept in 70% alcohol again. After that tissues were transferred to 
90% alcohol and kept in it overnight. Next morning all tissues were transferred 
into 100% alcohol and kept for 3h. Then the tissues were transferred to xylene 
and kept till they become transparent. 
Microtomy 
Tissues were fixed on melted paraffin in wooden blocks, so that sectioning can be 
performed. Several sections of 3 µm thickness were taken from each tissue and 
sections with uniform shape and size were selected for histology. Selected 
sections were fixed on the clear glass slide with the help of egg albumin. 
  
HISTOPATHOLOGICAL STUDY  
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Staining 
Tissues were stained using Heamotoxyllin and Eosin (H & E) stain. 
 
Slides          Xylene                  100% alcohol               90% alcohol 
          20 min         2-3 dips      1-2 min 
 
Distilled            30% alcohol                        50% alcohol               70% alcohol 
  Water                              2-5 min      2-5 min     2-5 min 
2-5 min  
 
            
Heamatoxyllin           running                       1% acid                          Ammonia water 
      stain           tap water                     alcohol                   2-4 drops 
   2-4 min          5-10 min                   2-4 drops 
 
 
 
Acetone     Eosin stain               Running   Distilled water 
2-3 min                                tap water            2 min 
                      5 min           
 
 
   Dry            Xylene                   DPX mounting 
            48 hrs 
 
 
 
 
Preparation of column chromatography for isolation of compound 
Dried power of methanol extract (Extract M) was loaded on a glass column (60 X 
3cm) packed with silica gel G (40g, 160-200#, spectrochem Pvt. Ltd.) as a 
stationary phase. Gradient elution was performed using different proportion of 
methanol: water: acetone: glacial acetic acid (1:0-80:0.5:0.1).Total 115 fractions 
of eluent were collected. 
Collected factions were analyzed by thin-layer chromatography to determine a) 
if fraction contains more than one component and b) if fractions can be 
combined without affecting the purity of those fractions. 
                                                          vbbbbbbbbbbb 5.6 Isolation and characterization of iron chelating active constituent of wheatgrass 
ticum aestivum (wheatgrass) 
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Figure 5.2: Assembly set up for column chromatography 
Isolation and identification of compound PI1: 
Fraction 71-76 eluted using methanol: water: acetone: glacial acetic acid (1:0-
80:0.5:0.1) was subjected to concentrate which yielded brown crystals. On 
recrystallization from methanol gave needles (8.2mg) having melting point 215-
218 0C. An IR spectrum was recorded on FT-IR-8400S, Shimadzu instrument. 
Mass spectra was obtained using 2010EV LCMS Shimadzu instrument. 
The identity of isolated compound was confirmed by TLC plate. These isolated 
compound gave black colour spot after spraying of 5 % ferric chloride solution 
on TLC that suggest nature of these compound was belonged to phenolic group.  
Isolated compound was subjected to determine in-vitro quantitative analysis of 
phenolic content, in-vitro and in-vivo iron chelating activity. 
 
 
The chelation of ferrous ions by extracts was estimated by method of Dinis et al., 
1994.  Briefly, 50 μl of 2 mM FeCl2 was added to 1 ml of different concentrations 
of extract (0.2, 0.4, 0.8, 1.6 and 3.2 mg/ml). The reaction was initiated by the 
addition of 0.2 ml of 5 mM ferrozine solution. The mixture was vigorously shaken 
and left to stand at room temperature for 10 min. The absorbance of solution 
was thereafter measured at 562 nm. The percentage inhibition of ferrozine–Fe2+ 
complex formation was calculated as [(A0- AS)/ AS] X 100, where A0 was the 
                                                          vbbbbbbbbbbb 5.7 In-vitro evaluation of iron chelating activity in active constituent of wheatgrass 
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absorbance of control, and As was absorbance of extract/standard. Na2EDTA was 
used as positive control. 
  
 
Male Sprague-Dawley rats initially weighed 150-200 gm were used for these 
experiments. The rats were given single i.p. injections of iron-dextran (25 
mg/l00 gm body wt.) which resulted in condition of acute iron overload. Control 
rats were injected with an equal volume of dextran at same time.  (British journal 
of hematology, 1990) 
The experimental animals were divided into four groups, (n=6). 
Group 1: Normal control received dextrose solution 
Group 2: Disease control treated with iron dextran                                                                            
(25 mg/l00g body wt. for 2 days) 
Group 3: Disease control treated with desferoxamine                                                                               
(40 mg/kg, p.o for 2 days) 
Group 4: Disease control treated with isolated compound PI1                                                                
(40 mg/kg, p.o. for     2 days) 
 
At the end of day two, urine samples were collected under fasting conditions. 
Urine sample was subjected for estimation of iron using fully automated 
biochemistry Dimension-Rx L Max-Dade Behring Analyzer. 
  
                                                          vbbbbbbbbbbb 5.8 In-vivo evaluation of iron chelating activity in active constituent of wheatgrass 
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At the end of 30 days period of iron overloaded conditions, animal were 
sacrificed by spinal cord dislocation technique and liver homogenates were 
prepared. The prepared homogenates were used to estimate tissue protein levels 
(of Lowry et al., 1951), SOD by Misra et al (1984), catalase by Aeibi et al., 1974, 
reduced Glutathione (GSH) by Beutler et al (1963)  and tissue lipid peroxidation, 
malondialdehyde-MDA by Ohkawa et al (1979).  
Preparation of tissue homogenate: 
Reagents 
1. 0.25M sucrose solution: 85.57 gm of sucrose was dissolved in 1000 ml of 
distilled water. 
2. Tris HCl buffer (10mM, pH 7.4) solution: 1.21 gm of Tris was dissolved in 900 
ml of distilled water; pH was adjusted to 7.4 with 1 M HCl and diluted up to 
1000ml with distilled water. 
Procedure:  
Animal were sacrificed by spinal dislocation technique and liver was dissected 
out, rinsed with ice cold distilled water followed by sucrose solution (0.25 M). It 
was blotted free of blood and tissue fluid then weighed on analytical balance. 
Then it was cross-chopped with surgical scalpel into fine slices and was placed in 
chilled sucrose solution, quickly blotted on a filter paper. The tissue was minced 
and homogenized in ice-cold 10 mM Tris HCl buffer at a concentration of 10% 
(w/v) with 25 strokes of tight Teflon pestle of glass homogenizer at a speed of 
2500 RPM. 
The prepared homogenates were centrifuged in cooling centrifuge at 6000 RPM 
for 20 minutes; temperature was maintained at -5 to 1oC during centrifugation. 
Clear supernatant was separated and used to estimate tissue protein levels, SOD, 
Catalase, Reduced Glutathione (GSH) and tissue lipid peroxidation 
(Malondialdehyde-MDA).  
 
                                                          vbbbbbbbbbbb 5.9 Investigation of anti-oxidant property of T. aestivum in iron overload condition 
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A. Estimation of tissue protein levels 
The liver tissue protein was estimated by the methods of Lowry et al., 1951. 
Reagent A: 2%Na2CO3 in 0.1N NaOH solution 
Reagent B: 0.5% CuSO4.5H2O in 1% sodium potassium tartrate  
Reagent C: alkaline copper sulphate solution (mixture of 50ml of Reagent A and 
1ml of Reagent B) 
Reagent D: dilute Folin Phenol Reagent (1N) 
The Folin Phenol Reagent was titrated with NaOH solution to a phenolphthalein 
end point. On the basis of this titration, the Folin Phenol Reagent was diluted 
(about 2 fold) to make it 1N in acid.  
Working standard: It was prepared from human serum diluted 100 to 1000 fold 
(approximate 700-70  per ml). This in turn was titrated with standard solution 
of crystalline Bovine Serum Albumin. The 1 gm is equivalent to 0.97  of serum 
protein.  
Procedure: 
To a sample of 5-100  of protein in 0.2 ml in a test tube, 1 ml of reagent C was 
added. Mixed well and allowed to stand for 10 min or longer at room 
temperature. About 0.1 ml of reagent D was added very rapidly and mixed within 
a second or two.  After 30 min or longer the samples were read in a 
spectrophotometer. For the range 5-25  of protein per ml of final solution, it 
was described to make reading at or near =750 n, the absorbance peak. For 
stronger solution, the reading might be kept in a workable range by reading near 
=500 nm. Final calculation was made from the standard curve. 
B. Measurement of Malondialdehyde (MDA) level  
Lipid peroxidation product MDA was estimated as per the method described by 
Ohkawa et al (1979).  
Principle 
One molecule of MDA reacts with two moles of Thio barbituric acid under mildly 
acidic conditions to from a pink colored chromogen optically measured at 532 
nm. 
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Procedure:  
Supernatant (0.2 ml) was mixed with 0.2 ml of 8% W/V sodium dodecyl sulfate, 
1.5 ml of 20% acetic acid in 0.27 M hydrochloric acid, 1.5ml freshly prepared of 
thiobarbituric acid (TBA) (1%W/V) and 0.6 ml of distilled water. The mixture 
was heated in a water bath at 95 oC for 45 minute, cooled and 2 ml of the mixture 
was mixed with 2 ml of 10% trichloro acetic acid. The resulting mixture was 
centrifuged at 1000 rpm for 5 min. The intensity of pink color developed was 
read against blank at 532 nm. The amount of (MDA) (thiobarbituric acid reactive 
material) was calculated using molar extinction coefficient 1.56 X 10 5 M-1 Cm-1 
and reported as nmoles of MDA/mg protein. 
C. GSH level (Reduced Glutathione)  
Reduced GSH levels in tissue homogenates were estimated as per the method 
described by Beutler et al (1963).  
Principle 
All of the non protein sulfhydryll groups in form of GSH-DTNB (5, 5’-dithiobis 2-
nitro benzoic acid) is a disulfide compound which is readily reduced by 
sulfhydryll compound, forming a highly colored yellow anion, optically measured 
at 412 nm. 
Procedure:  
To 1 ml of sample (tissue homogenate), 1 ml of 10%TCA was added. The 
precipitated fraction was centrifuged and to 0.5 ml supernatant, 2 ml of DTNB 
reagent was added. The final volume was made up to 3ml with phosphate buffer. 
The color developed was read at 412 nm. Standard curve for GSH was prepared 
using glutathione. Results were expressed as µmole of GSH/mg tissue. 
D. Superoxide dismustase (SOD) 
SOD was estimated as per the method described by Misra et al (1984).  
Principle 
Rate of auto oxidation of epinephrine and the sensitivity of this auto oxidation to 
inhibition by SOD were augmented as pH was raised from 7.8-10.2, O2 generated 
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by xanthine oxidase reaction, caused by the oxidation of epinephrine to 
adrenochrome and the yield of adrenochrome produced per O2 introduced. The 
auto oxidation of epinephrine proceeds by at least two distinct pathways only 
one of which is free radical chain reaction involving O2 and hence inhabitable by 
SOD. 
Procedure:  
Supernatant (0.1ml) of sample was mixed with 0.1 ml EDTA (1x10-4 M), 0.5 ml of 
carbonate buffer (pH 9.7) and 1 ml of Epinephrine (3x 10-3M). The optical 
density of formed adrenochrome was read at 480 nm for 3 min at an interval of 
30 sec. the enzyme activity has been expressed in terms of U/min/mg protein. 
One unit of enzyme activity is defined as the concentration required for the 
inhibition of the chromogen production by 50% in one minute under the defined 
assay conditions.  
E. Catalase  
Decomposition of H2O2 in presence of catalase was estimated by Aeibi et al., 
1974.  
Principle 
In U.V. range H2O2 shows a continual increase in absorption with decreasing 
wavelength. The decomposition of H2O2 can be followed directly by the decrease 
in absorbance at 240 nm. The difference in absorbance per unit time is a 
measure of catalase activity.  
Procedure:  
A 50 l supernatent was added to buffered substrate (50 mM phosphate buffer, 
pH 7 containing 10 mM H2O2) to make total volume 3 ml. The decrease in the 
absorbance was read at 240 nm for 2.5 min at an interval of 15 sec. The activity 
was calculated using extinction co-efficient of H2O2 0.041/ moles/cm2. Results 
were expressed as moles of H2O2 utilized/min/mg protein. 
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Healthy male wistar rats weighed 150-200 gm were used for present study. 
Thrombocytopenia was induced in rats by busulfan according to methods of 
Evensen et al. 1968 and Deeg HJ 1999. Busulfan at a final concentration of 10 
mg/ml in polyethylene glycol was prepared and was infused doses of 25 mg 
busulfan/kg body weight each at 1, 5, 10 and 15 days of treatment period which 
produced significant reduction in platelet counts in rats, which showed severe 
bleeding conditions as found in thrombocytopenia. Busulfan is an alkylating 
agent with myeloablative properties and activity against non-dividing marrow 
cells and, possibly, non-dividing malignant cells. 
Treatment protocol 
The experimental animals were divided into five groups, six animals in each 
group.  
Group I    :   Normal healthy control   
Group II  : Diseases control, busulfan induced thrombocytopenic rats                                    
(25 mg busulfan/kg) 
Group III :   Busulfan induced thrombocytopenic rats treated with wheat grass 
fresh juice (5 ml/kg, p.o., day) 
Group IV :   Busulfan induced thrombocytopenic rats treated with methanol   
extract (50 mg/kg, p.o., day) 
Group V : Busulfan induced thrombocytopenic rats treated with wheat grass 
acetone extracts   (50 mg/kg, p.o., day) 
All the studies were carried for a period of three weeks. After 21 days of 
treatment period blood samples were collected under fasting conditions and 
were subjected to estimations.  
 
 
 
                                                          vbbbbbbbbbbb 5.10 Evaluation of therapeutic enefit of Triticum aestivum in thrombocytopenia 
Induction of thrombocytopenia 
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Blood samples were collected in clean dry centrifuge tubes at the end of three 
weeks of treatment period by retro orbital plexuses under light ether anesthesia 
and were collected in EDTA tube to prevent clot formation at room temperature.  
A. Estimation of hematological parameters 
   Various hematological parameters like  
a. Hemoglobin content 
b. Total RBC, PCV, MCV, MCH, MCHC 
c. Total WBC count  
d. Differential WBC count 
Neutrophil, Lymphocyte, Eosinophil, Basophil counts and Total 
lymphocyte count and  
e. Platelet count  
   were estimated using fully automated hematoly analyzer - Model XS-800i – 
Sysmex.  
B. Determination of clotting time [Lee and white method] 
Principle: During coagulation sol form of the blood is changed to gel from. The 
time elapsed between the moment of escape of blood outside the vessel and the 
observation of physical change is taken as clotting time. 
Apparatus: 
1. Sterile disposable pricking needle or lancet 
2. Stop watch 
3. Dry glass capillary tube (narrow diameter 1 top 2 mm, minimum 10 cm 
long.) 
4. Cotton Swab of absorbent cotton 
5. Spirit wetted, cotton swab. 
Chemicals: 
    70 % v/v ethyl alcohol or 70 % v/v denatured spirit 
Blood sample collection and blood analysis  
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Procedure: 
1. Blood was collected from animal by retro orbital plexus method under light 
anesthetic conditions.  
2.  Immediately stop watch was started. 
3.  After every 30 seconds, a small piece of capillary was breaked. 
4. Step 3 was repeated till fibrin thread appeared at broken end of capillary 
tube.  
5. Clotting time was recorded as interval between pricking finger and first 
appearance of fibrin thread at broken ends of capillary tube.   
 
C.  Determination of bleeding time  
Principle 
The time elapsed between the moment blood escapes from vessel and the 
cessation of its flow is defined as the bleeding time the usual bleeding time is 1-3 
minutes and clotting time is 4-10 minutes. Bleeding time is prolonged during 
thrombocytopenia. 
Procedure: 
1. The tip of finger of rats was sterilized with spirit and bold prick was given 
so that blood flows freely. The stopwatch was immediately started. 
2. The blood was soaked on a filter paper (while soaking, the filter should not 
touch the skin of finger). This was repeated every 10 seconds till no blot 
appears on the papers. 
3. The time from the first appearance of the blood to the cessation of bleeding 
was the bleeding time.  
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Experimental animals 
Experimental animals Albino Wistar rats weighed between 180–220 gram and 
Swiss albino mice weighed between 25–35 gram were used for present study.  
Treatment protocol: The animals were distributed into 4 groups (n=6). The 
first group served as control, second group received standard drug – Ocimum 
sanctum extract (OSE) at a dose of 100 mg/kg orally, third and fourth group 
received fresh juice (5 ml/kg/p.o/day) and methanolic extracts (100 
mg/kg/p.o./day) of Triticum aestivum respectively. 
 
 
A.  Carbon clearance test                                                                                                                                 
(Das M et al., 1998, Gokhale AB et al., 2003, Jayathirtha MG et al., 2004) 
 The four groups of swiss albino mice were administered drug or vehicle for 5 
days orally. After 48 hours of last dose of drug, mice were injected with 0.1 ml 
of indian ink via tail vein. Blood samples were withdrawn at 0 min and 15 min. 
A 50 μl blood sample was mixed with 4 ml of 0.1% sodium carbonate solution 
and absorbance of this solution was determined at 660 nm. The phagocytic 
index K was calculated using following equation: 
  K = (Loge OD1-Loge OD2)/15 
 Where OD1 and OD2 were the optical densities at 0 and 15 min 
respectively. 
B. Cyclophosphamide induced Neutropenia:  
 (Thatte UM et al., 1987, Heppner GH et al., 1976) 
 Swiss albino mice received the drug or vehicle orally for 10 days. On 10th day, 
a neutropenic dose of cyclophosphamide (200 mg/kg, sc) was administered 
and this day was labeled as day zero. Blood samples were collected through 
retro-orbital vein. The total leucocyte count (TLC) and DLC were performed 
prior to and on day 3 after injection of cyclophosphamide. The TLC and DLC in 
treated groups were compared with the values of the control group. 
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C. Neutrophil adhesion test  
Fulzele SV et al., 2003, Shinde UA et al., 1999. 
Albino Wistar rats were divided into different groups and were treated orally 
with drug or vehicle for 14 days. On day 14, blood samples were collected 
from retro orbital plexus into heparinized vials and differential leukocyte 
count was determined. After initial counts, blood samples were incubated 
with 80 mg/ml of nylon fibres for 10 min at 37°C. The incubated blood 
samples were again analyzed for DLC. The difference in the neutrophils count 
before and after incubation of blood sample with nylon fibers was determined. 
 
 
 
Results are presented as mean ± SEM.  Statistical differences between the means 
of the various groups were evaluated using one-way analysis of variance 
(ANOVA) followed by Tukey’s test. Data were considered statistically significant 
at P < 0.05 and highly significant at P < 0.001. Statistical analysis was performed 
using Sigma stat statistical software. 
 
 
 
 
Statistical analysis  
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          Macroscopic and microscopic studies     
Macroscopical features -    
In our investigation, certified samples of specie of wheat viz. Triticum aestivum 
was used to grow in plastic trays as per the standard procedure mentioned in 
material and method chapter. In conformation with description in literature; the 
leaves were near glabrous, auriculate, with blades narrow to broadly linear, 2–20 
mm wide, flat and without cross venation. (Percival, J. 1974) The leaf blade was 
linear and parallel–veined with mid rib projecting on the back, continuing 
someway along the sheath.  
 
Fig 6.1.1: Triticum aestivum (Wheat grass) and wheat grass juice. 
Microscopical studies - 
Microscopic studies of transverse sections, surface preparations and powder 
studies of wheatgrass viz Triticum aestivum, were conducted using high-
resolution microscope. The structure of wheatgrass leaf showed elaborate 
epidermis with characteristic stomata and trichomes, green assimilating 
parenchyma, conducting vascular bundles and longitudinal strands of fibrous 
stereome or supporting tissue.  
 
                                                          vbbbbbbbbbbb 6.1 Pharmacognostic studies of Triticum aestivum (wheatgrass) 
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Surface preparations of Triticum aestivum - 
The epidermis of the blade of the leaf was found to be composed of a number of 
diverse elements arranged in parallel rows along the long axis. Some of the 
individual rows consisted entirely of elongated cells placed end to end, each cell, 
with convex cutinized outer wall 4-5 m thick, appearing in longitudinal section 
as a narrow rectangle 150-300 m long and 15-20 m wide. In other rows 
characteristic lines of long cells alternating with stomata were also present, 
trichomes or hairs of various lengths were found scattered along the rows at 
more or less at regular intervals. The trichomes or hairs were always unicellular. 
To the right and left of the central line were rows of long cells interspersed with 
hairs. Parallel to these, at the base of the ridge, there were single or double lines 
of stomata. In the furrow between two ridges was a band of three to seven rows 
of elongated cells, whose walls were thinner and not so distinctly parallel to each 
other are bulliform cells or motor cells (Figure 6.1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Unicellular trichome,    
2. Stereome fiber    
3. Double raw of stomata    
4. Rows of mot 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.2 Surface preparation of T. aestivum 
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Transverse section of Triticum aestivum leaf (General description) -    
On the upper surface of the leaf there was a series of longitudinal ridges or ribs, 
the lower surface being almost flat. The epidermal cells covering ridges differed 
in form and arrangement from those over the furrows and along the edge of the 
leaf. Running along the summit of each ridge there was a single row of elongated 
thick-walled and pitted cells alternating with hairs. On the flank of the ridge, 
right and left of the central line, there were three to five rows of long cells 
interspersed with short one and hairs. Parallel to these, at the base of the ridge, 
were single or double lines of stomata. In the furrow between two ridges there 
was a band of three to seven rows of elongated cells, whose walls were thinner. 
They were not distinctly parallel to each other are bulliform cells or motor cells.  
The trichomes or hairs were always unicellular, and varied in length and 
stoutness. Some of them were blunt on the edges of older leaves where as others 
were short and stout, 20-30 πm long, with fine curved points rendering the 
surface scabrid. On the leaves of T. aestivum, ample numbers of hairs were 
present, while in T. dicoccum and T. durum they were sparsely distributed on the 
surface of the leaf. These were usually more on the upper epidermis than the 
lower epidermis. Each stoma on the leaf consisted of four cells, the two guard 
cells being narrow, with specially thickened walls round the stomatal pore and 
thin-walled widely dilated ends: the pore when closed appears as a narrow slit 
30-40 πm long. The ratio of the number of stomata on the upper and lower 
epidermis respectively was about 10:7. In the transverse section the pores of the 
stomata were seen to be in communication with large intracellular cavities in the 
mesophyll, called lacune.  The parenchyma of the leaf consists chiefly of thin-
walled assimilating tissue, containing lenticular chloroplasts 4.5-6 πm in 
diameter. The cells of the chlorophyll-containing tissue in the central part of the 
leaf were much more irregular in shape and are loosely packed, with large 
intracellular spaces between them. Chloroplasts were present especially present 
in the subepidermal layers. In each cell on the outside of stereome, and between 
the vascular bundles, there was a single crystal or cluster of crystals of calcium 
oxalate. Vascular bundles were somewhat nearer to the lower surface than the 
upper surface of the leaf. All vascular bundles were collateral, with the xylem 
towards the upper surface of the leaf and the phloem bellow. In the xylem there 
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were one or two vessels 20 πm in diameter with annular or spiral thickening 
with narrow elliptical pits. Each bundle was surrounded by an inner and outer 
sheath; the former (the ‘mestome’) enclosed the vascular strand, and was 
composed of elongated thick-walled cells; the outer or ‘parenchyma sheath’ was 
more conspicuous and consisted of thin-walled cells, almost circular in 
transverse section. Above and below the bundles, and arranged parallel with 
them along the leaf were strands of stereome or supporting tissue consisting of 
sclerenchymatous fibers. 
Transverse section of Triticum aestivum leaf - 
It had more number of trichomes than other species, mostly in lower epidermis. 
Motor cells were clearly seen, almost equal in size on both the sides. The 
parenchymatous cells of outer bundle sheath were larger and also more in 
number than other verities. The cells of epidermis were nearly circular in shape. 
The medial vein was broader than other species. Xylem vessels were 4-5 in 
number. Outer sheath of vascular bundle was complete (Figure 6.1.3).   
 
 
 
 
 
 
  
 
 
 
1. Epidermis   2. Motor cells  3. Stomata   4. Lacuna   5. Xylem  6. Phloem                                          
7. Inner sheath of vascular bundle  8. Outer sheath of vascular bundle                                                        
9. Mesophyll   10. Parenchyma   11. Guard cell  12. Stereome 
 
 
 
 
Figure 6.1.3 Transverse section (Cellular) of Triticum aestivum 
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Characteristics of various species of Triticum powder - 
Powder characters of Triticum aestivum –  
Epidermal cells in surface view were elongated and rectangular having few numbers of 
stomata. Trichomes were simple, uniseriate, unicellular and long with pointed end and 
swollen bases. Smaller ones were hook-shaped with broad base while longer trichomes 
were more in number than smaller ones. Fibers were scattered here and there, found as 
single or in groups. They were thin-walled and lignified. Vessels were single or together 
in groups of 2-3, pitted, reticulated and annular type. Pitted vessels were more in 
number (Figure 6.1.4).  
  
1 
2 
3 
4 
6 
5 
7 
Figure 6.1.4 Characters of T. aestivum 
powder 1. Reticulated vessels 
2. Group of fibers 
3. Hook-shaped trichome 
4. Pitted vessels with pitted parenchyma 
5. Broken trichome 
6. Epidermis in surface view with stomata 
7. Uniseriate, unicellular simple trichome 
  
                             6. Results 
127  
 
 
      
            Preliminary phytoprofile 
Powder leaves were subjected to successive solvent extraction. The different 
extracts were examined for their % yield (table 6.2.1).  
The extracts obtained from successive solvent extraction process were subjected 
to various chemical tests to determine the presence of phytochemical constitutes 
like phenolics, tannins, and flavanoids. The resulted are reported in table 6.2.2.  
      Table 6.2.1: % yield of various extracts of Triticum aestivum using 
soxhlet apparatus. 
Sr. 
No. 
Extracts of                     
T. aestivum 
Colour of 
extracts 
Consistency of 
extracts 
% yield 
W/W 
1.  Petroleum 
ether 
Light green Sticky 2.8 
2.  Chloroform Green Semi solid Sticky 3.4 
3.  Acetone Dark green Semi solid Sticky 4.3 
4.  Methanol Brownish 
green 
Semi solid Sticky 4.1 
5.  Water Pale yellow Sticky 5.3 
  
Successive solvent extracts of wheatgrass with petroleum ether, chloroform, 
acetone, methanol and water were prepared, employing soxhlet apparatus. 
Highest extractive value was that of water extract (5.3 %), followed by acetone 
(4.3 %), methanol (4.1 %), chloroform (3.4 %) and petroleum ether with lowest 
extractive value of 2.8 %.  
There is a direct relation beteween iron chelatory activity and the contents of 
phenolic and flavonoids in some extracts as reported by Ebrahimzadeh et al., 
2008. Hence, the extracts obtained from successive solvent extraction process 
were subjected to shinoda and FeCl3 tests to determine the presence of 
phenolics, tannins and flavanoids. Methanol and water extracts showed presence 
                                                          vbbbbbbbbbbb 6.2 Phytochemical screening of various extracts of Triticum aestivum 
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of phenolics, tannins and flavanoids, while petroleum ether, chloroform and 
acetone extracts had no phenolic and flavanoids components. (Table 6.2.2) 
Table 6.2.2: Qualitative chemical tests of different extracts of Triticum 
aestivum.  
Class of 
compounds 
Petroleum 
ether 
extract 
Chloroform 
extract 
Acetone 
extract 
Methanol 
extract 
Water 
extract 
Phenolics/ 
tannins 
- - - + + 
Flavanoids - - - + + 
 
 
           Quantitative determination of total phenolic in extracts using                               
Folin Ciocalteau (FC) method 
Phenolic compounds are known as powerful chain breaking antioxidants 
(Shahidi F et al., 1992) and also possess chelating property (Ebrahimzadeh et al., 
2008).  Phenols are very important plant constitute because of their scavenging 
ability due to their hydroxyl groups (Hatano T et al., 1989). In addition, it has 
been reported that phenolic compounds are associated with anti-oxidant activity 
and play a crucial role in stabilizing lipid peroxidation (Yen GC, et al., 1993).  
The total phenolic content present in methanol and water extracts of Triticum 
aestivum   were shown in table 6.1.3. In methanol and water extracts 506.92 + 
16.36 and 198.5 + 10.61 µg Gallic acid equivalent of phenol content were 
detected. Phenolic content of methanol extract was found to be higher compared 
to water extract. 
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Table 6.2.3: Estimation of total phenolic content in methanol and water 
extract of T. aestivum. 
Sample 
Total Phenolics  
(µg/mg Gallic acid equivalent) Mean + SEM 
I II III 
Methanol extract 492.58 503.45 524.75 506.92  + 16.36 
Water   extract 210.21 189.51 195.78 198.5 + 10.61 
 
 
 
Fig 6.2.1: Total phenolic content in methanol and water extracts of wheatgrass.  
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Fig 6.2.2: Iron chelating activity of various extracts of wheatgrass and its 
comparison with desferoxamine and EDTA. 
 
 
 
The chelating of Fe2+ by extracts was estimated by the method of Dinis et al. 
1994. Ferrozine can quantitatively form complexes with Fe2+. However, in the 
presence of chelating agents, the complex formation is disrupted with the result 
that the red colour of the complex is decreased. Measurement of colour 
reduction, therefore, allows the estimation of the chelating activity of the 
coexisting chelator. The transition metal ion, Fe2+ possess the ability to move 
single electrons by virtue of which it can allow the formation and propagation of 
many radical reactions, even starting with relatively non-reactive radicals 
(Aboul-Enein AM et al., 2003). The main strategy to avoid ROS generation that is 
associated with redox active metal catalysis involves chelating of the metal ions.  
Methanol and water extracts of T. aestivum, interfered with the formation of 
ferrous and ferrozine complex, suggesting that it has chelating activity and 
captures ferrous ion before ferrozine.  % inhibition of chelating effect of various 
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extracts of Triticum aestivum, disodium EDTA and desferoxamine on Fe2+ and 
ferrozine complex formation is shown in table 6.3.1.  
Table 6.3.1: Iron chelating property (% inhibition of complex formation 
between Fe2+ -ferrozine) of methanol and water extracts of T. 
aestivum, EDTA and Desferoxamine. 
Concentratio
n of Sample 
% inhibition of complex formation 
EDTA Desferoxamine 
Methanol 
extract 
Water   
extract 
0.2 mg/ml 6.70 ± 0.21 9.14 ± 0.83 4.37 ± 0.13 0.79  ± 0.02 
0.5 mg/ml 15.06 ± 0.35 17.18 ± 2.01 12.68 ± 1.53 7.61 ± 1.40 
1.0 mg/ml 49.80 ± 1.85 61.18 ± 5.37 32.64 ± 3.18 14.71 ± 1.86 
2.0 mg/ml 89.11 ± 3.24 80.19 ± 6.23  59.22 ± 4.08  19.75 ± 3.11 
 
Values are expressed as Mean + S.E.M 
 
Iron chelating property of methanolic and water extracts of T. aestivum were 
compared to standard iron chelator drug desferoxamine which is use in 
treatment of iron overload patients of thalassemia and EDTA at different 
concentration level (table 6.3.1).  % inhibition of complex formation between 
Fe2+ -ferrozine were found in desferoxamine, EDTA, methanolic and water 
extracts of T. aestivum in acceding order. In-vitro iron chelating activities of 
EDTA, desferoxamine and both extracts were found to be increased with 
increase in their concentration with highest activity at concentration of 2 mg/ml. 
The chelating activity of methanol extract (59.22 ± 4.08) was found to be 
significantly higher compared to water extract (19.75 ± 3.11).  
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BIOLOGICAL EVALUATION / PHARMACOLOGICAL STUDIES OF VARIOUS 
EXTRACTS OF Triticum aestivum (Wheatgrass) 
Various extracts T. aestivum were subjected for beneficial effects in iron 
overload induced thalassemia model, antioxidant activities, 
thrombocytopenia and immunomodulatory in various animal models. 
 
 
Intraperitoneal injections of iron-dextran (12.5 mg/l00 g body wt.) evenly 
distributed over a 30 days period that results in condition of chronic iron 
overload (serum iron - 6099 ± 252 µg/dl)  which is found as same as iron 
overload conditions as in thalassemia. Control rats were injected with an equal 
volume of dextran at the same time showed normal level of iron (serum iron - 
203 ± 17 µg/dl) in rats.  
All the studies were carried out for a period of 30 days. During the blood sample, 
urine sample and facial sample were collected on 15 and 30 days under fasting 
conditions.  
          Hematological parameters 
Beneficial effects of wheatgrass on hemoglobin and RBC parameters on 
iron overloaded rats 
Iron overloaded group rats exhibited significant decrease in Hb count (10.78 ± 
0.84 gm/dl) and RBC count (6.77 ± 0.29 m/cmm) as compared to normal control 
group rats (Hb-14.57 ± 0.61 gm/dl, RBC- 8.65 ± 0.49 m/cmm) suggesting toxic 
effect of iron excess on Hb and RBC synthesis. 15 days treatment with 
desferoxamine (Hb-13.5 ± 0.51 gm/dl, RBC- 7.86 ± 0.58 m/cmm), water extract 
(Hb-13.83 ± 0.31 gm/dl, RBC- 7.69 ± 0.52 m/cmm) and methanol extract (Hb-
14.03 ± 0.68 gm/dl, RBC- 8.13 ± 0.87 m/cmm) in iron over loaded rats produced 
significant increase in Hb levels and RBC counts. The increase in RBC count 
indicates that wheatgrass may have stimulated haemopoietic process while rise 
in hemoglobin content indicates stimulation of hemoglobin synthesis in 
individual RBC. Treatment with acetone extract in iron overload rats did not 
produce any significant increase in Hb level (10.67 ± 0.68 gm/dl) and RBC count 
(7.13 ± 0.44 m/cmm) as compared to iron overloaded rats (Figure 6.2.1). Over 
                                                          vbbbbbbbbbbb 6.4 In-vivo evaluation of iron chelating activity in various extracts of wheatgrass 
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all, there was improvement in Hb level and RBC count after treatment with 
wheatgrass extracts after 15 and 30 days in iron overload rats.  (Table 6.4.1).  
 
Table 6.4.1: Erythropoetic effects of various extracts of wheatgrass on day 
15 and 30 on iron overload induced thalassemic rats. 
 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
  
 
Hematologi
cal 
Parameters 
NC 
(n=6) 
DC 
(n=6) 
DCD     
(n=6) 
DCWT 
(n=6) 
DCMT 
(n=6) 
DCAT 
 (n=6) 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
Hb gm/dl 
14.57
±   
0.61 
13.93
±  
0.98 
10.78
± 
0.84* 
  9.92  
± 
0.87* 
13.53
± 
0.51# 
14.5  
± 
0.77# 
13.83
± 
0.31# 
14.15
± 
0.39# 
14.03
± 
0.68# 
15.08
± 
0.47# 
10.67
±  
0.68 
11.95
±  
0.72 
RBC m/cmm 
8.65  
±  
0.49 
8.21  
±  
0.48 
6.77  
± 
0.29* 
6.38  
± 
0.37* 
    7.86  
± 
0.58# 
 8.33 
± 
0.18# 
  7.69 
± 
0.52# 
  8.71 
± 
0.71# 
8.13  
± 
0.87# 
8.30  
± 
0.25# 
7.13   
±  
0.44 
7.48  
±  
0.42 
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Fig 6.4.1: Increase erythropoetic activity of activity of various extracts of 
wheatgrass in iron overloaded animals. 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
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Beneficial effects of wheatgrass on defense system and platelet count on 
iron overloaded rats 
Accumulation of iron in body leads to suppression of bone marrow resulting in 
reduction of total and differential leucocytes counts. This was observed in iron 
overloaded rats of disease control group (3.89 ± 0.24 103/πl) as compared to 
placebo group (5.98 ± 0.41 103/πl). After 15 and 30 days treatment with 
desferoxamine (4.01 ± 0.23 103/πl), water extract (4.93 ± 0.27 103/πl) and 
methanol extract (4.53 ± 0.32 103/πl) of wheatgrass in iron over loaded rats total 
WBC count was significant increased. (Table 6.4.2) The increase in leukocyte 
count indicates that wheatgrass may have stimulating effect on bone marrow 
and also on synthesis of all types of leucocytes. Treatment with acetone extract 
in iron overload rats did not produce any significant increase in total and 
differential leucocytes counts as compared to iron overloaded group rats. (Fig 
6.4.2) These results indicate beneficial effect of wheatgrass on immune system. 
Similarly, treatment with methanol extract (699.6 ± 38.6 103/πl) and water 
(793.6 ± 43.5 103/πl) extract of wheatgrass, significantly increased platelet 
counts in iron over loaded group rats as compared to diseases control group rats 
(530.2 ± 32.6 103/πl). Acetone extract did not produce any significant increase in 
platelet count (590.5 ± 59.5 103/πl) as compared to disease control group. These 
data indicate beneficial effect of wheatgrass in platelet deficiency disorders.  
(Table 6.4.2) 
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Tale 6.4.2: Effect of Wheatgrass on patients with -thalassemia (major) 
with respect to    changes in parameters related to platelet and 
natural defense mechanism of the body.  
 
 
 Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
Hematological 
Parameters 
NC 
(n=6) 
DC 
(n=6) 
DCD    
 (n=6) 
DCWT 
(n=6) 
DCMT 
(n=6) 
DCAT  
(n=6) 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
Platalet 
(103/πl) 
933.6
± 
66.7 
976.9 
±  
54.9 
530.2 
±  
32.6* 
412.6    
±  
51.2* 
601.4
± 
 48.5# 
598.3  
±  
51.2# 
793.6
± 
 43.5# 
839.5 
± 
 35.7# 
699.6 
± 
 38.6# 
748.4 
 ± 
 56.3#  
590.5 
± 
 59.5 
521.3 
±  
62.1 
Total WBC counts 
WBC 
(103/πl) 
5.98 
 ± 
0.41 
5.84 
 ± 
0.51 
3.89 
 ± 
0.24* 
3.26 
± 
 0.31* 
4.01 
 ± 
0.23# 
4.09 
±  
0.41# 
4.93 
 ± 
0.27# 
5.13 
 ± 
0.41# 
4.53  
± 
 0.32# 
4.72  
±  
0.42# 
3.99  
± 
 0.26 
3.44  
± 
 0.39 
Differential WBC counts 
Neutrophil 
(103/πl) 
2.63 
 ± 
0.13 
2.87  
±  
0.16 
1.86  
± 
 0.09* 
1.72 
± 
 0.12* 
2.07  
±  
0.15# 
2.16 
±  
0.20# 
2.43  
±  
0.21# 
2.67 
±  
0.31# 
2.23  
±  
0.24# 
2.32  
±  
0.20# 
1.98  
±  
0.16 
2.01  
±  
0.19 
Lymphocytes 
(103/πl) 
1.52 
±  
0.11 
1.62  
± 
 0.13 
1.02  
±  
0.07* 
0.98 
±  
0.08* 
1.13  
±  
0.12# 
1.31  
±  
0.09# 
1.34  
±  
0.12# 
1.54  
±  
0.17#  
1.25  
±  
0.08# 
1.42  
±  
0.14# 
1.06 
±  
0.09 
1.21  
±  
0.15 
Monocytes 
(103/πl) 
0.44  
±  
0.03 
0.48  
±  
0.03 
0.18  
±  
0.02* 
0.14  
±  
0.01* 
0.26  
±  
0.02# 
0.31 
±  
0.03# 
0.39  
±  
0.03# 
0.44  
±  
0.04# 
0.36  
±  
0.03# 
0.43  
±  
0.05# 
0.22  
±  
0.03 
0.23  
±  
0.02 
Eosinophil 
(103/πl) 
0.13 
± 
 0.01 
0.14  
±  
0.01 
0.04  
± 
0.005
* 
0.02  
± 
0.005
* 
0.06  
±  
0.01# 
0.08 
±  
0.01# 
0.12  
±  
0.02# 
0.13  
±  
0.02#  
0.07  
±  
0.01# 
0.09  
±  
0.01# 
0.04  
±  
0.01 
0.05  
±  
0.01 
Basophil 
(103/πl) 
0.11 
±  
0.01 
0.12  
±  
0.01 
0.03  
± 
0.005
* 
0.04  
± 
0.005
* 
0.05  
±  
0.01# 
0.07 
±  
0.01# 
0.11  
±  
0.01# 
0.12  
± 
0.01#  
0.08  
±  
0.02#  
0.10  
±  
0.02#  
0.03  
± 
 0.01 
0.06  
±  
0.01 
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Fig 6.4.2: Beneficial effects of various extracts of wheatgrass on platelet 
counts, total and differential WBC counts. 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
 
0
200
400
600
800
1000
1200
NC DC DCD DCWT DCMT DCAT
P
la
ta
le
t 
(1
0
3
/π
l)
Platalet  counts 15 days
30 days
*
*
#
#
#
#
*
0
1
2
3
4
5
6
7
NC DC DCD DCWT DCMT DCAT
W
B
C
 (
1
0
3
/π
l)
Total WBC  counts 15 days
30 days
*
*
##
#
#
#
#
  
                             6. Results 
138  
 
 
 
 
Fig 6.4.2: Beneficial effects of various extracts of wheatgrass on platelet 
counts, total and differential WBC counts. 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
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Beneficial effects of wheatgrass on different hematological parameters on 
iron overload rats 
Iron overloaded rats showed  significant reduction in HCT (%), MCV(fL), 
MCH(pg), MCHC(g/dl), RDW-SD(fL), RDW-CV(%), PDW(fL), MPV (fL), P-LCR(%) 
and PCT(%) counts as compared to normal control rats which indicates toxic 
effects of iron on blood (Table 6.4.3). After 15 and 30 days treatment with water 
and methanol extracts of wheatgrass showed increase in these parameters which 
indicates beneficial effects of wheatgrass on various blood disorders.  Acetone 
extracts was not produced significant effects as water and methanol extracts.  
Table 6.4.3: Beneficial effects of wheatgrass on different hematological 
parameters on   iron overloaded rats. 
 
Hematological 
Parameters 
NC 
(n=6) 
DC 
(n=6) 
DC                  
(n=6) 
DCWT 
(n=6) 
DCMT 
(n=6) 
DCAT              
(n=6) 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
HCT (%) 47.2 
± 
3.9 
46.1  
±    
 4.5 
28.9  
±  
1.99 
28.5
± 
3.76 
32.8  
±      
4.8 
35.7 
±   
5.2 
36.8   
±      
4.9 
42.7 
±      
6.4 
30.8 
±     
2.9 
38.4 
±  
4.8 
25.8  
±      
2.8 
32.3 
±      
3.6 
MCV(fL) 55.4 
± 
6.1 
53.9 
±      
3.8 
44.0 
±      
3.7 
36.9 
±   
3.1 
46.0   
±      
4.8 
46.9 
±   
5.2 
53.6  
±      
4.0 
55.6  
±     
3.2 
45.7   
±      
5.6 
55.9 
±   
4,7 
43.8   
±     
4.9 
44.9  
±     
5.7 
MCH(pg) 22.1 
± 
1.9 
19.8 
±            
2.3 
14.2 
±     
0.9 
13.7 
±   
2.1 
15.7 
±      
0.9 
18.4
± 
2.3 
18.9 
±      
1.6 
19.4 
±      
2.7 
16.3  
±      
0.9 
18.9 
±   
2.5 
15.3   
±      
1.8 
16.3   
±     
2.8 
MCHC(g/dl) 31.8 
± 
4.1 
30.2 
± 
3.6 
24.3 
± 
2.7 
23.9 
± 
3.5 
26.8 
± 
2.6 
27.8 
± 
3.9 
30.6 
± 
3.4 
32.7  
± 
5.8 
28.1 
± 
2.6 
27.9 
± 
3.7 
25.0 
± 
4.2 
27.4 
± 
3.7 
RDW-SD(fL) 27.8 
± 
4.1 
28.4 
± 
3.8 
23.7 
± 
3.9 
22.5
± 
2.4 
24.7 
± 
4.1 
23.6 
 ± 
3.6 
26.3 
± 
2.8 
27.8 
± 
4.1 
24.8 
± 
1.9 
25.9 
± 
3.3 
23.9 
± 
2.2 
24.9 
 ± 
4.0 
RDW-CV(%) 16.9 
± 
1.7 
 
18.9 
± 
1.8 
13.6 
± 
2.6 
12.7 
± 
1.8 
14.8 
± 
2.6 
15.3 
± 
2.6 
15.2 
± 
3.8 
17.4 
± 
4.2 
13.8 
± 
2.6 
16.6 
± 
2.6 
13.9  
± 
3.1 
14.7 
± 
2.0 
PDW(fL) 8.9 
± 
1.1 
9.3 
± 
2.1 
5.9 
± 
1.3 
5.4 
± 
0.98 
6.4 
± 
1.3 
6.8 
± 
0.95 
7.8 
± 
1.9 
8.4 
± 
1.1 
6.9 
± 
2.0 
7.1 
± 
1.4 
6.2 
± 
0.87 
6.1 
± 
0.79 
MPV (fL) 8.2 
± 
1.2 
 
8.4 
± 
1.6 
5.7 
± 
0.57 
5.1 
± 
0.6 
6.1 
± 
0.82 
6.9 
± 
0.47 
7.7 
± 
1.4 
7.9 
± 
1.1 
6.3 
± 
0.73 
7.1 
± 
0.6 
5.9 
± 
0.7 
6.8 
± 
0.78 
P-LCR(%) 10.4 
± 
1.3 
 
11.2 
± 
1.6 
8.1 
± 
1.5 
7.9 
± 
0.98 
8.7 
± 
0.98 
9.5 
± 
1.2 
10.1 
± 
2.1 
11.3 
± 
0.99 
9.4 
± 
1.3 
10.5 
± 
1.7 
8.3 
± 
1.1 
8.5 
± 
0,92 
PCT(%) 78 
± 
4 
 
79 
± 
7 
67 
± 
6 
63 
± 
5 
71 
± 
6 
72 
± 
8 
76 
± 
8 
77 
± 
8 
73 
± 
7 
75 
± 
6 
70 
± 
8 
69 
± 
6 
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Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
 
           Beneficial effects of wheatgrass on iron overload  
A. Serum iron and serum ferritin levels 
Intraperitoneal injections of iron-dextran (12.5 mg/l00 g body wt.) evenly 
distributed over a 30 days period on Sprague dwaley rats resulted in condition of 
chronic iron overload (serum iron - 6099 ± 252 µg/dl). Control group rats 
injected with an equal volume of dextran showed normal level of iron (serum 
iron - 203 ± 17 µg/dl). There was significant increase in serum ferritin level in 
iron overloaded group rats (1.13 ± 0.07 mg/dl) compared to normal control 
group rats (4.83 ± 0.51 mg/dl). All the studies were carried out for a period of 30 
days. Blood, urine and feacal samples were collected on 15th and 30th days under 
fasting conditions and were subjected for various biochemical parameters. (Fig 
6.4.3) 
After 15 days of treatment, there was significant reduction in serum iron and 
ferritin levels in desferoxamine group (serum iron - 2876 ± 281 µg/dl, serum 
ferritin - 2.74 ± 0.42 mg/dl). There were significant reduction in serum iron and 
ferritin levels after treatment with water extract group (serum iron - 3510 ± 264 
µg/dl, serum ferritin - 3.32  ±  0.19 mg/dl) and methanol extract group (serum 
iron - 4636 ± 142 µg/dl, serum ferritin - 3.97 ± 0.29 mg/dl) of wheatgrass 
compared to disease group. Treatment with acetone extract did not significantly 
reduce serum iron or ferritin levels (serum iron - 5222 ± 314 µg/dl, serum 
ferritin – 4.64 ± 0.38 mg/dl) compared to disease control. (Fig 6.4.3) 
These data suggest water and methanol extracts have effectiveness in reduction 
of iron overload which may be benefits in iron overload disorders as 
desferoxamine. (Table 6.4.4) 
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Table 6.4.4: Beneficial effects of various extracts of wheatgrass on iron over 
load rats with respect to changes in parameters related to its 
mechanism of action. 
 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
 
 
 
 
 
Parameters 
NC 
(n=6) 
DC 
(n=6) 
DCD   
  (n=6) 
DCWT 
(n=6) 
DCMT 
(n=6) 
DCAT 
 (n=6) 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
Serum Iron 
 µg/dl 
203    
±       
17 
221  
±    
31 
6099 
±    
252* 
6640 
±   
291* 
2876 
±   
281# 
2193 
±   
128# 
4636 
±   
142# 
4293  
±   
132# 
3510 
±   
264# 
3173    
±              
202# 
5222 
±   
314 
5130   
±     
216 
Serum 
Ferritin 
mg/dl 
1.13  
±  
0.07 
1.19 
± 
0.08 
4.83   
±   
0.51* 
6.45 
± 
0.68* 
2.74  
±  
0.42# 
2.29  
± 
0.39#     
3.97  
±  
0.29# 
4.24  
±  
0.58# 
3.32  
±  
0.19# 
3.60  
±  
0.60# 
4.64  
±  
0.38 
5.89    
±    
0.45 
Urine Iron 
 µg/dl 
26.2  
±     
6.4 
21.9 
±    
7.4 
69.2   
±       
7.7*           
80.8  
±  
11.0* 
422.5
±  
79.1# 
488.9 
±  
73.7# 
256.0
±  
32.6# 
293.4       
±  
39.4# 
296.5
±  
33.8# 
322.8
±  
11.6# 
94.0  
±  
11.9 
105.3  
±    
15.7 
Faces Iron 
 µg/dl 
2.83  
±     
0.3 
2.75 
± 
0.25 
9.17   
±       
2.5* 
11.0 
±   
1.2* 
31.0  
±     
5.3# 
40.0  
±     
3.0# 
17.67
±     
2.1# 
23.0  
±     
2.6# 
30.33
±     
2.5# 
32.5  
±     
1.5# 
12.0  
±  
1.01 
12.67  
±       
1.2 
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Fig 6.4.3: Beneficial effects of various extracts of wheatgrass on iron over 
load rats with respect to changes in parameters related to its 
mechanism of action. 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
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B. Urine iron and faces iron levels 
No changes were observed in urine and fecal iron in iron overloaded group rats 
(urine iron – 69.2 ± 7.7 µg/dl, faces iron – 9.17 ± 2.5 µg /dl) and placebo group 
(urine iron – 26.2 ± 6.4 µg/dl, faces iron – 2.83 ± 0.3 µg /dl), because iron does 
not excrete from body. There was significant increase in urine iron and faces iron 
levels in desferoxamine group (urine iron - 422.5 ± 79.1 µg/dl, faces iron - 31.0 ± 
5.3 µg /dl), water extract group (urine iron - 256.0 ± 32.6 µg/dl, faces iron - 
17.67 ± 2.1 µg /dl) and methanol extract group (urine iron - 296.5± 33.8 µg/dl, 
faces iron - 30.33 ± 2.5 µg /dl) compared to iron overloaded group rats (urine 
iron - 69.2 ± 7.7 µg/dl, faces iron - 9.17 ± 2.5 µg /dl). (Fig 6.4.4) Increase in urine 
and faecal excretion of iron in rats treated with water and methanol extracts of 
wheatgrass indicate iron chelating property of wheatgrass that was comparable 
to desferoxamine group. Similarly there were beneficial effects observed after 30 
days treatment period with wheatgrass in iron overloaded rats. (Table 6.4.4) 
Treatment of acetone extracts did not produce any significant increase in urine 
iron (94.0 ± 11.9 µg /dl) and faces iron (12.0 ± 1.01 µg /dl) levels compared to 
diseases control group. These data suggest effectiveness of water and methanol 
extracts in reduction of iron overload in rats by increase iron excretion in urine 
and faeces. 
These data suggest water and methanol extracts have effectiveness in reduction 
of iron overload which may be benefits in iron overload disorders as 
desferoxamine. (Table 6.4.4) 
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Fig 6.4.4: Beneficial effects of various extracts of wheatgrass on iron over load rats 
with respect to changes in parameters related to its mechanism of 
action. 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
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C. Protective effects of wheatgrass on iron overload complications on vital 
organs 
Excess iron in vital organs, even in mild cases of iron overload, increases the risk 
for liver disease (cirrhosis, cancer), kidney diseases, heart attack or heart failure, 
diabetes mellitus etc. and in some cases premature death.  
SGPT and SGOT levels 
There were significant increases in SGPT (101.9 ± 8.7 µg/l) and SGOT (170.9 ± 
11.3 µg/l) levels in iron overloaded group as compared to normal control group 
(SGPT –  12.4 ± 1.9 µg/l, SGOT - 46.28 ± 5.2 µg/l). After treatment with water and 
methanol extracts of wheatgrass there was significant reduction in these enzyme 
levels (water extract SGPT – 95.65 ± 6.9 µg/l, SGOT - 148.0 ± 6.5 µg/l; methanol 
extract SGPT – 81.9 ± 5.8 µg/l, SGOT - 132.4 ± 8.8 µg/l) indicating protective 
effects of extracts in liver complications due to iron overload.  (Table 6.4.5) 
Serum Creatinine and Creatinine Kinase Levels  
Serum creatinine and creatinine kinase levels were significant increased in iron 
overloaded rats group (serum creatinine- 1.76 ± 0.08 mg/dl and creatinine 
kinase- 398.2 ± 23.7 µg/l) as compared to placebo group (serum creatinine- 0.67 
± 0.08 mg/dl and creatinine kinase- 91.8 ± 8.76 µg/l). Methanol and water 
extracts treated animals showed reduction in levels of these enzymes (water 
extract, serum creatinine- 1.59 ± 0.05 mg/dl and creatinine kinase- 335.7 ± 17.9 
µg/l; methanol extract, serum creatinine- 1.45 ± 0.07 mg/dl and creatinine 
kinase- 316.5 ± 11.5 µg/l) indicating that these extracts prevent damage to vital 
organs like kidney and heart in iron overload complications. (Table 6.4.5) 
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Table 6.4.5: Beneficial effect of various extracts of Triticum aestivum on 
iron over complications on major organ heart, liver and 
kidney. 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
 
 
Parameters 
NC 
(n=6) 
DC 
(n=6) 
DCD        
(n=6) 
DCWT 
(n=6) 
DCMT 
(n=6) 
DCAT    
(n=6) 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
15 
days 
30 
days 
SGOT  µg/l 
 
46.28
± 
5.2 
48.03
± 
3.4 
170.9  
±   
11.3* 
191.6
± 
12.0* 
117.3
±   
5.7# 
105.9
±   
5.6# 
148.0
±   
6.5# 
144.5
±    
3.8# 
132.4
±   
8.8# 
126.4
±   
5.7# 
170.3
±     
7.8 
168.8
±    
6.9 
SGPT  µg/l 
 
12.8  
±     
2.5 
12.4   
±       
1.9 
101.9  
±         
8.7* 
160.4
± 
14.6* 
77.20
± 
11.0# 
63.8  
±        
5.2# 
95.65
±   
6.9# 
128.1
±   
5.7# 
81.9  
±   
5.8# 
89.1  
± 
10.3# 
97.8  
±     
3.7 
155.3
±    
5.7 
Serum 
creatinine 
mg/dl 
0.67   
±  
0.08 
0.63    
±  
0.63 
1.76    
±    
0.08* 
1.90   
± 
0.06* 
1.31  
± 
0.11# 
1.12  
± 
0.09# 
1.59  
± 
0.05# 
1.49  
± 
0.04# 
1.45  
± 
0.07# 
1.33  
± 
0.09# 
1.70  
±  
0.11 
1.63  
±  
0.11 
Creatine 
kinase 
(CKMB)              
µg/l 
91.8  
±  
8.76 
80.7  
±   
10.3 
398.2  
±   
23.7* 
446.0 
± 
12.1* 
219.0 
± 
23.8# 
189.2 
± 
15.4# 
335.7 
± 
17.9# 
325.7 
± 
14.4# 
316.5 
± 
11.5# 
271.4 
± 
16.0# 
360.1 
±  
15.6 
378.1 
±    
9.1 
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Fig: 6.4.6 Beneficial effect of various extracts of Triticum aestivum on iron 
overload induce liver complication. 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
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Fig: 6.4.7 Beneficial effects of various extracts of Triticum aestivum on iron 
overload induce kidney and cardiac complications. 
 
Values are expressed as Mean + S.E.M 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
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 D. Histopathological study of liver, kidney and heart 
 
Beneficial effects of wheatgrass on Iron overloaded Liver complications 
Hepatotoxicity is the most common finding in iron over-load because liver is the 
main recipient of the excess iron. (Zurlo MG et al., 1989)  
Results of histopathological study of liver suggested that chronic treatment with 
desferoxamine and water, methanol and acetone extracts of wheatgrass reduce 
iron pigmentation, pleomorphism, vaculation, fibrosis, disarrangement and 
degeneration of hepatocytes as compared to iron overloaded group animals. The 
degree of protection was found to be minimal with acetone extracts group. (Fig. 
6.4.8) 
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Fig 6.4.8: Protective effects of various extracts of wheatgrass on iron overloaded liver 
complications. 
  
 
      a. Normal  control                                             b. Iron overloaded Diseases control                                                   
 c. iron overload rats treated with  desferoxamine                                     d. iron overload rats treated with  water 
extract                                     
e. iron overload rats treated with  methanol  
extract                                    
 f. iron overload rats treated with  acetone 
extract                                    
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Beneficial effects of wheatgrass on Iron overloaded Kidney complications 
It was reported that an iron-deficient diet or iron chelators prevent the 
development of tubulointerstitial disease and renal functional deterioration in 
nephrotoxic serum nephritis. Baliga et al. have demonstrated that cytochrome 
P45012 and, more specifically, cytochrome P4502B1, an isozyme present in the 
glomerulus, are sources of catalytic iron that participate in glomerular injury. 
The evidence reviewed suggests the possibility of using iron chelators to halt the 
progression of kidney disease. Lin et al. have shown that chelation therapy with 
ethylenediaminetetraacetic acid (EDTA) in patients with chronic renal 
insufficiency results in a reduced rate of decline in the glomerular filtration rate 
(Lin JL et al., 2003). 
Normal structure of the cortex and medulla was observed in the kidney of 
normal control rats (Figs 6.4.9). The animals exposed to chronic iron dextran 
showed damage of renal tubules and glomeruli. Hypertrophy of epithelial cells 
and degeneration of epithelia of renal tubules with infiltration of mononuclear 
cells, dilation of glomerul and mononuclear cell infiltrates were evident in all 
diseases control rats. (Fig 6.4.9). Pathological changes in kidney ultra structure 
(injured brush-border microvilli and swollen proximal convoluted tubular cells) 
were observed when iron dextran.  
Histology of kidney in iron overload group rat treated with desferoxamine, a iron 
chelator, showed reduced damage of renal tubules and glomeruli. Pathological 
changes was also prevented by desferoxamine. Our result suggest protective 
effects of methanol, water and acetone extracts of wheatgrass in iron overload 
kidney complications as it reduced damage of kidney ultra structure (injured 
brush-border microvilli and swollen proximal convoluted tubular cells). 
Protective effects found much better in methanol extract and less in acetone 
extract. (Fig 6.4.9) 
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a. Normal control - kidney                                   b. Diseases control – kidney 
                 
c. Diseases control - with desferoxamine           d. Diseases control – with methanol extract 
 
 e. Diseases control – with water extract              f. Diseases control– with acetone extract 
Fig 6.4.9: Protective effects of various extracts of wheatgrass on iron    
overloaded kidney complications 
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Beneficial effects of wheatgrass on Iron overloaded cardiac complications 
Iron-overload cardiomyopathy is a common cause of CV death worldwide in 
subjects in their second and third decades of life. (Weatherall DJ, Clegg JB et al., 
1996, Olivieri NF, 1999) Indeed, iron-overload cardiomyopathy is the most 
important determinant of survival in European, (Olivieri NF, 1999) North 
American, (Weatherall DJ, 2001) and Chinese (Li CK, et al., 2002) patients with 
thalassemia major.  Long-term follow-up studies in beta-thalassemia patients 
have established that the level of cardiac iron accumulation correlates directly 
with both the occurrence of heart disease and mortality, (Brittenham GM et al., 
1994) while in patients with primary haemochromatosis, CV disease also 
contributes significantly to their mortality and morbidity. (Niederau C, 1996)  
Hearts from rat injected chronically with iron displayed extensive interstitial 
fibrosis and myocyte vacuolar degeneration with mild inflammatory infiltrate 
compared to placebo (Figure 6.4.10) there was vascular hemorrhage and 
hypertrophy observed in iron overload rats compared to placebo. 
Treatment with desferoxamine and extracts of methanol and water of 
wheatgrass showed protective effects on myocytes as well as reduces fibrosis 
and hypertrophy of myocytes. Vascular hemorrhages were also found to be 
reducing in iron overloaded group rats treated with methnoal and water 
extracts. Treatment with acetone extracts was produce less protective effects. 
(Figure 6.4.10) 
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a. Normal control                                            b. Diseases control 
                                       
c. Diseases control with desferoxamine           d. Diseases control with methanol extract 
                        
e. Diseases with water extract         f.  Diseases with acetone extract 
Fig 6.4.10: Protective effects of various extracts of wheatgrass on iron 
overloaded cardiac complications. 
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                                                          vbbbbbbbbbbb 
                                                                                                                                                                                                    
6.5 Isolation and characterization of iron chelating active 
constituent of wheatgrass  
Since, the results, obtained so far, revealed maximum chelating activity in 
methanol extract group, we decided to process the methanol extract further, for 
the purpose of isolation of active iron chelator constituent form Triticum 
aestivum. 
Column chromatography fraction 71-76 eluted using methanol: water: acetone: 
glacial acetic acid (1:0-80:0.5:0.1) solvent system followed by concentration 
yielded brown crystals. On recrystallization with methanol produced needle 
shaped crystals of the active compound (PI1), having melting point of 215-218 0C. 
 
            TLC Study 
The identity of the isolated compound PI1, was confirmed by comparing the Rf 
value 0.682 on TLC plate. The isolated compound gave black colored spot on 
spraying 5 % ferric chloride solution on TLC plate suggesting phenolic nature. 
 
           Spectroscopic analysis 
The isolated iron chelator compound was subjected to LCMS and IR 
spectroscopic analysis, for its molecular characterization. The compound was 
found to be aromatic in nature containing phenolic group. The data of Spectral 
analysis, IR and GC-MS of isolated pure compound mentioned in table 6.5.1. 
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Fig 6.5.1: IR spectroscopy of isolated compound PI1 from Triticum aestivum. 
 
Fig 6.5.2: Mass spectroscopy of isolated compound PI1 from Triticum 
aestivum. 
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                                                          vbbbbbbbbbbb 
                                                          vbbbbbbbbbbb 
Table 6.5.1: IR and MASS spectral value of isolated pure compound PI1. 
Spectra Spectral value Inference 
IR 3168.82 Cm-1 -OH (Phenolic) (stretching) 
1585.56 Cm-1 aromatic group 
1060.46 Cm-1 
C-O again prove that OH is from phenol 
or alcohol not carboxylic acid 
MASS 264.9 – 247=17 Removal of -OH group 
 
 
 Quantitative determination of total phenolic using Folin-Ciocalteau 
(FC) method 
The total phenolic content in isolated compound from methanol fraction of 
Triticum aestivum, using Folin-Ciocalteau (FC) method, was found to be 434.14 + 
28.02 µg Gallic acid equivalent of phenol. 
 
                                                                                                                                                                                                    
6.6 In-vitro evaluation of iron chelating activity in active constituent                            
of wheatgrass 
In-vitro iron chelating activity of isolated compound was compared with 
standard iron chelator drug, desferoxamine at 1.0 mg/ml concentration level. % 
inhibition of complex formation between Fe2+ -ferrozine were found 61.18 ± 5.37 
in desferoxamine and 30.27 ± 2.98 in isolated compound PI1.   
 
            6.7 In-vivo evaluation of iron chelating activity of active constituent of 
wheatgrass 
Intraperitoneal injections of iron-dextran (12.5 mg/l00g of body wt.), evenly 
distributed over a 2 days period, resulted in condition of acute iron overload, in 
SD rats. Control group rats injected with an equal volume of dextran, showed 
normal serum level of iron. At the end of day 2, urine samples were collected and 
analyzed for iron content. No significant changes in urine iron levels were 
observed in iron overloaded rats (34.25 ± 3.8 µg/dl) and normal control rats 
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(26.2±6.4 µg/dl). 2 day’s treatment with desferoxamine (urine iron- 108.75±7.4 
µg/dl) and isolated compound (urine iron- 62.21±9.4 µg/dl) in iron overloaded 
rats produced significant increase in urine iron levels compared to diseases 
control rats. The chelating power or efficacy of the isolated compound was 
34.5% compared to that of desferoxamine. 
Table 6.7.1: Comparison of excretion of iron in urine between 
desferoxamine and isolated compound of Triticum aestivum.  
 
 
Fig 6.7.1: Iron chelating property of isolated compound PI1 compared to 
desferoxamine. 
 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 5: Disease control treated with isolated compound PI1 (100 mg/kg, p.o., per day) (DCMT) 
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                                                          vbbbbbbbbbbb              6.8 Investigation of anti-oxidant property of Triticum aestivum in iron 
overload condition 
At the end of 30 day period of iron overloaded conditions, animal were sacrificed 
by spinal dislocation technique and liver homogenate was prepared. The 
prepared homogenates were used to estimate tissue protein levels (of Lowry et 
al., 1951), SOD by Misra et al (1984), Catalase by Aeibi et al., 1974, Reduced 
Glutathione (GSH) by Beutler et al (1963)  and tissue lipid peroxidation, 
Malondialdehyde-MDA by Ohkawa et al (1979) to role of anti-oxidant and 
beneficial effects of wheatgrass on oxidative stress induce toxicities.  
In our study, at the end of 30 days treatment periods, liver homogenates of iron 
overloaded group rats showed significant increase in OFRs, MDA level (2.56 ± 
0.18 nmoles/mg protein) and decrease in SOD (0.73 ± 0.07 units/min/mg 
protein), catalase (0.98 ± 0.14 units/min/mg protein) and glutathione levels 
(7.22 ± 1.75 µgm/mg protein) compared to normal group rats (MDA- 0.74 ± 0.11 
nmoles/mg protein, SOD- 1.42 ± 0.1 units/min/mg protein, catalase- 4.59 ± 1.11 
units/min/mg protein , GSH- 12.69 ± 1.04 µgm/mg protein). Treatment with 
methanol and water extracts of wheatgrass significantly reduced MDA level (1.24 
± 0.06 and 1.16 ± 0.08 nmoles/mg protein) in the rat liver homogenates. There 
were significant improvements in GSH, SOD and catalase levels in iron 
overloaded group rats treated with methanol (SOD- 1.29 ± 0.13 units/min/mg 
protein, Catalase- 3.47 ± 0.17 units/min/mg protein, GSH- 10.8 ± 0.7 µgm/mg 
protein) and water extracts (SOD- 1.35 ± 0.11 units/min/mg protein, Catalase- 
3.78 ± 0.69 units/min/mg protein, GSH- 11.82 ± 0.51 µgm/mg protein). No 
significant changes were observed in MDA, SOD, catalase and glutathione levels 
in acetone extract treated group. These data indicate strengthening of 
antioxidant defense by wheatgrass in iron overload condition. (Table 6.8.1) 
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Table 6.8.1: Effect of T. aestivum on antioxidant parameters in iron over 
load induced thalassemic rats. 
 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) 
(DCAT)  
Anti-oxidant 
Parameters 
NC 
(n=6) 
DC 
(n=6) 
DCD    
(n=6) 
DCWT 
(n=6) 
DCMT 
(n=6) 
DCAT 
(n=6) 
SOD 
(units/min/mg 
protein) 
   1.42 
 0.10     
     0.73* 
 0.07 
1.20# 
  0.11 
1.35# 
  0.11 
    1.29# 
  0.13 
    0.95 
 0.09 
Catalase 
(units/min/mg 
protein) 
    4.59 
  1.11 
       0.98* 
   0.24 
2.08# 
  0.37 
3.78# 
  0.69 
      3.47# 
  0.17 
     1.89# 
 0.31 
MDA 
(nmoles/mg protein) 
    0.74 
  0.11 
    2.56* 
   0.18 
    1.79# 
  0.18 
     1.16# 
  0.08 
       1.24# 
  0.06 
     2.33# 
 0.10 
GSH 
(µgm/mg protein) 
     12.69 
    1.04 
     7.72* 
    1.75 
    9.21# 
   1.12 
   11.82#  
    0.51 
      10.8# 
 0.70 
   8.65 
 1.85 
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Fig 6.8.1: Beneficial effects of wheatgrass on anti-oxidant parameters in 
iron overload animals. 
 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
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Fig 6.8.1: Beneficial effects of wheatgrass on anti-oxidant parameters in 
iron overload animals. 
 
*- significantly different from normal control (p < 0.05) 
# - significantly different from diseases control (p < 0.05) 
Group 1: Normal control received dextrose solution (NC) 
Group 2: Disease control treated with iron dextran (12.5mg/l00g body wt.) (DC) 
Group 3: Disease control treated with desferoxamine (40 mg/kg, p.o., per day) (DCD) 
Group 4: Disease control treated with water extract of T. aestivum (100 mg/kg, p.o., per day) (DCWT) 
Group 5: Disease control treated with methanol extract of T. aestivum (100 mg/kg, p.o., per day) (DCMT) 
Group 6: Disease control treated with acetone extract of T. aestivum (100 mg/kg, p.o., per day) (DCAT) 
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For evaluation of effects of wheatgrass in thrombocytopenia, busulfan was used 
to induce experimental thrombocytopenia. Busulfan is an alkylating agent with 
myeloablative properties and activity against non-dividing marrow cells and 
possibly, non-dividing malignant cells. Busulfan solution, at concentration of 10 
mg/ml in polyethylene glycol, was prepared and infused in wistar rats at doses 
of 25 mg busulfan/kg body weight each, at 1, 5, 10 and 15 days of interval 
produced pancytopenia with significant reduction in platelet count mimicking 
severe bleeding conditions as found in thrombocytopenia. 
          Hemoglobin level and RBC count 
Disease control group rats which, received busulfan showed significant 
reduction in Hb (8.1 ± 0.75 gm/dl) and RBC count (5.4 ± 0.5 m/cmm) compared 
to normal healthy group rats (Hb- 10.9 ± 0.98 gm/dl, RBC- 6.8 ± 0.89 m/cmm) 
indicating anemia in iron overloaded rats. Treatment with fresh wheatgrass juice 
(Hb- 10.5±1.1 gm/dl, RBC- 6.7±0.59 m/cmm), methanol extract (Hb- 10.2 ± 1.2 
gm/dl, RBC- 6.1 ± 0.47 m/cmm) and acetone extract (Hb- 9.7 ± 0.89 gm/dl, RBC- 
6.3 ± 0.7 m/cmm) of wheatgrass, produced significant increase in Hb levels and 
RBC counts in diseased rats. Decrease in blood Hb level and RBC count in rats 
was significantly prevented by treatment with fresh juice, methanol and acetone 
extracts of wheat grass. Thus, wheatgrass seems to help improve blood 
purification and also, to increase hemoglobin level and RBC count near to 
normal.  (Table 6.9.1)  
Table 6.9.1: Beneficial effects of Triticum aestivum fresh juice, methanol 
and acetone extracts on Hb level and RBC count.  
Blood parameters Normal 
Control 
Diseases 
Control 
DWFJ DWM DWA 
Hemoglobin  (gm/dl) 10.9+0.98 8.1+0.75* 10.5+1.1# 10.2+1.2# 9.7+0.89 
RBC (106/πl ) 6.8+0.89 5.4+0.50* 6.7+0.59# 6.1+0.47# 6.3+0.7 
                                                          vbbbbbbbbbbb 6.9 Evaluation of therapeutic enefit of Triticum aestivum in thrombocytopenia 
  
                             6. Results 
164  
 
 
 
Fig 6.9.1: Beneficial effects of Triticum aestivum fresh juice, methanol and 
acetone extracts on Hb level and RBC counts. 
 
Values are expressed as Mean + S.E.M, *- significantly different from normal control (p < 0.05), # - 
significantly different from diseases control  (p < 0.05), DWFJ- Diseases rats treated with 
Wheatgrass Fresh Juice, DWM- Diseases rats treated with Wheatgrass Methanol extract, DWA- 
Diseases rats treated with Wheatgrass Acetone extract 
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           Total WBC count 
Disease control group rats which received busulfan showed significant reduction 
in total WBC and differential WBC counts compared to normal healthy group 
rats. Treatment with fresh wheatgrass juice, methanol extract produced 
significant increase in total WBC counts and differential WBC counts, in busulfan 
induced pancytopenic rats. Treatment with acetone extract did not produce 
significant increase in total WBC counts. Disease control group rats showed 
pancytopenia (reduction in all blood cells count) compared to normal healthy 
control group rats. Treatment with fresh wheatgrass juice and different extracts 
showed increase in WBC counts compare to disease control group.   (Table 6.9.2) 
Table 6.9.2: Effect of Triticum aestivum fresh juice, methanol and acetone 
extracts treatment on differential WBC count and other blood 
parameters on control and disease rats.  
 
Blood 
parameters 
Normal 
Control 
Diseases 
Control 
DWFJ DWM DWA 
WBC (103/πl) 4.98+0.49 3.26+0.31* 4.78+0.52# 4.58+0.43# 3.89+0.26 
Differential WBC 
Neutrophil 
(103/πl) 
2.63+0.35 1.89+ 0.28* 2.45+ 0.09# 2.01+ 0.11# 2.32+ 0.12# 
Lymphocytes 
(103/πl) 
1.52+0.08 1.02+0.07* 1.63+0.08# 1.26+0.07# 1.48+0.09# 
Monocytes 
(103/πl) 
0.42+0.07 0.11+0.08* 0.43+0.06# 0.28+0.03# 0.37+0.03# 
Eosinophil 
(103/πl) 
0.12+0.01 0.02+0.003* 0.09+0.002# 0.03+0.0001# 0.11+0.01# 
Basophil 
(103/πl) 
0.11+0.002 0.04+0.003* 0.12+0.01# 0.07+0.004# 0.09+0.002# 
OTHER BLOOD PARAMETERS 
HCT (%) 44.2 33.5 43.9 42.5 38.2 
MCV(fL) 58.3 47.0 56.3 54.2 51.0 
MCH(pg) 19.2 15.2 17.2 16.1 16.3 
MCHC(g/dl) 32.7 25.6 31.8 30.0 27.8 
RDW-SD(fL) 32.1 27.1 30.2 29.3 28.9 
RDW-CV(%) 18.6 13.6 15.3 16.2 14.9 
PDW(fL) 8.5 5.8 7.2 7.7 7.2 
MPV (fL) 8.1 7.2 7.9 7.6 7.4 
P-LCR(%) 10.5 8.6 9.7 9.4 9.1 
PCT(%) 0.78 0.71 0.76 0.75 0.73 
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Fig 6.9.2: Beneficial effects of Triticum aestivum fresh juice, methanol and 
acetone extract on Total and differential WBC counts.  
Values are expressed as Mean + S.E.M, *- significantly different from normal control (p < 0.05), # - 
significantly different from diseases control (p < 0.05), DWFJ- Diseases rats treated with 
Wheatgrass Fresh Juice, DWM- Diseases rats treated with Wheatgrass Methanol extract, DWA- 
Diseases rats treated with Wheatgrass Acetone extract 
0
1
2
3
4
5
6
NC DC DWFJ DWM DWA
W
B
C
 c
o
u
n
ts
 1
0
3
/
π
l
Total WBC Counts 
*
#
#
#
0
0.5
1
1.5
2
2.5
3
3.5
NC DC DWFJ DWM DWA
W
B
C
 c
o
u
n
ts
 1
0
3
/
π
l
Differential WBC count
Neutrophil
Lymphocyte 
*
*
#
#
#
#
#
#
  
                             6. Results 
167  
 
 
 
Fig 6.9.2: Beneficial effects of Triticum aestivum fresh juice, methanol and acetone 
extract on Total and differential WBC counts.  
Values are expressed as Mean + S.E.M, *- significantly different from normal control (p < 0.05), # - 
significantly different from diseases control (p < 0.05), DWFJ- Diseases rats treated with 
Wheatgrass Fresh Juice, DWM- Diseases rats treated with Wheatgrass Methanol extract, DWA- 
Diseases rats treated with Wheatgrass Acetone extract 
 
           Platelet count 
In disease control group rats which received busulfan, there was significant 
reduction in platelet count (523 + 46 103/πl) compared to normal healthy group 
rats (905 + 82 103/πl) indicating thrombocytopenia. Treatment with fresh 
wheatgrass juice (804 + 72 103/πl), methanol extract (761 + 58 103/πl) and 
acetone extract (708 + 63 103/πl) produced significant increase in platelet count 
as compared to disease control group rats. Decrease in platelet count in these 
rats was significantly prevented by treatment with fresh wheatgrass juice, 
methanol and acetone extracts of wheatgrass. (Table 6.9.3) 
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           Bleeding time and clotting time 
Disease control group rats which received busulfan showed significant increase 
in bleeding (190 + 18 sec) and clotting time (390 + 35 sec) as a result of 
reduction in platelet counts compared to normal healthy group rats (bleeding 
time- 80 + 12 sec, clotting time- 130 + 22 sec) indicating hemophilia and 
thrombocytopenia in animals. Treatment with fresh wheatgrass juice (bleeding 
time- 98 + 13 sec, clotting time- 150 + 23 sec), methanol extract (bleeding time- 
106 + 17 sec, clotting time- 196 + 24 sec) and acetone extract (bleeding time- 
125 + 15 sec, clotting time- 214 + 30 sec) produced significant reduction in 
bleeding and clotting time in disease suffering rats. Increases in bleeding and 
clotting time in rats were significantly prevented by treatment with fresh juice, 
methanol and acetone extract of wheatgrass. Thus wheatgrass seems to help in 
reducing bleeding and clotting time, near to normal. (Table 6.9.3) 
Table 6.9.3: Effect of Triticum aestivum fresh juice, methanol and acetone 
extracts treatment on bleeding and clotting times on control 
and disease rats.  
 
Values are expressed as Mean + S.E.M, *- significantly different from normal control (p < 0.05), # - 
significantly different from diseases control (p < 0.05), DWFJ- Diseases rats treated with 
Wheatgrass Fresh Juice, DWM- Diseases rats treated with Wheatgrass Methanol extract, DWA- 
Diseases rats treated with Wheatgrass Acetone extract 
Blood parameters 
Normal 
Control 
Diseases 
Control 
DWFJ DWM DWA 
Platelet (103/πl) 905+102 523+ 46* 804+ 72# 761+ 58# 708+ 163# 
Bleeding time(sec) 80 + 12 190 + 18* 98 + 13# 106 + 17# 125 + 15# 
Clotting Time (sec) 130 + 22 390 + 35* 150 + 23# 196 + 24# 214 + 30# 
  
                             6. Results 
169  
 
 
 
Figure 6.9.3: Effect of Triticum aestivum fresh juice, methanol and acetone extracts 
treatment on platelet count, bleeding and clotting times on control 
and disease rats.  
Values are expressed as Mean + S.E.M, *- significantly different from normal control (p < 0.05), # - 
significantly different from diseases control (p < 0.05), DWFJ- Diseases rats treated with 
Wheatgrass Fresh Juice, DWM- Diseases rats treated with Wheatgrass Methanol extract, DWA- 
Diseases rats treated with Wheatgrass Acetone extract 
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For investigation of beneficial effects of wheatgrass on immune system, 
reduction in cyclophosphamide-induced neutropenia, Neutrophil adhesion test 
and carbon clearance test, were used in our study. 
 
           Carbon clearance assay  
 
Carbon clearance test was carried out to evaluate effect of drugs on the reticulo-
endothelial system (RES). It is a diffuse system of phagocytic cells, comprising of 
fixed tissue macrophages and mobile macrophages. The phagocytic cells in this 
system comprise of mononuclear phagocyte system (MPS). Macrophages are the 
major differentiated cell in MPS. Cells of the RES and MPS are known to be 
important in the clearance of particles from bloodstream. When colloidal ink 
containing carbon particles is injected directly into the systemic circulation, the 
rate of clearance of carbon from the blood by macrophage is governed by an 
exponential equation (Das M et al., 1998, Gokhale et al., 2003). Water and 
methanol extracts of wheatgrass showed significant increase in phagocytic index. 
Hence, we infer that wheatgrass may stimulate the reticuloendothelial system. 
(Table 6.10.1). 
 
Table 6.10.1: Effect on phagocytic index in carbon clearance assay. 
 
Treatment Phagocytic index 
Vehicle (1ml/kg, po) 0.0121 ± 0.0019 
Water extract  0.0345 ± 0.0038* 
Methanol extract 0.0685 ± 0.061* 
 
                                                          vbbbbbbbbbbb 6.10 Assessment of immunomodulatory activity of Triticum aestivum 
nti-oxidant property of Triticum aestivum in iron overload condition 
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Figure 6.10.1: Effect on phagocytic index in carbon clearance assay. 
 
All values are mean±SEM, n=5-6, *P<0.01 when compared to control group 
 
 
           Cyclophosphamide induced neutropenia 
 
Cyclophosphamide belongs to nitrogen mustard subclass of alkylating agents and 
acts as an immunosuppressive agent by causing alkylation of DNA, in turn by 
interfering in DNA synthesis and function. It is also used extensively as an 
immunosuppressant (Thatte UM et al., 1987). Administration of 
cyclophosphamide (200 mg/kg, sc) produced a decrease in neutrophil count in 
all groups. Water extract of Triticum aestivum decreased neutrophil count 
significantly compared to control group. (Table 6.10.2) 
 
  
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Vehicle Water extract Methanol extract
Phagocytic index
#
#
  
                             6. Results 
172  
 
 Table 6.10.2: Effects of cyclophosphamide induced neutropenia. 
Treatment 
Total leukocyte count 
(cell/mm3) 
Reduction 
in cell 
number 
% 
reduction 
% neutrophils 
Before After Before After 
Vehicle 
(1 ml/kg, p.o) 
5500                 
± 365.95 
2600              
± 223.23* 
2900.00             
± 227.65 
58.00 
   13.16     
± 1.01 
  7.50      
± 0.76* 
OSE 
(100 mg/kg, po) 
5041.65       
± 296.20 
2783.32       
± 259.70* 
2258.32 
± 315.80 
44.80 
  12.65       
± 1.30 
  8.83      
± 1.35* 
Water extract 
5862.12       
± 156.20 
3122.20      
± 215.41* 
  2739.08  
± 245.5 
46.65 
 12.83       
± 0.98 
  9.33    
± 1.11* 
Methanol 
extract 
6332.30       
± 468.80 
3332.20       
± 388.52* 
3000.10             
± 358.52 
52.64 
    
16.16   
± 0.87 
   9.00   
± 1.00* 
 
 
Figure 6.10.2: Effects of cyclophosphamide induced neutropenia. 
 
All values are mean±SEM, n=5-6, *P<0.01 when compared to control group 
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           Neutrophil adhesion test  
 
When blood samples were incubated with nylon fibers, a reduction in neutrophil 
percentage due to the adhesion of neutrophils to the nylon fibers was observed. 
There was significant increase in neutrophil adhesion to nylon fibres and 
increase in macrophage induced phagocytosis in carbon clearance test along 
with reduction in cyclophosphamide induced neutropenia. The methanol extract 
of wheatgrass was more effective than the water extract. The increase in 
adhesion of neutrophil to nylon fibres indicates migration of cells from blood 
vessels and the number of neutrophils reaching the site of inflammation (Shinde 
UA et al., 1999). Increase in neutrophil adhesion to nylon fibres may be due to up 
regulation of β2 integrins that are present on surface of neutrophils through 
which; they adhere firmly to nylon fibres. Hence, it can be inferred that 
wheatgrass causes stimulation of neutrophil migration towards the site of 
inflammation. Results of the present study also suggest that wheatgrass may 
stimulate cell mediated immunity. (Table 6.10.3) 
 
Table 6.10.3: Effect on neutrophil adhesion in rats. 
Treatment Neutrophil (%) Difference 
A-B UB (A) NFTB (B) 
Vehicle (1ml/kg,po) 24.50 ± 0.85 20.65 ± 1.08 3.85 ± 0.47 
OSE (100 mg/kg,po) 20.00 ± 1.86 10.32 ± 0.55 9.68 ± 1.58* 
Water extract 22.32 ± 1.05 11.50 ± 1.40 10.80 ± 1.16* 
Methanol extract 22.66  ± 1.05 10.66 ± 1.05 12.00 ± 0.78* 
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Figure 6.10.3: Effect on neutrophil adhesion in rats. 
 
All values are mean±SEM, n=5-6, *P<0.01 when compared to control group 
 
 
Thus, the results indicate beneficial effects of wheatgrass in iron overload 
condition, immnocompromised condition and thrombocytopenia. The active 
constituent isolated from wheatgrass also shows significant iron chelating 
potential.   
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7. DISCUSSION  
Patients with chronic anemias such as thalassemia, require regular blood 
transfusions in order to improve both quality of life and survival. Humans are 
unable to eliminate the iron released from the breakdown of transfused red 
blood cells and the excess iron is deposited as hemosiderin and ferritin in the 
liver, spleen, endocrine organs and myocardium. The accumulation of toxic 
quantities of iron causes tissue damage and leads to complications such as heart 
failure, endocrine abnormalities like diabetes, hypothyroidism, liver failure and 
ultimately early death (Taher et al., 2006; Rund and Rachmilewitz, 2005; 
Loukopoulos, 2005).  
Synthetic agents like desferrioxamine and deferiprone, used as chelators for the 
treatment of iron overload in thalassemia, are accompanied by serious side 
effects and certain limitaions including the need for parenteral administration, 
arthralgia, nausea, gastrointestinal symptoms, leucopenia, agranulocytosis and 
obviously the heavy cost. In addition, they are not suitable for use during 
pregnancy. Therefore the search for more effective and safer chelator for 
treatment of thalassemia and other blood disorders has become the need of the 
hour.  
Hence, the major objective of the present project was to evaluate beneficial effect 
of wheatgrass on iron overload and to isolate, characterize and evaluate the 
active phytochemical constituent in wheatgrass, responsible for its iron chelating 
activity. For this aqueous, acetone and methanol extracts of wheatgrass were 
prepared. Among all the extracts, water extract produced maximum yield while, 
petroleum extract produced least yield. Flavanoid, phenoics and tannins were 
found to be present in water and methanol extracts, while acetone extract did 
not contain these constitutes. This was confirmed using shinoda and FeCl3 in 
vitro qualitative tests. Phenolic compounds are known to possess chelating 
property (Ebrahimzadeh et al., 2008). Phenols are very important plant 
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constituents because of their scavenging ability due to their hydroxyl groups 
(Hatano T et al., 1989). Since, phenolic nature of a phytochemical constituent is 
closely related to its chelating activity, we decided to use detection method for 
phenolic compound as the method for detection and isolation of chelating 
compound in wheatgrass extracts.  
In our investigation, water and methanol extracts of wheatgrass were subjected 
to in vitro quantitative determination of total phenolic contents, using FC 
method. There was higher amount of total phenolic content in methanol extract 
compared to water extract. Thus, methanol extract showed promise of maximum 
concentration of iron chelating compound among all three extracts.  
In vitro quantitative estimation of iron chelating activity of various extracts of 
wheatgrass was carried out using Dinis et al. method.[8] Iron chelating activity of 
methanol extract was higher than that of water extract and significantly closer to 
desferoxamine, a standard drug used as a chelator in treatment of iron overload 
in thalassemia patients. This iron chelating property was found to be reversible, 
as confirmed by discoloration of red colored Fe2+-extract complex on heating at 
above 60o C. Thus, our in vitro investigations confirmed that methanol extract of 
wheatgrass has highest phenolic content and also highest concentration of iron 
chelating constituent among the three extracts.  
To confirm in vitro findings about presence of iron chelator constituent, the 
water extract, methanol extract and acetone extracts of wheatgrass were 
subjected to in vivo testing on rats and their iron chelating activities were 
compared with that of desferoxamine. Iron overload was induced in rats by intra 
peritoneal injections of iron-dextran (12.5 mg/l00 g body wt.) evenly distributed 
over 30 days period, which resulted in condition of chronic iron overload that 
resembled thalassemia. [9] [10] 
There was significant decrease in serum iron and serum ferritin levels in 
methanol and water extract treated animals, compared to untreated disease 
control group while, in acetone extract group there was no significant reduction 
in serum iron and serum ferritin levels, compared to untreated disease control 
group. However, rate of reduction was found to be higher in methanol extract 
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compared to water extract. Rate of reduction of serum iron and serum ferritin by 
methanol extract was near to desferoxamine treated group. Water and methanol 
extracts increased excretion of iron in urine and feaces which was found to be 
near to desferoxamine treated group. While in acetone group there was no 
significant increase in iron excretion. Thus, in vivo findings in our study suggest 
that possibly the same iron chelator constituent is present in both methanol and 
water extracts (probably in higher concentration in methanol extract) and that 
this constituent has comparable iron chelating activity to that of desferoxamine. 
The mechanism of this iron chelating activity seems to be through increase in 
excretion of iron in urine as well as in faeces and that the chelate complexation 
process with iron is reversible.    
Isolation of active chelating constituent from wheatgrass was a crucial step in 
our project. Since, the results, obtained so far, revealed that maximum chelating 
activity was exhibited by methanol extract, we decided to process the methanol 
extract further for the purpose. A solvent system suitable for phenolic 
compounds was designed (methanol: water: acetone: glacial acetic acid 
(1:6:0.5:0.1), using which the methanol extract was subjected to TLC. All spots on 
the TLC plate were sprayed with 5 % ferric chloride solution. Since, phenolic 
compound gives black color with FeCl3, the spot of phenolic compound could be 
easily identified on the TLC plate. The compound was later, isolated in larger 
quantity, using the same solvent system and same color technique, by column 
chromatography. During purification process, on recrystallization, the compound 
gave needle-shaped crystals having melting point 215-218 0C. The purified 
isolated compound PI1 was found to have Rf value 0.682. The total phenolic 
content present in this isolated compound was found to be 434.14 + 28.02 µg 
Gallic acid equivalent phenol. Thus, a potential chelating compound was isolated 
from wheatgrass in sufficient quantity for estimation of in vivo activity through 
animal studies and for spectral characterization.   
In vitro iron chelating power of the isolated compound was found to be 50% 
compared to standard iron chelator drug, desferoxamine. When subjected to in 
vivo study, the isolated compound significantly increased iron excretion in urine 
as compared to disease control group. The chelating power or efficacy of the 
compound was found to be 34.5% to that of desferoxamine.  
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The isolated iron chelator compound was subjected to LCMS and IR 
spcectroscopic analyses, for its molecular characterization.  The compound was 
found to be aromatic in nature containing phenolic group. 
Further, during estimation of iron chelating activity of wheatgrass extracts, blood 
samples collected from iron overloaded animals revealed some other beneficial 
effects of wheatgrass on blood composition, unrelated to its iron chelating 
activity.  
While, there was significant decrease in hemoglobin content and RBC count in 
iron overloaded rats compared to normal control rats, these parameters were 
significantly increased in water extract group and methanol extract group, 
compared to disease control group at the end of 15 days and 30 days treatment.  
Further, there was significant increase in total and differential WBC count in 
water and methanol extract groups compared to diseases control group. While in 
acetone extract these counts were not changed significantly. These data indicate 
that wheatgrass improves defense mechanism of body in iron overloaded 
patients.  
Also, there was significant increase in thrombocyte count in water and methanol 
extract groups compared to diseases control group. While in acetone extract 
these counts were not changed significantly.  Thus, data indicate that wheatgrass 
improves over all blood picture in iron overloaded patients.  
There were significant increases in SGOT, SGPT, Serum creatinine and creatine 
kinase levels in disease control group indicating damage to various vital organs. 
In water extract treated group and methanol extract treated group all these 
parameters were significantly decreased as compared to diseases control group 
while in acetone extract treated group there was no significant change in these 
parameters compared to disease control group. These data suggest protective 
effect of wheatgrass on vital organs like liver, kidney and heart in iron over load 
condition.  
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In iron overload condition, oxidative stress is ultimately involved in dysfunction 
of vital organs including cardiovascular system (Shinar and Rachmilewitz, 1990; 
Hebbel et al., 1990; Grinberg et al., 1995). Antioxidant and other supportive 
therapies protect RBC against oxidant damage (Kukongviriyapan et al., 2008; 
Filburn et al., 2007). Also, a higher rate of LDL oxidation in thalassemia patients 
is due to a lower concentration of vitamin E and C in the LDL particles. 
Enrichment with vitamins E and C was effective in preventing LDL oxidation in 
patients with thalassemia (Rachmilewitz et al., 1979; Livrea et al., 1996). Iron 
chelators mobilize tissue iron by forming soluble, stable complexes that are then 
excreted in the feces and/or urine. Chelation therapy reduces iron-related 
complications and thereby improves quality of life and overall survival (Shinar 
and Rachmilewitz, 1990; Hebbel et al., 1990). 
In our study, iron overloaded rats showed significant increase in OFRs, MDA 
level and decrease in SOD, catalase and glutathione levels in rat liver 
homogenates compared to normal rats. Treatment with methanol and water 
extracts of wheatgrass significantly reduced MDA level in the rat liver 
homogenates. There was significant improvement in GSH, SOD and catalase 
levels in iron overloaded rats treated with methanol and water extracts. There 
were no significant change in MDA or SOD, catalase and glutathione levels in 
acetone extract treated group. These data indicate strengthening of antioxidant 
defense by wheatgrass in iron overload condition. 
For evaluation of effects of wheatgrass in thrombocytopenia, busulfan was used 
to induce experimental thrombocytopenia. Busulfan is an alkylating agent with 
myeloablative properties and activity against non-dividing marrow cells and 
possibly, non-dividing malignant cells. Intraperitoneal injection of busulfan 
produced,  significant reduction of platelet count in wistar rats, resulting in 
severe bleeding tendency as found in thrombocytopenia. A significant loss of 
blood cells was evident in diseases control rats over the period of three weeks. 
Three weeks treatment with fresh wheatgrass juice (5 ml/kg, p.o.), methanol 
extract and acetone extract (100 mg/kg/p.o./day each) produced a significant 
increase in all blood cell counts. Treatment with fresh juice, methanol and 
acetone extracts showed significant increase in hemoglobin, RBC, total and 
differential WBC and platelet counts in pancytopenic rats as compared to disease 
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control group. Disease control rats showed significant increase in bleeding and 
clotting time indicating hemophilia and thrombocytopenia. Treatment with fresh 
juice, methanol and acetone extracts showed decrease in bleeding and clotting 
time period. Thus, data indicate beneficial effect of wheatgrass in 
thrombocytopenia. 
Chronic treatment with fresh juice, methanol and acetone extracts increased 
hemoglobin and RBC count indicating therapeutic usefulness of wheatgrass in 
anemia and other hemoglobin and RBC related disorders. 
For investigation of beneficial effects of wheatgrass on immune system, 
reduction in cyclophosphamide-induced neutropenia and carbon clearance test 
were used, in our study. Cyclophosphamide induces myelosuppression in the 
experimental animals. It belongs to nitrogen mustard subclass of alkylating 
agents and acts as an immunosuppressive agent by causing alkylation of DNA, in 
turn by interfering in DNA synthesis and function. It is also used extensively as 
immunosuppressant (Thatte UM et al., 1987). There was an increase in 
neutrophil adhesion to nylon fibres, increase in macrophage induced 
phagocytosis in carbon clearance test and reduction in cyclophosphamide 
induced neutropenia. The methanol extract of wheatgrass was more effective 
than water extract. The adhesion of neutrophil to nylon fibres indicates the 
migration of cells in the blood vessels and the number of neutrophils reaching 
the site of inflammation (Shinde UA et al., 1999). Increase in neutrophil adhesion 
to nylon fibres may be due to upregulation of β2 integrins that are present on 
surface of neutrophils through which, they adhere firmly to nylon fibres. Hence, 
it can be inferred that wheatgrass causes stimulation of neutrophils towards the 
site of inflammation. The results of the present study also suggest that 
wheatgrass may stimulate cell mediated immunity.  
Carbon clearance test is carried out to evaluate effect of drugs on the reticulo- 
endothelial system (RES). This is a diffuse system comprising of phagocytic cells, 
comprising of fixed tissue macrophages and mobile macrophages. The 
phagocytic cells in this system comprise of mononuclear phagocyte system 
(MPS). Macrophages are the major differentiated cell in MPS. Cells of the RES and 
MPS are known to be important in the clearance of particles from bloodstream. 
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When colloidal ink containing carbon particles are injected directly into the 
systemic circulation, the rate of clearance of carbon from the blood by 
macrophage is governed by an exponential equation (Das M et al., 1998, Gokhale 
et al., 2003). Water and methnol extracts of wheatgrass showed significant 
increase in phagocytic index. Hence, we infer that wheatgrass may stimulate the 
reticuloendothelial system. 
Thus, we conclude that regular intake of wheatgrass can be useful in 
management of iron overload diseases and can possibly, replace the current 
regime of painful, expensive and harmful drugs like desferoxamine or 
deferiprone. We have also, isolated a new iron chelator compound from 
wheatgrass. Further characterization as well as detailed toxicological and clinical 
studies of the iron chelator molecule, may provide a new chemical entity for 
better management of iron overload diseases like thalassemia. Our study also 
confirms, scientifically, the traditional use of wheatgrass in immnocompromised 
conditions and thrombocytopenia.  
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 8. CONCLUSION 
In nutshell, our investigation reveals following important inferences – 
1. We have confirmed iron chelating activity of wheatgrass and its various 
extracts.  
2. We have isolated, purified and characterized a potential iron chelating 
compound from wheatgrass. The chelating power of the compound was 
found to be 34.5% compared to desferroxamine. 
3. The mechanism of iron chelating activity of wheatgrass seems to be the 
increase in excretion of iron through urine as well as faeces and that the 
chelate complexation process with iron is reversible.   
4. Data of our study indicate that wheatgrass improves overall blood picture 
in iron overloaded patients by increasing Hb, RBC, WBC and platelet 
counts. 
5. Our data suggest that wheatgrass protects vital organs like liver, kidney 
and heart in iron over load conditions like thalassemia.  
6. The results of our study indicate strengthening of antioxidant defense of 
body by wheatgrass in iron overload condition. 
7. Our data indicate potential beneficial effect of wheatgrass in 
thrombocytopenia. 
8. Our results indicate that wheatgrass possesses immunomodulatory 
activity through stimulation of reticuloendothelial system and cell 
mediated immunity. 
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